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ABSTRACT 
Background  
Joint replacement surgery is one of the most cost-effective interventions leading to 
considerable improvements in function and quality of life. The rise in multimorbidity in the 
UK is leading to an increasing number of patients with long-term conditions (LTCs) 
undergoing joint replacement surgery. Financially stretched commissioners of health 
services are seeking to restrict access to routine elective surgery, including hip and knee 
replacements, despite a lack of evidence to support these decisions.  It is therefore 
important to understand the factors that limit the safety and effectiveness of surgery and 
how LTCs might have an impact on access to and outcomes of joint replacement. 
Methods 
In this thesis, national patient-level datasets and both quantitative and qualitative research 
methods were used to investigate the access to and outcomes of hip and knee replacement 
surgery for patients with 11 different comorbidities. This involved three components: a 
literature review, methodological work, and empirical work. The literature review explored 
the outcomes for patients with different comorbidities. The methodological work assessed 
the agreement between patient-report and administrative data derived comorbidities. 
Finally, the empirical work explored the severity of joint problems before surgery and the 
safety and effectiveness outcomes for patients with comorbidities. Semi-structured 
interviews with healthcare professionals that are involved in the referral and selection of 
patients for joint replacement surgery were undertaken to provide insight into the factors 
that influence the access to surgery for patients with comorbidities.  
Results 
The systematic review on outcomes to hip and knee replacement surgery showed that 
there was limited evidence of the impact of comorbidities on patient-reported outcomes 
related to effectiveness of joint replacement surgery. Patients with comorbidities reported 
more severe joint problems before surgery compared to patients without comorbidities, 
suggesting that patients with comorbidities may be undergoing hip and knee replacement 
surgery later in the course of their joint disease. This was further supported by the findings 
from the qualitative study that patients with comorbidities who were considered 
unsuitable for surgery were ‘lost to the system’ and left to self-manage their comorbidities 
before being reconsidered for joint replacement surgery. With regards to outcomes, 
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patients with comorbidities have a moderately increased risk of adverse outcomes after hip 
and knee replacement surgery but benefit almost to the same extent as patients without 
comorbidities. Patients with comorbidities reported only slightly smaller improvements in 
severity of joint problems and no difference in quality of life after surgery compared to 
patients without comorbidities. Patients with multiple comorbidities (two or more 
comorbidities) reported more severe joint problems before surgery and a slightly higher 
increased risk of adverse outcomes but nevertheless benefitted considerably from the 
surgery.  
 
Conclusions 
This thesis demonstrates that patients with comorbidities may experience inequalities in 
access to hip and knee replacement surgery even though they benefit almost as much as 
patients without comorbidities. This finding indicates that the restriction of access to joint 
replacement surgery based on the presence of comorbidities alone is difficult to justify 
considering the beneficial impact of the surgery on patients’ lives. 
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1 INTRODUCTION 
 
1.1 Rationale for investigating access and outcomes to hip and knee 
replacement surgery in patients with comorbidities  
One of the biggest challenges currently facing the UK National Health Service (NHS) is the 
increase in the number of patients living with long-term conditions (LTCs) [1]. Elective hip 
and knee replacement surgery is one of the most common and effective surgeries and it is 
increasingly being used [2]. More and more patients undergoing hip and knee replacement 
surgery have LTCs. In a previous study of hip and knee replacement surgery patients in 
England, more than 60% of patients for these operations reported at least one LTC [3]. This 
number is expected to continue to rise as the number of people living with multiple LTCs is 
on the increase [4]. 
 
In the UK, the NHS was founded on the principle of equity in access to care. However, 
evidence shows that there are inequities in provision and utilisation of health services. 
Research has demonstrated that such inequities in healthcare provision include major 
surgical interventions such as cardiac surgery, liver transplantations and joint replacement 
[5]. The focus of research has been on sociodemographic characteristics such as age, 
gender, ethnicity and socioeconomic status and studies have shown these characteristics 
have an important impact on the likelihood of receiving surgery [6-10].  
 
Furthermore, there are indications that access to elective surgery, such as hip and knee 
replacement surgery, is being restricted by commissioners of health services in a bid to cut 
spending budgets [11]. This could introduce inequalities in access, specifically 
disadvantaging patients with comorbidities and thereby may be creating inequities.  For 
example, some Clinical Commissioning Groups (CCGs) have restricted access to elective 
surgery by imposing minimum eligibility criteria for severity of preoperative function [12] 
and pain [11], smoking status [13],  the requirement that a patient’s body mass index (BMI) 
is lower than 30kg/m2 [14, 15] and the optimisation of pre-existing comorbidities [16]. 
However, there is no clinical or economic justification for any of these eligibility criterion 
[17, 18] and they are not supported by the National Institute for Health and Care Excellence 
(NICE) clinical guidelines [19].   
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Commissioners assume that for patients with a high BMI, surgery is less safe and effective 
[20, 21]. High BMI and obesity however rarely come as an isolated diagnosis and are often 
accompanied  by other LTCs (e.g. diabetes, heart disease) that are considered to increase 
the risk of surgical complications after surgery [22]. For example, diabetes is considered to 
be a risk factor for surgical site infections after surgery [23].  Little is known however about 
the impact of a variety of specific LTCs on the safety and effectiveness of elective surgery.  
 
This thesis will seek to fill this gap in the literature and focus on hip and knee replacement 
surgery as the healthcare resource of interest.  In England, Patient Reported Outcome 
Measures (PROMs) survey data have been collected since 2009 for four elective surgeries: 
knee replacement surgery, hip replacement surgery, varicose vein surgery and hernia 
repair. PROMs data provide an opportunity to explore and evaluate differences in access to 
(focusing on patient-reported severity and duration of joint problems just before surgery) 
and outcomes of elective surgery.  PROMs data has previously been used to assess the 
impact of socioeconomic status on severity and duration of joint problems before surgery 
[9, 24]. Joint replacement surgery, the replacement of the articulating surfaces of the hip or 
knee joint, is an ideal condition to choose to study evidence of inequalities in healthcare. Its 
provision is widely used as an indicator of equity because it is a common procedure with 
about 87 000 primary hip replacements and about 98 000 primary knee replacements 
conducted in the year 2015/16 in the UK alone [25], but also because it leads to big 
improvements in health-related quality of life (HRQoL) [26-28].  
 
To determine whether there are any inequalities in provision, it is necessary to compare 
patterns of service provision relative to clinical need, however this is difficult as the data on 
the latter are not routinely available. I therefore relied on data on patients having surgery 
to make inferences about access to joint replacement surgery for people with different 
LTCs. The NHS provides a unique opportunity to investigate variation in healthcare and 
utilisation because of the data it collects routinely about hospital activity [29].  These 
administrative datasets have traditionally been used for health service planning, 
commissioning and performance management. It has now been recognised that they are a 
valuable source of data for health service research [30]. I used these administrative 
datasets to explore the variation in patient-reported health prior to hip or knee 
replacement surgery and describe the extent to which comorbidities explain observed 
variation in access to and outcomes for patients with and without different LTCs.  
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1.2 Defining terms 
The next section will define the two main terms that will be used throughout the thesis: 
access and long-term condition/comorbidity.  
 
 Access 
Access to healthcare has long been a term that is difficult to define and interpret. Whilst 
various indicators of access have been considered including availability of services and 
consumer satisfaction, it is very difficult to observe access directly [31]. The choice of 
approach to measuring access is commonly dictated by the data that is available. Direct 
approaches to measuring access involve collecting data directly from healthcare users’ on 
access problems via large expensive surveys.  As a result, the most common 
methodological approach is to measure access indirectly using the population standard 
approach. The population standard approach uses utilisation of health services data, rate at 
which services are actually used, to compare use relative to need [32]. Utilisation 
measures, for example, include the number of contacts with the General Practitioner (GP) 
and the rate of hip and knee replacement surgery. Due to data on unmet need not being 
routinely available, utilisation data is usually used.  
Using the terminology of Aday and Andersen, utilisation of health services reflects ‘realised 
access’ irrespective of ‘potential access’ [33]. ‘Potential access’ is influenced by the 
characteristics of the healthcare system (e.g. the distribution of medical resources and 
waiting times) and the characteristics of the population at risk (e.g. age, sex, ethnicity and 
perceptions of health and illness) [33]. In other words, variation in utilisation reflects 
variation in ‘realised access’ and this variation may be directly influenced by the 
characteristics of the healthcare system or the patient population at risk.  
If I apply this to the patient pathway to joint replacement surgery, one can initially 
recognise a population of patients who are in need of joint replacement surgery (see Figure 
1). A proportion of these patients will go to their GPs for their hip and knee pain and will 
have ‘potential access’ to joint replacement surgery. At this point, patients may not be 
referred on because their GP considers that their joint problems are not severe enough and 
can be managed in primary care or the patients do not want to be referred. For those 
patients who are referred to secondary care, patients again may not be selected for surgery 
either because the surgeon does not consider the patient suitable for surgery or the patient 
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is unwilling to undergo surgery. Only those who undergo the hip or knee replacement 
surgery will have ‘realised’ their access.  
 
Figure 1 – ‘Realised access’ in hip and knee replacement surgery 
 
 
This study will use utilisation data on patients who have undergone hip and knee 
replacement surgery to determine if there are any inequalities in ‘realised access’ for 
patients with comorbidities compared to patients without comorbidities. In applied health 
research, inequality means a difference without any moral judgement. In contrast inequity, 
a subset of inequality, involves a judgement of what we think is avoidable and unfair [32]. It 
is important to further distinguish between the vertical and horizontal dimensions of 
equity: vertical equity refers to access according to variation in need whilst horizontal 
equity refers to equal access to healthcare for people in equal need [31]. Determining the 
presence of inequity in access is beyond the scope of this thesis. However, whether any 
inequalities suggest inequities, specifically in relation to the horizontal dimension of equity, 
is considered in the discussion section of this thesis.  
 
 LTCs and comorbidities 
LTCs which may also be known as chronic diseases or noncommunicable diseases, will be 
defined using the World Health Organisation definition which is “any disease that tends to 
be of long duration and is a result of a combination of genetic, physiological, environmental 
and behavioural factors” [34].  
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In research studies, the burden of LTCs is denoted using the term ‘comorbidities’. Several 
definitions have been suggested for comorbidity but all are based on a single core concept: 
the presence of more than one distinct condition in an individual [35]. In the case of this 
research, comorbidity will be used to convey the notion of burden of illness or disease in 
addition to the primary indication for surgery (i.e. osteoarthritis). Multiple comorbidities 
will be used to describe the extension of this, as having two or more comorbidities. Having 
multiple comorbidities adds a more complex dimension but to overcome this complexity 
this thesis used an approach based on counting of comorbidities (2, 3 and 4 or more 
comorbidities).  
 
Table 1 – Summary of definitions of terms 
Term Definition 
Long-term condition 
(policy) 
Any disease that tends to be of long duration and is a result of a 
combination of genetic, physiological, environmental and 
behavioural factors 
Comorbidity 
(research) 
Presence of additional diseases in relation to an index disease (i.e. 
osteoarthritis) in one individual 
Multiple comorbidities 
(research)  
Presence of two or more additional diseases in relation to an index 
disease (i.e. osteoarthritis) in one individual 
 
 
1.3 Long-term conditions  
One of the biggest challenges currently facing the NHS is the increase in the number of 
patients living with LTCs. Estimates from 2010 suggest that around 15 million people in 
England have at least one LTC [1]. Increasingly patients are also living with multiple LTCs, 
also known as multimorbidity [36]. This increase will likely have an important impact on 
healthcare utilisation. Patients with LTCs are users of all parts of the health system 
including community services, urgent and emergency care and acute services. They have 
been shown to account for at least 50% of GP appointments, outpatient appointments and 
inpatient bed days [1].  It is therefore important to measure accurately the presence of 
LTCs to quantify their impact on access to health interventions, to quantify the outcomes of 
such interventions, and to show the implications this has for the organisation and delivery 
of healthcare services that provide support for patients with LTCs.  
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 Identifying patients with LTCs in epidemiological research 
In epidemiology, the occurrence of comorbidity needs to be measured for multiple reasons. 
Firstly, to account for confounding of comorbidities and secondly to understand how 
comorbidity interacts with the outcome [37]. Data on comorbidities can be collected by 
directly interviewing patients, by patients self-reporting (patient-report), by reviewing 
medical records, or by extraction from administrative databases [38]. This study focused on 
comorbidities derived from administrative data and patient-report.  
 
1.3.1.1 Administrative data-derived comorbidities 
Administrative datasets are often large in size and used for administrative purposes in 
health, including reimbursement for health services or for insurance payments. In England, 
the Hospital Episode Statistics (HES) dataset is the administrative data that is used to 
reimburse NHS providers.  Due to the complexity of these large databases, comorbidity 
indices have been developed to identify comorbidities and quantify their impact on the 
outcome. Comorbidities indices are a means to categorise comorbidities and the most 
widely used indices are based on the International Classification of Disease (ICD) diagnosis 
codes that are used in administrative data to record diagnoses.  
The most commonly used comorbidity indices are the Charlson Comorbidity Index (CCI) and 
the Elixhauser comorbidity indices. Each comorbidity index includes different 
comorbidities. Each comorbidity index was also originally developed to predict a certain 
outcome such as 1-year mortality (CCI), length of stay, hospital charges or in-hospital 
mortality (Elixhauser). The majority of the studies comparing different comorbidity indices 
were carried out in the United States and in Canada using Medicare and Medicaid data and 
show that comorbidity indices vary in their predictive ability [39-41]. 
Due to the variability in the comorbidities included in the indices, and the outcomes they 
were developed to predict, researchers have been forced to modify these indices so they 
are more suitable to the study population they are interested in. As a result, there are 
many modifications of the Charlson and Elixhauser comorbidity indices (see Appendix H for 
more detail on different comorbidity indices).  
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1.3.1.2 Patient-reported comorbidities 
Patient-report is an attractive alternative source of data on comorbidities to chart review 
and administrative data. This is because it engages the patient in their healthcare and is 
thought to encourage patient-centred care.  Questionnaire studies are very resource-
intensive to deliver however and are therefore more expensive than using already existing 
administrative data.  
Several measures have been developed to assist the patient with objectively reporting their 
medical history such as the Self-Administered Comorbidity questionnaire, which uses not 
only the patient’s own report of conditions but also the symptoms and their severity to be 
able to characterise total disease burden without depending on a current diagnosis [42]. 
This questionnaire has been shown to have a modest relationship with widely used 
medical-record-based comorbidity instruments [43].  
In England, the Patient-Reported Outcome Measures (PROMs) questionnaire asks patients 
if they have ever been told by a doctor whether they had any of 12 comorbidities (see Box 
1). The PROMs survey comorbidity categories were originally chosen based on the work of 
Bayliss et al [44]. Bayliss et al searched the literature to determine the health conditions 
that were most frequently assessed in measuring comorbidity and then subsequently pre-
tested the instrument for clarity with patients [44]. 
 
 
 
 
 
 
 
 
 
 
Box 1: PROMS questionnaire comorbidities 
In the PROMs pre-operative questionnaire patients were asked: “Have you ever 
been told by a doctor that you have any of the following conditions?” 
 Heart disease (for example angina, heart attack or heart failure) 
 High blood pressure 
 Problems caused by stroke 
 Leg pain when walking due to poor circulation 
 Lung disease (for example asthma, chronic bronchitis or emphysema) 
 Diabetes 
 Kidney disease 
 Diseases of the nervous system (for example, Parkinson’s disease or multiple 
sclerosis) 
 Liver disease 
 Cancer (within the last 5 years) 
 Depression 
 Arthritis 
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There are concerns however, that patients cannot report their comorbidities accurately 
due to recall bias. These scores derived from patient-reported data have therefore been 
validated against comorbidity indices calculated from administrative data. Several studies 
have specifically compared the performance of a CCI adaptation derived from patient-
reported data with the same index derived from administrative data or chart review. They 
found that patient-reported data and administrative data adaptations had similar ability to 
predict various outcomes [45, 46]. Several studies have shown that patients can accurately 
and reliably report certain medical conditions although levels of agreement (as measured 
by the kappa statistics and sensitivity) varied significantly [42, 47, 48]. 
 
1.4 Factors determining access to hip and knee replacement surgery 
A wide variation in the access to hip and knee replacement surgery has been reported and 
there are many possible reasons for this variation. These include differences in severity of 
joint problems, and a variety of patient-related factors such as age, socioeconomic 
deprivation and patients’ willingness to undergo surgery. Other factors include differences 
in health-system related factors and differences in medical-professional related factors [49, 
50]. This variation may have led to underutilisation in some areas and overutilisation in 
others which can lead to poor or even harmful care for some patients [51, 52].  
 
 Severity of joint problems 
One of the main determinants of a patient’s decision to undergo surgery and an 
orthopaedic surgeon to select a patients for surgery is the severity of the joint problem 
[53].  In end-stage osteoarthritis, patients reporting lower ability to function and more pain 
have been shown to be more likely to undergo knee replacement and hip replacement [54]. 
Specific problems such as getting up from a chair, climbing up stairs and walking difficulties 
predicted undergoing knee replacement within two years [55]. Pain however is the single 
most important influential factors in the decision to undergo hip or knee replacement [56]. 
Patients reporting worse severity of joint problems (as measured by the WOMAC score) as 
well as HRQoL were more likely to undergo joint replacement surgery [57].  
 
17 
 
 Patient-related factors 
Evidence suggests that patient-related factors have a large impact on the use of hip and 
knee replacement surgery in the UK and other countries. These include factors such as age, 
gender, ethnicity, socioeconomic status and patients’ willingness to undergo surgery.  
 
One of the simplest indicators of need is age. This is particularly true for LTCs whose 
prevalence increases with age. The primary indication for total hip or knee replacement is 
osteoarthritis (>90% of patients).  Osteoarthritis, a progressive degeneration of the 
articular cartilage, is most common in elderly populations [58].  Osteoarthritis increases 
with age, with projections showing that ageing alone will lead to the population with 
osteoarthritis increasing by 50% over the next two decades [59]. Recently there has also 
been an increasing number of younger patients (<65 years) undergoing knee replacement 
surgery and a study found that this cannot be fully explained by variations in clinical 
decision-making [60]. 
 
Previous studies have reported that gender plays a role in the use of surgery. In both 
Canada and the UK, the GP is less likely to refer women to surgeons [7, 61] and this is 
despite reports that women have worse pain and disability than men just before surgery 
[24, 27, 62].  Studies have shown that the gender of the patient also affects the health 
professionals’ treatment recommendations [6, 63]. Researchers have suggested this is 
likely to be a result of an unconscious gender bias already pervasive in society and 
healthcare professional hearing from other health professionals that women don’t benefit 
as much as men from knee replacement surgery. Furthermore, this inappropriate 
preconception may be because women are more risk averse and therefore usually receive 
surgery at a more advanced stage of disease than men [64, 65].   
 
Studies have also found that there are ethnic disparities in the provision of hip and knee 
replacement surgery. In a large-scale study using Medicare data in 1991 the use of knee 
replacement surgery was 36% lower for patients from a Black ethnic background compared 
to a White ethnic background and this difference persisted over an 18-year study period. In 
2008, it was 40% lower for patients with Black ethnic backgrounds compared to White 
ethnic backgrounds [66]. Another study in the UK found that symptoms also tended to be 
more severe and of a longer duration in patients from South Asian and Black ethnic 
backgrounds than in patients from White ethnic background just before surgery [67].  
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Studies have found that there is an under-provision of surgery in socioeconomically 
deprived areas, compared to estimates of the need for surgery [68-74]. A study found that 
more socioeconomically disadvantaged patient groups are less likely to undergo primary 
total hip replacement than more affluent groups [75]. This may be in part due to the 
differences in patients’ perceptions, preferences for care and differences in their 
expectations of a positive outcome of surgery. Another possible reason is that 
socioeconomically deprived people generally have worse health, often have several LTCs 
and therefore may be considered inappropriate candidates for surgery [76].   
 
Patient’s willingness to undergo surgery also plays a role in the access to surgery. A number 
of studies have reported differences in patient preferences and expectations for joint 
replacement surgery according to sex, ethnic group and socioeconomic status [77-79]. 
Some patients may decide not to want a major surgery which requires a long recovery 
period. In particular, some elderly people may prefer to manage the pain and to live with 
limited mobility [80]. Similarly, more socioeconomically deprived people are thought to be 
more willing to accept chronic pain and functional limitations before seeking help or having 
surgery [81].  
 
 Health system-related factors 
Another possible reason for the observed disparity in access is the differences in regional 
availability of orthopaedic surgeons in a rapidly ageing population with the concomitant 
increase in rates of joint replacement surgery. The suggested optimal provision of 
orthopaedic surgeons for the UK is 4-6.7 FTE per 100,000 but the actual figure, 3 surgeons 
per 100,000 for the UK falls well below this [82, 83]. In a study of access to primary care 
practitioners and orthopaedic surgeons in Canada the findings suggest that in areas with 
fewer available orthopaedic surgeons patients were less likely to have an orthopaedic 
consultation and less likely to receive surgery [84].  
 
 Medical-professional related factors  
Disparities in access to hip and knee replacement surgery can occur at several points in the 
patient’s trajectory from access to referring health professionals and referral to 
orthopaedic surgeons through to entering the waiting list for surgery and subsequent 
progression along this list. In general, differences in access to surgery appears more likely 
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to occur at the referring health professional stage due to a variation in clinical decision-
making.  
 
Specifically, research has suggested the variation is due to the clinical indication criteria 
used when referring or selecting patients for surgery [85-87]. In most countries, the 
indication criteria for total knee replacement and total hip replacement surgery are not 
clearly defined or evidence-based [88]. For example, in a study of 15 hospitals in Spain, the 
researchers estimated that as many as 25% of the knee replacement and hip replacement 
could be considered inappropriate [89]. A lack of consensus will lead to disparities in the 
provision of joint replacement surgery. 
 
In many countries, GPs act as gatekeepers for referral to hip replacement surgery and 
studies have found that GPs and orthopaedic surgeons do not have the same views on who 
should have joint replacement surgery. In a multi-centred survey study of 304 orthopaedic 
surgeons and 314 referring practitioners across 12 European countries, the study found 
that the latter think that patients need to have more severe symptoms to offer surgery 
than do the surgeons. In addition, referring physicians were more likely to associate age 
and obesity with a less favourable outcome than the orthopaedic surgeons [90]. The 
referring physicians may therefore be holding back patients who might have been offered 
surgery, had they consulted an orthopaedic surgeon [85].  
 
There is also evidence of wide variation in orthopaedic surgeons’ indications for total joint 
replacement and that comorbidities play a role in the selection of patients for surgery [91, 
92]. In 1996, a study carried out a postal survey of orthopaedic surgeons in which the 
surgeons reported no consensus but agreed that the key indication for knee replacement 
surgery was severe daily pain. A patient’s willingness to undergo surgery and motivation to 
improve was also reported as a common reason for proceeding with surgery.  
Comorbidities however was given as a reason for avoiding recommendation for surgery 
[91]. Similarly, in a qualitative study with four surgeons and two Extended Scope 
Physiotherapists (ESPs) in England, intermediate care professionals that work in 
musculoskeletal assessment centres, one of the key indicators for referral or selection for 
surgery, was the presence or absence of comorbidity. Comorbidities were considered when 
assessing whether a hip replacement would be a worthwhile investment for the patient 
[93]. Another study found that after adjustment for confounders the deciding indications 
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for the surgeon’s decisions were the presence or absence of severe cardiovascular disease 
and the SF-36 (HRQoL) physical score [92].  
 
 
1.5 Outcomes after hip and knee replacement surgery 
The three pillars of quality in healthcare are thought to be patient safety clinical 
effectiveness and patient experience [94]. In this thesis, the approach to measuring 
outcomes was to look at all of the domains of quality of healthcare that reflect outcomes of 
the care received. Due to data on patient experience being unavailable, the focus was 
therefore on outcomes relating to patient safety and clinical effectiveness after hip or knee 
replacement surgery. To ensure the patient perspective was captured the focus was on 
investigating patient-reported outcomes.  
Outcomes after hip and knee replacement have been improving over the last few decades. 
Hip and knee replacement surgery now offers considerable improvement in function and 
HRQoL in patients suffering with osteoarthritis or inflammatory arthritis [95-98].  In 2014, 
of the 76 576 PROMs hip replacements and 79 769 knee replacement that were performed 
in England, over 80% showed improvements in function and HRQoL [99]. Despite the 
success of joint replacement surgery and the reduction in mortality, a small number of 
patients continue to have surgical complications, pain and in some cases no improvement 
in function after surgery [100].  
 
 Patient safety outcomes 
In this thesis, patient safety outcomes refers to outcomes that measure the risk of short-
term (<90 days) adverse outcomes after surgery related to the exposure to medical care. 
These include: surgical complications, short-term mortality, readmissions and length of stay 
(LOS) [101]. 
 
1.5.1.1 Surgical complications 
Surgical complications after total knee replacement are rare.  For example, infective 
complications of the prosthesis occurs in 1-3% of patients undergoing hip and knee 
arthroplasty [102]. If they do occur they can lead to significant patient morbidity and cost 
to the healthcare system [102].  As with other major surgery, complications may occur, and 
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these include anaesthesia-related risks, exacerbating comorbidities such as a myocardial 
infarction, infections, medication and allergic reactions and venous thromboembolism 
[103]. 
 
1.5.1.2 Short-term mortality 
All surgery carries risk of some kind, including death. In England and Wales, the risk of 
death in the 90 days following hip replacement surgery is less than 1% and is lower than in 
the age and sex matched population [104]. In a systematic review of 32 studies published 
between 2003 and 2013 looking at 30-day or 90-day mortality following hip replacement, 
the estimated incidence of mortality during the first 30 days was 0.30% (95% CI 0.22 to 
0.38) and 0.65% (95% CI 0.50 to 0.81) in the 90 days following the surgery [105]. The risk 
factors for early mortality most commonly identified were increasing age, male gender and 
comorbidities, particularly cardiovascular disease. Cardiovascular complications appear to 
be the lead cause of death followed by embolism after hip replacement [105]. 
 
1.5.1.3 Readmissions 
The 30-day or 90-day readmission rate after hip and knee replacement is commonly used 
as a surrogate measure of adverse outcomes such as surgical complications [106]. A large 
study in England looking at readmission rates over a 10-year period for patients undergoing 
hip and knee arthroplasty, found that readmissions rates have been decreasing [107]. 
Specifically, readmission rates decreased for patients with acute myocardial infarction, 
chronic obstructive pulmonary disease and heart failure, but increased for patients with 
pneumonia and diabetes [107]. The most common causes of readmissions have been 
shown to be infections and surgical complications such as venous thromboembolism [108]. 
 
1.5.1.4 Length of stay (LOS) in hospital 
LOS in hospital following joint replacement surgery measured in days is a common 
outcome measure and a key outcome in the measure of the overall cost of the procedure. 
LOS has fallen substantially between 1997 and 2014 in England following joint replacement 
surgery [109]. In previous studies of hip and knee patients, prolonged LOS has been 
associated with advanced age [110], social deprivation [110], gender [111] and 
comorbidities [112]. Concerns have been reported however about the approach to 
22 
 
measuring LOS.  Most studies on LOS after joint replacement are limited by small sample 
sizes and as such using mean LOS can be misleading [112]. In addition, it is difficult to 
ascertain what constitutes prolonged LOS as a previous study found that some measures of 
prolonged LOS do not agree with coded complications [113].  
 
 Clinical effectiveness outcomes 
In this thesis, clinical effectiveness outcomes refers to long-term outcomes (>90 days after 
surgery) that reflect the act of achieving optimum process and outcomes of healthcare 
services for patients. These include patient-reported outcome measures such as function, 
pain, HRQoL, patient satisfaction with the outcome as well as the likelihood of revision 
surgery.  
 
1.5.2.1 Patient-reported outcome measures (PROMs) 
PROMs, such as disease-specific and general quality of life measures, are new tools which 
have been proposed to strengthen patient engagement and enable patient-centred care 
[114]. PROMs were initially developed in clinical trials to measure people’s subjective 
health and HRQoL and are now used widely to measure the performance and quality of 
healthcare services.  
There are challenges to using PROMs data to measure outcomes for patients with 
comorbidities however. There is a general assumption that the impact of comorbidities is 
not captured by these PROMs such as disease-specific measures like the Oxford Hip (OHS) 
or Knee (OKS) Score. This notion is not properly understood so must be further explored.   
 
1.5.2.1.1 Hip or knee function  
The main aim of hip and knee replacement surgery is to improve hip or knee function and it 
has been effective in doing so.  Hip and knee function is commonly measured using 
disease-specific quality of life measures such as the OHS/OKS and the WOMAC score. In a 
literature review of 62 studies published between 1995 and 2003 looking at the function 
and HRQoL after joint replacement it was found that hip and knee replacement leads to 
significantly improved function. This benefit was perceived as greater by healthcare 
professionals than by patients [115].  In a European collaborative study of 1327 patients 
with total hip replacement, it was found that, despite hip replacement being effective in 
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the majority of cases, between 14% and 36% of patients reported no improvement or being 
worse 12 months after surgery [116]. Factors such as age and socioeconomic status have 
been found to have an impact on the improvement in function reported by patients after 
total joint replacement surgery. A study looking at a sample of 121 893 patients in England, 
found that patients living in socioeconomically deprived areas reported less improvements 
in function after surgery due to differences in overall health and joint disease severity than 
patients from more affluent areas [9]. 
 
1.5.2.1.2 Pain 
Alongside function, pain is also measured when using patient-reported disease-specific 
outcome measures. Despite the significant improvements in function, patients continue to 
report pain after total joint replacement and reports of persistent pain are not uncommon 
[117, 118]. In an in-depth interview study with 10 patients 6-months after their joint 
replacement surgery, 8 out of these 10 patients still experienced pain and mobility issues 
[117]. In a systematic review of 14 articles published up until January 2011 investigating the 
proportion of patients reporting long-term pain after hip or knee replacement for 
osteoarthritis the best quality studies reported 9% of patients after hip replacement and 
about 20% of patients after knee replacement reported long-term pain after surgery [118].  
 
1.5.2.1.3 Health related quality of life (HRQoL) 
Linked to the aim to improve hip and knee function is the aim to improve the HRQoL of 
patients with hip or knee pain. A large systematic review of 74 prospective cohort studies 
published between 1980 and 2003 concluded that total hip and knee arthroplasties were 
effective in improving HRQoL [119]. Another study looking at overall improvement in 
HRQoL after knee replacement surgery found an overall improvement which seemed to 
continue six months after the procedure [120]. The main predictors of improved HRQoL 
were function, pain, patient satisfaction, better quality of sleep and adequate social and 
familial support after surgery. The factors that predicted poor improvements in HRQoL 
were obesity, advanced age, comorbidities, persistence of pain after the procedure and 
waiting a long time for the operation [120]. 
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1.5.2.1.4 Patient satisfaction with the outcomes  
An additional aspect of patients’ perception of the impact of their surgery is their level of 
satisfaction with the outcome of the surgery. Research has predominantly focused on 
satisfaction with the processes of care rather than patients’ satisfaction with their 
condition and the outcome of their treatment [121]. The most common causes of 
dissatisfaction include pain and limited function and poor recovery after surgery. The 
possible determinants of dissatisfaction that have been explored include age, gender, 
patient’s expectations and comorbidities [122]. There is little consensus on the impact of 
age and gender as predictors of dissatisfaction. A patient’s expectations however has found 
to be the strongest predictor of dissatisfaction suggesting managing patients’ expectations 
before surgery is important [123, 124]. Comorbidities have also been found to have an 
impact on satisfaction. Patients with depression have been shown to be more dissatisfied 
with their surgery although conflicting findings have been reported [125, 126].  
 
1.5.2.2 Revisions 
Hip and knee replacements may require revision surgery in both the short-term and the 
long-term. The rate of revisions in the first couple of years following hip and knee 
replacement surgery remain low. A study in England found that in the first three years of 
surgery only about one in 75 patients needed a revision of their joint replacement [127]. 
The risk factors for short-term implant failures include age, high comorbidity score, an 
uncemented prosthesis as well as complications (e.g. infections) [128].  Hip and knee 
prostheses however, do not continue to function effectively for the lifetime of patients. 
Implants are likely to require revision surgery after 20 years of use due to wear and 
prosthetic loosening with a 20-year implant survival rate of 85% for hip replacement and 
89.7% for knee replacement [129]. As a consequence, surgery is recommended to be 
avoided in younger patients [130, 131]. 
In a systematic review of 86 papers published between 2000 and 2010, factors found to be 
associated with revision included younger age, greater comorbidity, fewer surgeons 
available, and, anatomically, the femoral head size. Men also had a higher rate of revisions 
due to aseptic loosening (the failure of the bond between bone and hip or knee implant) 
and post-operative infection. Longer operating time was associated with revision due to 
the higher risk of infection. Smaller femoral head size was associated with revision due to 
an increased risk of dislocation [132]. 
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2 RESEARCH DESIGN OVERVIEW 
To determine if there were any inequalities in access to and outcomes of hip and knee 
replacement surgery, literature review, administrative data analysis, and qualitative 
methods were used. First, a literature review of published articles on access to and 
outcomes of hip and knee replacement surgery for patients with comorbidities was 
conducted. In parallel, a qualitative study was conducted to explore the complexity of the 
patient pathway to access hip and knee replacement surgery for patients with 
comorbidities. Administrative data along with patient-reported data were used to 
quantitatively assess the variation in access and outcomes related to both safety and 
effectiveness of hip and knee replacement surgery.   
This chapter gives an overview of the research design. Further detail of the methods for 
each study can be found in each of the individual chapters.  
 
2.1 Aims and objectives 
The overall aim of this research was to use both administrative and patient-reported data 
and qualitative study to assess the impact of comorbidities on access to and safety and 
effectiveness outcomes of hip and knee replacement surgery for patients with 
comorbidities.  
The specific objectives were: 
Objective 1 (RP1): To conduct a systematic review of the literature on access to and 
outcomes of hip and knee replacement surgery for patients with different comorbidities. 
Objective 2 (RP2): To conduct a qualitative study to understand the barriers to and 
facilitators for accessing elective hip and knee replacement surgery for patients with 
comorbidities. 
Objective 3 (RP3): To investigate how comorbidities reported by patients agree with 
comorbidities recorded in administrative datasets. 
Objective 4 (RP4): To investigate the variation in access to hip and knee replacement 
surgery for patients with different comorbidities.   
Objective 5 (RP5): To investigate the variation in outcomes related to the safety of hip and 
knee replacement surgery for patients with different comorbidities.   
26 
 
Objective 6 (RP6): To investigate the variation in outcomes related to the effectiveness of 
hip and knee replacement surgery for patients with different comorbidities.   
The outputs of this research are in the form of six research papers (RP1-6) which are 
expected to provide further understanding of the variation in access to and outcomes for 
patients with comorbidities and the implications this has for further organisation and 
delivery of healthcare services to support this group of patients.  
 
2.2 Data sources  
This section gives an overview of the data sources used in each study of this programme of 
research.  
 
Existing published research (RP1) 
A literature review on the outcomes of hip and knee replacement for patients with 11 
different comorbidities was conducted.  Three databases, Medline, Embase and CINAHL 
Plus, were searched for all relevant papers in the English language up until May 2017 that 
compared the outcomes of hip and knee replacement surgery between patients with and 
without comorbidities. Search terms for hip and knee replacement were combined with 
search terms for health outcomes and search terms for 11 common comorbid conditions: 
heart disease, high blood pressure, stroke, leg pain due to poor circulation, lung disease, 
diabetes, kidney disease, diseases of the nervous system, liver disease, cancer and 
depression. 14 894 studies were identified through this search (after deduplication) and 70 
studies were eligible for inclusion.  
 
Semi-structured interviews (RP2) 
20 healthcare professionals along the orthopaedic referral pathway (orthopaedic surgeons, 
GPs and intermediate care professionals) were interviewed to understand the impact of 
comorbidities on the referral and selection for joint replacement surgery. Orthopaedic 
surgeons were selected from a list of all orthopaedic surgeons specialising in hip or knee 
replacements in the NIHR CLAHRC North Thames (North Central and East London, Essex 
and Hertfordshire) area. Consultant orthopaedic surgeons (senior surgeons who have 
completed all their specialist training) were contacted via email. GPs were recruited 
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through the local teaching networks using snowballing techniques from a sample of GP 
practices across the NIHR CLAHRC North Thames area. Intermediate care professionals 
were recruited, using snowballing techniques, from intermediate services used by GPs and 
surgeons who had been interviewed. The interviews were recorded and then transcribed.  
 
Datasets (RP3-6) 
The three datasets used were Patient Reported Outcome Measures (PROMs) data, Hospital 
Episode Statistics (HES) and Office for National Statistics (ONS) mortality data. Further 
detail on the data linkage and data cleaning is available in Appendix J. 
 
1. PROMs dataset 
In England, PROMs data have been collected before and after four elective surgeries since 
2009. The ones currently in use are for knee replacement surgery, hip replacement surgery, 
varicose vein surgery and hernia repair. Patients complete a questionnaire before their 
operation either at the preoperative assessment clinic or on admission to hospital (Q1). 
They are then sent a questionnaire six months (3 months for varicose vein surgery and 
hernia repair) after surgery (Q2). The questionnaires include both a disease-specific 
instrument, a generic instrument and additional questions about the patients’ health, 
symptoms and experience. This dataset provides a new opportunity to explore and monitor 
variation in access and outcomes of elective surgery between groups. 
 
2. HES Admitted Patient Care dataset  
The HES database has been in existence since 1989 and records all patients currently 
admitted to NHS hospitals in England. It includes several separate datasets which cover 
hospital admissions, outpatient appointments, and A&E attendances in NHS hospitals. The 
data includes records of diagnoses and procedures during a patients stay in hospital and it 
is predominantly used to reimburse hospitals for the care they deliver. In this programme 
of work, only the HES Admitted Patient Care dataset was used.  
The unit of care in HES data is a single consultant episode of care (the total time a patient 
spends under the care of an individual consultant). The dataset, therefore, a large 
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collection of separate unique records of these episodes. A record can include data on 
diagnoses and operations, hospital site where the patients was admitted, patient 
characteristics, administrative information such as time waited, admission and discharge 
methods, and geographical information of where the patient lives.  
 
3. ONS mortality dataset 
ONS mortality data is a database of all deaths registered in England and Wales broken 
down by age, sex and cause of death. 
 
 Dataset linkage (RP3-6) 
The programme of research required linkage of all three datasets: HES Admitted Patient 
Care data, PROMs data and ONS mortality data.  PROMs data were linked with the 
corresponding HES episode for the hip or knee replacement procedure, historical and 
subsequent HES episodes (from 2003/04 to current) and ONS mortality data. Linkage to 
historical HES episodes was required to identify comorbidities recorded in HES and 
compare these with comorbidities reported in the pre-operative PROMs questionnaires.  
Linkage to subsequent HES episodes and ONS mortality data is required to identify patient 
outcomes following surgery (see further detail in Appendix J).  
The study population consist of patients who have undergone hip or knee replacement 
surgery and who have participated in the PROMs programme from April 2009 (programme 
start date) to November 2016. Patients were excluded if they do not have a linked HES 
episode for their PROMs procedure.  
Table 2 – Datasets used in RP3-6 
Research paper Datasets used 
RP3 - Identifying comorbidities - HES Admitted Patient Care data  
- Pre-operative (Q1) PROMs data 
RP4 - Access - HES Admitted Patient Care data  
- Pre-operative (Q1) PROMs data 
RP5 - Safety - HES Admitted Patient Care data  
- Pre-operative (Q1) PROMs data  
- ONS mortality data 
RP6 - Effectiveness - HES Admitted Patient Care data  
- Post-operative (Q2) PROMs data 
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2.3 Study Design 
This section provides a summary of the research design used in each chapter of the thesis. 
All studies described achieved their specific research objectives outlined above and have 
been presented in the form of six research papers (RP1-6). At the time of submission, two 
papers have been published, one is under review while three are in preparation for 
submission.   
 
RP1: “Impact of comorbid conditions on outcomes of hip and knee replacement surgery: 
a systematic review and meta-analysis.” 
See Chapter 3, Pages 37-48 
The first research paper (objective 1) was a systematic review and meta-analysis of 
published literature on 10 short-term and long-term outcomes after hip and knee 
replacement for patients with 11 different comorbidities. This involved the grouping of 
heterogeneous studies as definitions of outcomes and comorbidities varied. To make the 
results comparable and to be able to conduct any form of meta-analysis, some comorbid 
conditions were grouped together, outcomes were categorised as short and long-term, and 
continuous outcomes were converted to odds ratio using the Hasselblad and Hedges 
approach.  The systematic review was intended to inform the quantitative components, 
and understand the outcomes that were commonly measured after hip and knee 
replacement surgery.  The output of this study was a published research paper which is 
presented in chapter 3.   
 
RP2: “Comorbidities and the referral pathway to access joint replacement surgery:  An 
exploratory qualitative study” 
See Chapter 4, Pages 52-59 
The second research paper (objective 2) was a qualitative study exploring the referral and 
selection of patients with comorbidities for hip and knee replacement surgery. It involved 
interviews with healthcare professional along the referral pathway to joint replacement 
surgery. There was an endeavour to recruit a variety of different professionals including 
both men and women with a range of years of experiences and from both urban and rural 
settings. This qualitative study and the quantitative investigation of access (RP4) were 
intended to be complimentary and to inform each other. The qualitative study informed 
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the interpretation of the quantitative results by providing insight into the health-system 
factors at the pathway level which may influence access.  The output of this study was a 
published research paper which is presented in chapter 4.  
 
RP3: “The agreement between chronic diseases reported by patients and derived from 
administrative data in patients undergoing joint arthroplasty” 
See Chapter 5, Pages 63-81 
The third research paper (objective 3) was a methodological study exploring the agreement 
between patient-reported and hospital administrative-data derived comorbidities.  
Sensitivity and specificity of 11 patient-reported comorbidities were estimated with 
hospital administrative data as the reference standard. The challenge was how to best 
interpret these measures of agreement. This study was essential to develop a measure of 
comorbidity that would identify the list of comorbidities that would form the basis of the 
analysis in the subsequent three results chapters. The results of the analysis have been 
presented as a research paper which has been submitted for publication.   
 
RP4: “Patients with comorbidities have joint replacement surgery later in their joint 
disease based on patient-reported pain and functional status” 
See Chapter 6, Pages 85-109 
The fourth research paper (objective 4) analysed the impact of comorbidities on access to 
hip and knee replacement surgery by analysing differences in patient-reported pre-
operative functional status, pain and duration of joint problems just before surgery. If there 
were differences in access, we might expect to see differences in the severity of joint 
problems and in duration of problems just before surgery. Linear regression analysis was 
conducted comparing patients with and without comorbidities (adjusted for relevant case-
mix criteria). The challenge however, was how to account for the potential influence of 
comorbidities on the OHS/OKS score. Functional status and pain OHS/OKS scores were 
therefore investigated separately as pain is less likely to be influenced by comorbidities 
than functional status. The results of the analysis have been presented as a research paper 
which is in preparation for its submission.  
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RP5: “Impact of comorbidities on adverse outcomes after hip or knee arthroplasty: a 
study of 640 832 patients in England” 
See Chapter 7, Pages 113-136 
The fifth research paper (objective 5) explored the impact of comorbidities on a number of 
adverse outcomes that reflect safety of hip and knee replacement surgery. The literature 
on safety measures have predominantly focused on surgical complications and as result the 
focus was on health service use associated with adverse outcomes after surgery.  
Outcomes included mortality, emergency readmissions, transfers to another consultant 
and LOS.  Due to a low number of events, and the number of outcomes explored, individual 
outcomes were combined into a composite measure. The challenge of using a composite 
measure was then how to draw meaningful conclusions. Logistic regression analysis was 
conducted comparing patients with and without comorbidities while adjusting for relevant 
case-mix criteria. The results of the analysis have been presented as a research paper, 
which is in preparation for submission for publication.  
 
RP6: “The impact of comorbidities on the effectiveness of hip or knee replacement 
surgery: a national population-based study” 
See Chapter 8, Pages 140-161 
The sixth research paper (objective 6) explored the impact of comorbidities on the 
effectiveness of hip and knee replacement surgery. The challenge was what outcomes to 
choose that would reflect effectiveness. Primary outcomes related to effectiveness 
included severity of joint problems (OHS/OKS) and HRQoL (EQ-5D). Secondary outcomes 
included patient satisfaction with the results of the operation and overall improvement 
after hip or knee replacement surgery. Linear and logistic regression analysis was 
conducted comparing patients with and without comorbidities (adjusted for relevant case-
mix criteria). The findings are presented as a research paper, which is in preparation for 
submission for publication.   
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2.4 Ethics 
 Quantitative component 
Ethics approval from the Health Research Authority (HRA) Ethics Committee and the 
Confidentiality Advisory Group (CAG) was sought for the quantitative components. Ethics 
approval was sought because it was required as part of the data application to NHS Digital. 
Further approval, directly from ONS for mortality data, was also required because date-of-
death data is sensitive and can, potentially, be used to identify an individual.  PROMs data 
access itself did not require further ethics approval because the study population, as part of 
their participation in the PROMS programme, have explicitly consented for their data to be 
collected, used for research and linked to other data held by the NHS. All hospital 
admissions for patients undergoing hip and knee replacement surgery and who were 
participants in the PROMs programme included the request for consent, and while the data 
does not allow the patient to be identified, it was important to ensure adherence to 
confidentiality and data security.  
The data were received, managed, stored and analysed at the Clinical Effectiveness Unit (an 
academic collaboration between the Department of Health Services Research & Policy at 
LSHTM and the Royal College of Surgeons (RCS) of England). The data were stored in a 
restricted access folder on a secure server at the RCS. Only the minimum data that was 
required to carry out the analyses was requested from NHS Digital.  
Ethics Approval by the HRA Proportionate Review Sub-committee of the Wales REC 6 was 
granted on the 3 August 2016 (Reference: 211186). CAG approval was granted on 1 
September 2016 (Reference: 16/CAG/0113). Ethics approval was also sought from the 
London School of Hygiene & Tropical Medicine ethics committee and granted on the 3 
October 2016 (Reference: 11628) (see Appendix D for all approvals). 
 
 Qualitative component 
NHS Ethics approval was also sought for the qualitative study at the same time as the 
quantitative study. This was because NHS staff might have been interviewed on NHS 
premises.  One NHS Ethics application was submitted for both the quantitative and 
qualitative components.  
All participants of the qualitative study were given all the information on the study and 
asked to sign a consent form before participating (see Appendix E and F). They were 
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reminded that they could opt out at any stage if they wished to. In addition, participants 
were assured that any quotes used from the transcripts would be reported anonymously. 
The qualitative data were stored on the secure server at London School of Hygiene & 
Tropical Medicine (LSHTM). Interview recordings and transcripts were anonymised, given 
an identification number, were password protected and stored securely on computers at 
LSHTM. The recording device were wiped clean after transcription, and paper transcripts 
stored in locked secure boxes at LSHTM which were then destroyed following completion 
of the study. Consent forms were stored separately and only accessed by the research 
team.  
 
2.5 Patient and Public Involvement 
Prior to commencing this programme of research, the protocol was assessed for relevance 
and appropriateness by patient representatives on the National Institute for Health 
Research (NIHR) Collaboration for Leadership in Applied Health Research and Care 
(CLAHRC) North Thames Patient and Public Involvement committee. Their comments, 
which specifically related to the approach to recruitment of healthcare professionals to the 
qualitative study, the selection of outcomes that were relevant to patients as well as the 
interpretation of access, were incorporated in the protocol and guided further analysis.  
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3 RESULTS CHAPTER – Systematic Review 
 
The first component of this programme of research was a systematic review and meta-
analysis assessing the outcomes of elective hip and knee replacement surgery for patients 
with different comorbidities. The results have been presented in the form of a published 
research paper. The supplementary information referred to in the paper is available in 
Appendix C.  
 
Title: Impact of comorbid conditions on outcomes of hip and knee replacement surgery: a 
systematic review and meta-analysis 
 
The online PDF version can be accessed at:  
https://bmjopen.bmj.com/content/8/7/e021784.info 
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3.1 Research Paper 1 (RP1) 
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4 RESULTS CHAPTER – Qualitative Study 
 
The second component of this programme of research was a qualitative study exploring 
how patients with comorbidities are referred and selected for elective hip and knee 
replacement surgery.  The results have been presented in the form of a published research 
paper. The supplementary information referred to in the paper is available in Appendix G 
(Interview Topic Guides). 
 
Title: Comorbidities and the referral pathway to access joint replacement surgery:  An 
exploratory qualitative study 
 
The online PDF version can be accessed at: 
https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-018-3565-0 
 
 
Further additional information can be found in the appendix: 
Appendix D – Ethics approval  
Appendix E – Participant Information Sheet  
Appendix F – Consent form  
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4.1 Research Paper 2 (RP2) 
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5 RESULTS CHAPTER – Identifying comorbidity 
 
The third component of this research programme investigated the agreement between 
patient-reported and administrative data-derived comorbidities. The results have been 
presented in the form of the submitted research paper.  The supplementary material 
referenced to in the paper can be found in Appendix I (mapping of comorbidities).   
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5.1 Research Paper 3 (RP3) 
 
The agreement between chronic diseases 
reported by patients and derived from 
administrative data in patients undergoing 
joint arthroplasty 
 
 
Bélène Podmore MPH1,2, Andrew Hutchings MSc1,2, Sujith Konan MD3,  Jan van der Meulen 
PhD1,2 
 
1. Department of Health Services Research & Policy, London School of Hygiene & 
Tropical Medicine, UK, 15-17 Tavistock Place, WC1H 9SH 
2. Clinical Effectiveness Unit, The Royal College of Surgeons of England, UK, 35-43 
Lincoln’s Inn Fields, WC2A 3PE. 
3. University College London Hospitals NHS Foundation Trust, UK, 235 Euston Rd, 
NW1 2BU 
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 Abstract  
 
Background: This study examined the agreement between patient-reported chronic 
diseases and hospital administrative records in hip or knee arthroplasty patients in England. 
 
Methods: Survey data reported by 676 428 patients for the English Patient Reported 
Outcome Measures (PROMs) programme was linked to hospital administrative data. 
Sensitivity and specificity of 11 patient-reported chronic diseases were estimated with 
hospital administrative data as reference standard. 
 
Results: Specificity was high (>90%) for all 11 chronic diseases. However, sensitivity varied 
by disease with the highest found for ‘diabetes’ (87.5%) and ‘high blood pressure’ (74.3%) 
and lowest for ‘kidney disease’ (18.8%) and ‘leg pain due to poor circulation’ (26.1%). 
Sensitivity was increased for diseases that were given as specific examples in the 
questionnaire (e.g. ‘parkinson’s disease’ (65.6%) and ‘multiple sclerosis’ (69.5%), compared 
to ‘diseases of the nervous system’ (20.9%)). 
 
Conclusions: Patients can give accurate information about the presence of chronic diseases 
if the description in the patient questionnaire is precise and if the disease is familiar to 
most patients and has significant impact on their life. Such patient questionnaires need to 
be validated before they are used for research and service evaluation projects. 
 
  
65 
 
 Background 
Patient surveys are often used in epidemiology to collect health data. However, the 
reliability and accuracy of patient-reported data, including patients’ own accounts of 
whether or not they have been diagnosed with a particular chronic disease, have been 
questioned [1]. Administrative data – hospital data collected for a range of administrative 
purposes including managing payments to the healthcare providers for every hospital 
admission and procedure – offer an alternative source of data [2]. 
To be able to record accurately chronic diseases is essential. Healthcare providers depend 
on accurate coding to be reimbursed for the care they provide especially when treating 
complex patients with multiple chronic diseases.  In patients undergoing hip and knee 
arthroplasty the number of complex patients is likely to rise with more than 60% of 
patients for these operations reporting at least one comorbid chronic disease [3]. This 
number is expected to continue to rise as the number of people living with multiple chronic 
diseases is on the increase [4].  In addition, good quality coding is essential when looking at 
outcomes of hip and knee arthroplasty which may be affected by chronic diseases and 
analyses must therefore adjust for this effect.  
Few studies have assessed the accuracy of patient-reported chronic diseases compared to 
chronic diseases derived from administrative data [5-7]. The studies that did were 
predominantly cohort studies with relatively small sample sizes that reported single 
measures of agreement, such as the kappa statistic [1, 8]. A few larger scale studies 
investigated the agreement of a small number of patient-reported chronic diseases, with 
the most common being high blood pressure, stroke, heart disease and diabetes [5-7]. 
These studies found results for the agreement between patient-reported chronic diseases 
and hospital administrative data to vary significantly [1, 9-11]. 
We used the national Patient-Reported Outcome Measures (PROMs) programme of the 
English National Health Service (NHS), one of the largest collections of patient-reported 
data in the world, to assess the agreement of patient-reported chronic diseases against 
disease condition derived from hospital administrative data in patients undergoing hip or 
knee arthroplasty. 
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 Methods 
 
Study sample  
The study sample of 676 428 patients was drawn from patient-reported data collected by 
the national PROMs programme in the English NHS [12]. All hospitals providing elective hip 
or knee arthroplasty funded by the English NHS are required to participate and patients are 
asked to complete pre-operative and post-operative questionnaires about their hip or knee 
condition and general health. 
The data sample comprised completed pre-operative questionnaires linked with routinely 
collected administrative hospital data, Hospital Episode Statistics (HES) data, on all patient 
who had a hip or knee arthroplasty carried out in the English NHS between April 2009 and 
March 2016. The HES database contains a record of every inpatient hospital admission in 
the English NHS and is used primarily for reimbursement purposes [13]. A linked pre-
operative PROMs questionnaire and HES record is available for 71% of eligible hip and knee 
arthroplasties [12]. 
We created a dataset comprising one unique linked patient-reported record for each 
individual patient. Duplicate records were excluded if more than one pre-operative 
questionnaire was linked to a procedure or more than one procedure in HES was linked to 
the same questionnaire. The first linked HES record for each patient was included but 
linked records for any subsequent procedures were excluded. Patients were also excluded 
if they reported seven or more comorbidities in the preoperative PROMs questionnaire due 
to the concerns about the validity of the responses. Patients appeared to report the 
absence rather than the presence of a chronic disease. 
 
Chronic disease according to the PROMs programme  
In the PROMs pre-operative questionnaire patients were asked: ‘Have you ever been told 
by a doctor that you have any of the following conditions? Heart disease (for example 
angina, heart attack or heart failure), high blood pressure, problems caused by stroke, leg 
pain when walking due to poor circulation, lung disease (for example asthma, chronic 
bronchitis or emphysema), diabetes, kidney disease, diseases of the nervous system (for 
example, Parkinson’s disease or multiple sclerosis, liver disease, cancer (within the last 5 
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years), depression, [or] arthritis’. ‘Arthritis’ was excluded from our analyses because it is 
the primary a reason for hip or knee arthroplasty (81% patients reported having arthritis).  
 
Chronic disease according to administrative data  
The 11 patient-reported chronic diseases were identified within HES data using 
International Classification of Disease (ICD-10) codes from the corresponding linked HES 
record of the hip or knee arthroplasty and from HES records of any other hospital 
admission within the previous 12 months or five years. Each HES record includes up to 20 
ICD-10 diagnosis codes.  
The initial set of ICD-10 codes for each of the 11 chronic diseases was derived from three 
chronic disease indices that have been used to identify chronic diseases in administrative 
data: The Royal College of Surgeons of England Charlson Comorbidity Index (RCS CCI) [14], 
the Quan Charlson Comorbidity Index (Quan CCI)[15] and the Elixhauser Comorbidity index 
[16]. The RCS CCI was chosen because it was designed to predict outcomes in surgical 
patients and has been validated for total hip arthroplasty using English HES data [14]. The 
Quan CCI is an adaptation of the Deyo CCI [15], and was chosen because it uses ICD-10 
coding and is similar to other CCI adaptations in predicting both short-term and long-term 
mortality [17]. The Elixhauser Comorbidity Index was chosen because there is evidence that 
it may predict mortality better than other adaptations of the CCI [18]. 
The set of ICD-10 codes derived from the three chosen comorbidity indices were then 
mapped to the 11 diseases included in the PROMs questionnaire (see supplementary 
material). A further 16 ICD-10 codes were added to the chronic disease mapping through 
the process of ‘backward coding’. ‘Backward coding’ involved reviewing linked HES records 
of hospital admissions in patients who had reported a chronic disease but who had no 
mapped records (ICD-10 codes) of the chronic disease in their HES records. First, relevant 
ICD-10 chapters were identified for each of the 11 chronic diseases. The most common 
(>1% of patients reporting the chronic disease) and clinically relevant codes at the ICD-10 
three-character category level were then identified. Second, the codes identified at the 
ICD-10 three-character level were further investigated at the ICD-10 four-character 
subcategory level. The prevalence of each four-character code in the administrative data 
were compared between patients who had and those who had not reported a specific 
chronic disease. The four-character code was added to the mapped ICD-10 codes if the 
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proportion of patients reporting presence of a chronic disease was at least twice that in 
patients not reporting the chronic disease. For the main analyses, this final set of codes was 
used to determine the presence of chronic disease according to administrative data from 
the corresponding linked hospital record and from records of admissions within the 
previous 12 months or five years. 
 
Statistical analysis 
The patient-reported chronic diseases at the point of surgery were compared with 
recorded diagnoses in the corresponding administrative record of the linked hospital 
admission and the records of previous admissions in two ways. First, agreement between 
patient-reported and administrative records was evaluated using sensitivity and specificity 
with administrative data as the reference standard. Second, we calculated the kappa 
statistic as an alternative measure of the agreement between patient-reported and 
administrative data for each condition. The kappa statistic is an agreement measure that 
takes into account chance agreement. A value of one indicates perfect agreement and a 
value of zero indicates no agreement above that expected by chance. Kappa values are 
often categorised in the following way: < 0.40 ‘poor agreement’, 0.40-0.60 ‘moderate 
agreement’, 0.61-0.80 ‘substantial agreement’, and 0.81 – 1.00 ‘near perfect agreement’ 
[19]. 
The sensitivity of patient-reported chronic disease was also explored further at the chronic 
disease subcategory level derived from administrative data.  We grouped the set of ICD-10 
codes for each of the 11 comorbid conditions according to clinically relevant subcategories 
(see supplementary material). ICD-10 codes were grouped according to whether they 
reflected a cause (e.g. subarachnoid haemorrhage), a manifestation (e.g. asthma), or a 
consequences of disease (e.g. renal failure). For each comorbid condition ICD-10 codes that 
did not fit into any these grouping, the codes were put into an ‘other’ group. The sensitivity 
of the patient-reported chronic diseases compared to these chronic disease subcategories 
derived from administrative data were presented in a forest plot.  
 
Sensitivity analysis  
The impact of the length of the look-back period on the performance of the combined 
chronic disease measure in administrative data was also investigated [20-22]. Some chronic 
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diseases such as ‘heart disease’ are diseases that can fluctuate and others, such as ‘stroke’ 
are single events. For that type of chronic diseases, a longer look-back ensures that records 
of chronic diseases coded in admissions that occurred further in the past are also captured. 
In the PROMs questionnaire, patients were asked to recall cancer within the last five years 
which is another reason to use a 5-year look-back period as an alternative to the one-year 
look-back period. 
 
 Results  
 
Study sample  
Agreement between chronic disease measures reported by patients and derived from 
administrative data was examined in 676 428 patients who underwent a hip or knee 
arthroplasty between 2009 and 2016 in the English NHS and who participated in the 
PROMs programme from a total 791 369 linked records. Records were excluded for the 
following reasons: duplicate pre-operative questionnaires (10 762), duplicate HES 
procedures (140), subsequent procedures for patients included in the analyses (103 395), 
and patients reporting seven or more chronic diseases on their pre-operative questionnaire 
(644) (see Figure 1). 50.6% of the patients underwent knee arthroplasty. The average age 
of the population was 68 years (18-105). The majority of the patients had a white ethnic 
background (86.3%) and 58.0% of the study cohort were female (see Table 1). Patients 
living in the most socioeconomically deprived areas were slightly under-represented in the 
sample: those in the bottom two deprivation groups based on quintiles made up only 
34.5% of patients undergoing a primary hip or knee arthroplasty whereas 40% is expected 
given that the quintiles reflect the national distribution. 
 
Agreement between patient-reported chronic disease and administrative data 
Sensitivity, specificity, and the kappa statistic for patient-reported chronic disease against 
chronic diseases derived from administrative data using a 1-year look-back are reported in 
Table 1. Patient-reported chronic diseases had high specificity (ranging between 90.3% for 
‘high blood pressure’ and 99.7% for ‘disease of the nervous system’ and ‘liver disease’), but 
sensitivity varied (ranging from 18.8% for ‘kidney disease’ to 87.5% for ‘diabetes’). 
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According to the kappa statistic, there was ‘substantial agreement’ between patient-
reported and administrative results for ‘high blood pressure’ (κ =0.65) and ‘almost perfect 
agreement’ for ‘diabetes’ (κ =0.88) (see Table 2). There was ‘moderate agreement’ for 
‘heart disease’ (κ =0.54) and ‘lung disease’ (κ =0.55). In contrast, there was ‘poor 
agreement’ for ‘stroke’, ‘liver disease’, ‘leg pain due to poor circulation’, ‘kidney disease’ 
and ‘depression’.  
 
Agreement between patient-reported chronic diseases and chronic disease subcategories 
derived from administrative data 
Further investigation comparing patient-reported chronic disease against chronic disease 
subcategories derived from administrative data demonstrated that the sensitivity varied if 
the patient-reported results were compared against subcategories defined according to 
administrative data (see Figure 2). Sensitivity ranged from 1.3% for patient-reported ‘leg 
pain due to poor circulation’ compared against ‘gangrene’ according to administrative data 
to 91.6% for patient-reported ‘diabetes’ compared against ‘insulin-dependent diabetes’ 
according to administrative data. 
The sensitivity was considerably higher in subgroups of chronic diseases where specific 
examples of the chronic diseases were given as examples in the questionnaire used for the 
PROMs survey in the PROMs survey. For example, we saw that the sensitivity of ‘diseases 
of the nervous system (for example Parkinson’s disease or multiple sclerosis)’ was much 
higher in subgroups of patients who had these two specific diseases quotes as examples in 
their administrative data (65.6% and 69.5%, respectively) than in entire group of patients 
who had the generic term ‘diseases of the nervous system’ in the administrative data 
(20.9%). We saw a similar effect for the examples given in ‘heart disease (for example 
angina, heart attack or heart failure)’. The sensitivity in the subgroup of patients with the 
specific term ischemic heart disease in the administrative data was significantly higher 
(64.9%) than in all patients who had the generic term ‘heart disease’ according to 
administrative data (46.4%). 
 
Impact of length of look-back period on agreement 
The impact of the length of look-back period on the chronic diseases derived from 
administrative data was investigated. Increasing the look-back period for identifying 
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chronic diseases in administrative data from 12 months to five years had little impact on 
the sensitivity, specificity and kappa statistic (see Table 3). As expected, sensitivity 
decreased and specificity increased. The biggest change was the increase of the kappa 
statistic for ‘cancer’ from 0.37 with a 12-month look-back period to 0.69 with a 5-year look-
back period.  
 
 Discussion 
In this large study of patients undergoing hip or knee arthroplasty we determined that for 
11 patient-reported chronic diseases specificity was high but sensitivity varied greatly when 
the patient-reported results were compared to administrative data. Specifically, sensitivity 
was highest for ‘diabetes’ and ‘high blood pressure’ and lowest for ‘leg pain due to poor 
circulation’ and ‘stroke’. The variation in sensitivity also differed further when the patient-
reported chronic diseases were compared against chronic diseases subcategories derived 
from administrative data. Sensitivity is high if the description of the chronic disease in the 
patient questionnaire is precise and uses language familiar to most patients, if it requires 
daily treatment or drug administration for the patient, or the chronic diseases has a 
significant impact on patient’s lives. 
Sensitivity was high for comorbid conditions that describe a specific disease diagnosis (in 
terms of a cause, manifestation, or disease consequence) rather than a collection of 
symptoms. This might explain why ‘diabetes’ had higher sensitivity than ‘leg pain due to 
poor circulation’ and ‘problems caused by stroke’. Similarly, when looking at disease 
subcategories, sensitivity was higher when specific examples of chronic diseases were given 
in the PROMS questionnaire survey rather than the generic category for the chronic 
disease. This demonstrated that if a disease has a spectrum of severity, subcategories may 
be more useful categories to use to ask patients about the presence of any chronic 
diseases. 
While specificity was generally high for all chronic diseases, it did vary by up to 10%. It is 
important to note that administrative hospital data, HES, is not a perfect reference 
standard. Certain chronic diseases may not be fully recorded in administrative data 
because they may not be severe enough to significantly alter the treatment a patient 
receives in hospital or influence the hospital’s resource use related to a patient’s care. 
Further coding errors in hospital administrative data can also occur as coding is often 
undertaken by administrative staff who depend on medical notes so any errors in the notes 
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can lead to chronic diseases not being captured. On the other hand, conditions that are 
single events in time such as stroke and ischemic heart diseases may not be recorded in 
administrative data due to a limited look-back period [23-25]. Nevertheless, when we 
increased the look-back period from 12 months to five years there appeared to be little or 
no impact on sensitivity of patient-reported chronic disease relative to administrative data. 
An increase of the duration of the look-back period to five years did improve the 
agreement for cancer but this may just be a reflection of the PROMs question, which asked 
patients to report ever being diagnosed with cancer in the last five years. 
A study comparing patient-reported chronic disease against chart review suggested that 
low agreement, especially low sensitivity, may be due to the description of the conditions 
in the patient questionnaire, for example if the wording is based more on symptoms (‘leg 
pain due to poor circulation’) than disease (‘diabetes) or if the disease has stable or only a 
few symptoms (e.g. ‘kidney disease’) [26]. Similarly, previous studies found that conditions 
requiring ongoing management such as diabetes or hypertension had highest agreements 
in comparison to poorly defined diseases such as stroke or congestive heart failure [5-7, 
27]. 
With respect to the impact of the length of the look-back period, other studies had similar 
findings to ours in that they found limited benefits in increasing the look-back period 
beyond one year [6, 27]. 
These findings provide support for the use of patient-reported data to identify patients 
with chronic diseases if administrative data are unavailable. The questionnaire should 
however be validated beforehand with patients to ensure clarity, comprehension and ease 
of completion. This is especially important to improve the capture of less common and 
more complex chronic diseases such as kidney disease or diseases of the nervous system.  
There are several limitations to this study. As is the case for any cohort study the 
generalisability of our conclusions are limited by the characteristics of our population and 
the quality of the data. The PROMs questionnaires were completed by patients who 
underwent hip or knee arthroplasty and as a consequence, these patients were likely to 
have fewer and less severe chronic diseases than a population of older patients with 
arthritis because more severe cases are less likely to be eligible for surgery [28]. Disease 
status is often not clear-cut and the recording in hospital administrative data – our 
reference standard – will often be based on a ‘cut-off point’ with most misclassification 
occurring in those patients with a true disease status close to the cut-off point. The 
73 
 
combination of a relatively low prevalence and mild severity may therefore partly explain 
our finding of relatively low sensitivities and high specificities [29]. 
 
 Conclusion 
This study indicates that patients can give accurate information about the presence of 
chronic diseases. The sensitivity and specificity of patient-reported chronic disease can be 
high if the description in the patient questionnaire is precise and familiar to most patients 
and if the conditions have a specific impact on the patients’ lives. These findings may guide 
the development of questionnaires that can be used to ask patients whether or not they 
have particular chronic diseases. 
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 Figures and Tables 
 
Figure 1 - Flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 - Characteristic of PROMs study population (N=676,428) 
 Number (%) 
Age (mean, range) 69 (18-105) 
Gender 
Male  283 892 (42.0) 
Female  392 107 (58.0) 
Missing, not stated  429 (0.06) 
Socioeconomic status by quintile group 
1 (least deprived) 
151 850 (22.5) 
2 
159 353 (23.6) 
3 
125 160 (18.5) 
4 
118 487 (17.5) 
5 (most deprived) 
114 691 (17.0) 
Missing, not stated 
6 887 (1.02) 
Ethnicity 
White or White British 583 674 (86.3) 
Mixed background 1 469 (0.22) 
Asian or Asian British 12 126 (1.79) 
Black or Black British 5 377 (0.79) 
Chinese or other ethnic  2 991 (0.44) 
Missing, not stated 70 791 (10.5) 
 
PROMs  
N (791,369) 
Duplicates removed 
Q1 survey responses (10,762) 
HES episodes (140) 
 
Linked to HES records 
N (780,462) 
Excluded cases 
Not primary surgery (103,395)  
Coding errors (644) 
Analysis Sample 
N (676,428) 
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Table 2 – Sensitivity and specificity of patient-reported chronic diseases relative to chronic diseases derived from administrative data (1-year look-back) (N=676,428) 
Chronic disease Patient-
reported 
n (%) 
Administrative 
n (%) 
Prevalence in either patient-reported or administrative 
data, n (%) 
Sensitivity 
(%) 
Specificity 
(%) 
Kappa 
(κ) 
Both Admin 
only 
Patient-
reported 
only 
Neither 
Heart disease 67 425 
(9.97) 
122 219 
(18.1) 
56 736 
(8.39) 
65 460 
(9.68) 
10 689 
(1.58) 
543 543 
(80.4) 
46. 4 98.1 0.54 
High blood pressure 
282 785 
(41.8) 
335 958 
(49.7) 
249 
608 
(36.9) 
86 350 
(12.8) 
33 177 
(4.90) 
307 293 
(45.4) 
74.3 90.3 0.65 
Stroke 11 126 
(1.64) 
7 348 
(1.09) 
2 367 
(0.35) 
4 981 
(0.74) 
8 759 
(1.29) 
660 321 
(97.6) 
32.2 98.7 0.25 
Leg pain due to poor 
circulation 
48 298 
(7.14) 
10 917 
(1.61) 
2 855 
(0.42) 
8 063 
(1.19) 
45 444 
(6.72) 
620 067 
(91.7) 
26.1 93.2 0.07 
Lung disease 55 717 
(8.24) 
100 260 
(14.8) 
46 876 
(6.93) 
53 384 
(7.89) 
8 841 
(1.31) 
567 327 
(83.9) 
46.8 98.5 0.55 
Diabetes 75 998 
(11.2) 
78 816 
(11.7) 
68 952 
(10.2) 
9 864 
(1.46) 
7 046 
(1.04) 
590 566 
(87.3) 
87.5 98.8 0.88 
Kidney disease 12 435 
(1.84) 
36 823 
(5.44) 
6 910 
(1.02) 
29 913 
(4.42) 
5 542 
(0.82) 
634 080 
(93.7) 
18.8 99.1 0.26 
Diseases of the 
nervous system 
5 840 
(0.86) 
19 550 
(2.89) 
4 092 
(0.60) 
15 458 
(2.29) 
1 748 
(0.26) 
655 130 
(96.9) 
20.9 99.7 0.31 
Liver disease 3 585 
(0.53) 
4 120 
(0.61) 
1 412 
(0.21) 
2 708 
(0.40) 
2 173 
(0.32) 
670 135 
(99.1) 
34.3 99.7 0.36 
Cancer 32 384 
(4.79) 
12 710 
(1.88) 
8 740 
(1.29) 
3 970 
(0.59) 
23 644 
(3.50) 
640 074 
(94.6) 
68.8 96.4 0.37 
Depression 61 589 
(9.11) 
29 923 
(4.42) 
18 263 
(2.70) 
11 660 
(1.72) 
43 326 
(6.41) 
603 179 
(89.2) 
61.0 93.3 0.36 
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Table 3 - Sensitivity and specificity of patient -reported chronic disease relative to chronic disease derived from 
administrative data using a 5-year look-back period. 
Chronic disease Prevalence 
n (%) 
Sensitivity  
(%) 
Specificity  
(%) 
 
Kappa 
(κ) 
Heart disease 141 457 (20.9) 43.0 98.8 0.52 
High blood pressure 358 699 (53.0) 72.3 92.7 0.64 
Stroke 15 783 (2.33) 30.3 99.0 0.34 
Leg pain due to poor circulation 17 728 (2.62) 24.1 93.3 0.10 
Lung disease 112 774 (16.7) 43.6 98.8 0.53 
Diabetes 82 384 (12.2) 85.6 99.1 0.88 
Kidney disease 45 172 (6.68) 17.1 99.3 0.25 
Diseases of the nervous system 24 727 (3.66) 17.4 99.8 0.27 
Liver disease 7 173 (1.06) 24.6 99.7 0.32 
Cancer 31 649 (4.68) 71.2 98.5 0.69 
Depression 38 503 (5.69) 58.4 93.9 0.41 
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Figure 2 - Forest plot of sensitivity by chronic disease subcategories derived from administrative data (95% 
CI) 
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6 RESULTS CHAPTER – Access 
 
The fourth component of this research programme investigated the impact of 
comorbidities on the access to elective hip and knee replacement surgery.  Specifically the 
study looked at severity of joint problems (functional status and pain) and duration of 
symptoms just before surgery. This study worked with the assumption that if there were 
differences in access we might expect differences in severity of joint problems and the 
duration of these joint problems just before surgery. The results have been presented in 
the form of a research paper.  Supplementary information can be found at the end of the 
section.  
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 Abstract  
 
Background: An increasing number of patients with comorbidities are undergoing joint 
replacement surgery.  Comorbidities may delay access to surgery. If that is the case, pain, 
functional status and duration of joint problems just before surgery may vary according to 
comorbidities. 
 
Methods:  We analysed data reported by 640 832 patients who had hip or knee surgery 
between 2009 and 2016 in England.  Multivariable regression was used to estimate impact 
of 11 comorbidities on symptom severity as measured by the Oxford Hip (OHS) and Knee 
Score (OKS), ranging from 0 (worst) to 48 (best), just before surgery and on likelihood of 
having long-standing joint problems.   
 
Results: Patients with comorbidities reported more severe symptoms compared to patients 
without (OHS differences ranged from 1.1 to 2.5 and OKS differences from 0.5 to 2.6 for the 
11 comorbidities). Differences were observed for pain and for functional status when 
examined. Evidence for increased likelihood of long-standing problems was less consistent 
and observed in 6 out of 11 comorbidities in hip patients and 2 of 11 in knee patients.  
 
Conclusions: Patients with comorbidities reported more severe joint problems just before 
surgery which suggests they may have joint replacement later in the course of their joint 
disease. 
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 Introduction  
Hip and knee replacement surgery is one of the most common and effective surgeries, 
improving quality of life significantly [1]. Previous research has reported inequalities in 
access to hip and knee replacement surgery according to socioeconomic status [2], sex [3-
5], insurance status [6], ethnicity [7], and geography [8], but less attention has been given 
to the impact that comorbidities might have on access.  
Variation in access may be explained in part by the lack of consensus amongst clinicians 
with respect to the clinical indications for joint replacement surgery [9-12].  In addition, in 
England as well as in Canada, eligibility criteria restricting access to hip and knee 
replacement surgery have recently been introduced to limit inappropriate use of joint 
replacement surgery and reduce healthcare cost [13, 14]. In England, eligibility criteria such 
as severity of preoperative functional status [15] and pain [13], the requirement that a 
patient’s body mass index is lower than 30kg/m2 [16], and the optimisation of pre-existing 
comorbid conditions [17-19] have been imposed by some regional commissioners of 
healthcare. There is no evidence, however, to suggest that limiting access according to any 
of these criteria is justified and these policies are not supported by National Institute for 
Health and Care Excellence (NICE) guidelines [20].  
Previous research investigating variation in access to joint replacement surgery has used 
two different approaches to measuring access. Some papers have measured access 
indirectly from a population perspective by focusing on those not receiving surgery and 
seek to measure unmet need [21-23]. Others have looked at those who do have surgery, 
studying variation in utilisation of surgery according to factors such as regional variation 
[24] or socioeconomic status [25]. The Patient Reported Outcome Measures (PROMs) 
programme in England has provided a new opportunity to explore access as it provides 
information on severity of joint problems and duration of joint problems just before 
surgery. If there were differences in access, we might expect to see differences in severity 
of joint problems and in duration of problems just before surgery according to the presence 
of comorbidity. A similar approach has been used before to look at the impact of 
socioeconomic status [25] in joint replacement patients and patients with heavy menstrual 
bleeding referred to secondary care [26] and found that patients from a lower 
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socioeconomic status reported more severe symptoms which suggest delayed access to 
secondary care.    
Severity of joint problems is typically measured using disease-specific measures such as the 
Oxford Hip (OHS) and Knee (OKS) score. The challenge of these measures, which are 
designed to only assess the severity of the hip or knee problem, is that they may be 
capturing the impact of both joint problems and comorbidities [27-29]. To further explore 
this influence we looked at functional status and pain scores separately. We hypothesised 
that pain is more ‘joint-specific’ than functional status and that it is less likely to be 
influenced by comorbidities. In this paper, we examine associations of the severity of joint 
problems (pain and functional status), and duration of joint problems in patients with 
different individual comorbidities just before the hip or knee replacement surgery. 
 
 Methods 
 
Data sources 
We used data from the England’s national Patient Reported Outcome Measures (PROMs) 
programme for elective hip and knee replacement surgery. All NHS providers are required 
to participate and patients are asked to report their physical functioning and wellbeing at 
the preoperative assessment clinic or on admission to hospital and then again six months 
after surgery. Over 75% of eligible patients complete the preoperative questionnaire and 
the OHS/OKS [30]. The PROMs data were linked at patient level to data from the Hospital 
Episode Statistics (HES) database. HES contains administrative records of all admissions to 
all NHS hospitals in England. Eligibility was restricted to the first primary replacement 
surgery (see Figure 1).  
 
Defining comorbidities  
The 11 comorbidities that were included in the analysis were defined using ICD-10 codes in 
the linked hospital admissions HES data up to one year prior to the surgery. The 11 
comorbidities comprised heart disease; high blood pressure; problems caused by a stroke; 
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leg pain when walking due to poor circulation; lung disease; diabetes; kidney disease; 
nervous system disease; liver disease; cancer and depression.  These comorbidity 
categories are used in the PROMs questionnaire and are based on the work of Bayliss et al 
[31]. These comorbidity categories were used because it allowed for comparison with a 
combination of already existing ICD-10 diagnosis-based comorbidity indices. 
 
Measures 
We used the OHS and the OKS as our measures of severity of joint problems just before 
surgery. These are derived from patient responses to 12 questions about pain and limits on 
physical functioning and everyday activities caused by the hip or the knee (see 
supplementary information). Responses to each question are measured on a five-point 
scale, and values associated with each response are added up to produce an overall scale 
from 0 (worst) to 48 (best). The OKS and OHS have been validated and found to correlate 
with surgeon assessment of symptoms [32, 33].  
We also considered the questions related to pain and those related to functional status 
separately. We hypothesised that any impact of comorbidities was more likely to influence 
functional status rather than pain. This approach has been used before to predict patient 
satisfaction after hip and knee replacement surgery [34]. For the OKS, scores for the five 
questions on pain were added together as were those for the seven on functional status 
(see supplementary information). For the OHS, there were six questions each on pain and 
functional status.  
A categorical measure of symptom duration was derived from responses to a single 
question asking patients how long they had experienced problems with the hip or the knee 
on which they were about to have surgery. The four response categories included ‘Less 
than 1 year’, ‘1–5 years’, ‘6–10 years’, and ‘More than 10 years’. We defined long-standing 
hip or knee symptoms as problems with a duration of symptoms of more than 5 years.  
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Statistical analysis 
We estimated adjusted differences in mean preoperative pain and functional status using 
multivariable linear regression and calculated the mean scores according to the presence 
or absence of each comorbidity. We also estimated odds ratio (ORs) for having long-
standing hip or knee problems for each comorbidity using multivariable logistic regression. 
The impact of number of comorbidities (1, 2, 3, 4 or more comorbidities) on the severity of 
joint problems and duration of joint problems was also investigated to explore the effect of 
having multiple comorbidities.  
We adjusted for sociodemographic factors (age, sex, ethnicity and socioeconomic status) 
and other comorbidities. Information on age, sex, ethnicity and socioeconomic status [35] 
were derived from the HES records. Missing values for ethnicity, age, sex and 
socioeconomic status were imputed with chained equations. Analyses were run on each of 
the 10 imputed data sets and estimated parameters were combined using Rubin’s rules. 
Statistical results are presented with their 95% confidence interval and p-values. All 
statistical analysis were carried out using STATA V.15. 
 
 Results 
 
Patient characteristics  
640 832 patients were eligible (see supplementary material 1 and 3). The mean age was 68 
and 42% were male. About 3% of patients reported a minority ethnic background with 
Black or Black British being the largest group but there was a high percentage of missing 
data.  
Just before surgery, the mean score for symptom severity was 17.4 for the OHS and 18.3 
for the OKS. Nearly 20% of patients undergoing hip replacement and more than 40% of 
patients undergoing knee replacement had their joint problems for more than five years. 
Patients who reported long-standing problems tended to have more severe OHS and OKS 
scores but the average differences were small (less than one point).  
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The most common comorbidities were high blood pressure (52.8%), heart disease (17.8%), 
and lung disease (14.5%).  The least common comorbidity was liver disease (0.6%). 35% of 
patients had one comorbidity and 32% two or more. Of those with two comorbidities, 87% 
had high blood pressure and 37% had heart disease. Of those patients with three 
comorbidities, 94% had high blood pressure, 62% had heart disease and 42% had diabetes. 
Of those patients with four or more comorbidities, 97% had high blood pressure, 80% had 
diabetes and 58% had lung disease.  
 
Severity of joint problems 
Patients with any of the 11 comorbidities for both hip and knee replacement surgery 
reported more severe joint problems than patients without comorbidities just before 
surgery (see Table 1). For hip replacement, adjusted differences in severity of joint 
problems ranged from 1.06 (95% CI 0.93, 1.19) for kidney disease to 2.49 (95% CI 2.31, 
2.66) for diseases of the nervous system. For knee replacement surgery, adjusted 
difference in severity of joint problems ranged from 0.46 (95% CI 0.26, 0.66) for cancer 
patients to 2.58 (95% CI 2.42, 2.73) for patients with diseases of the nervous system.  The 
largest differences in severity of joint problems for both hip and knee replacement were 
reported by patients with diseases of the nervous system, depression and liver disease and 
the smallest differences for high blood pressure, cancer and kidney disease. 
We also performed regression modelling to establish the impact of comorbidities on pain 
and functional status scores separately. Patients with comorbidities reported not only 
worse functional status but also more pain just before surgery than patients without for 
each of the 11 comorbidities (see Table 2). Similar to the overall OHS and OKS score, the 
stronger impact on both functional status and pain scores was found in patients with 
diseases of the nervous system and depression and the lowest in patients with kidney 
disease and cancer.  
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Long-standing joint problems 
The likelihood of having long-standing hip or knee problems showed a mixed picture for 
patients with different comorbidities compared to patients without comorbidities (see 
Figure 1). For hip replacement surgery, patients with six out of the 11 comorbidities were 
more likely to have more long-standing problems compared to only two out of 11 
comorbidities for knee replacement surgery. In hip patients, the adjusted OR ranged from 
0.86 (95% CI 0.80, 0.93) for cancer to 1.17 (95% CI 1.07, 1.29) for stroke.  Patients with 
heart disease (OR 1.08, 95% CI 1.05, 1.11), diabetes (OR 1.14, 95% CI 1.10, 1.17) and stroke 
(OR 1.17, 95% CI 1.07, 1.29), were more likely to have long-standing problems.  In the case 
of knee replacement surgery only, patients with heart disease (OR 1.06, 95% CI 1.04, 1.08) 
and diabetes (OR 1.06, 95% CI 1.04, 1.09) were more likely to have long-standing problems. 
Patients with high blood pressure (OR 0.95, 95% CI 0.94, 0.96) and diseases of the nervous 
system (OR 0.84, 95% CI 0.81, 0.88) were less likely to have long-standing problems.  
 
Multiple comorbidities 
Severity of joint problems increased with the number of comorbidities after adjustment for 
age, sex, ethnicity and socioeconomic status (see Table 3). In hip replacement surgery, 
adjusted differences increased (worsened) from 1.45 (95% CI 1.38, 1.52) in patients with 
one comorbidity to 2.79 (95% CI 2.70, 2.87) for patients with two comorbidities. Patients 
with four or more comorbidities, with the most common combination being high blood 
pressure, heart disease, diabetes and lung disease, reported the largest adjusted 
differences (5.79, 95% CI 5.61, 5.96). In knee replacement surgery, adjusted differences 
indicated severity increased (worsened) from 1.06 (95% CI 0.99, 1.12) in patients with one 
comorbidity to 4.79 (95% CI 4.64, 4.94) for patients with four or more comorbidities. The 
same gradient was observed in knee replacement surgery patients and when looking at 
pain and functional status separately.  
The impact of the number of comorbidities on the likelihood of reporting long-standing 
problems was inconsistent. In hip patients, only patients with four or more comorbidities 
were more likely to report long-standing problems (OR 1.15, 95% CI 1.09, 1.23). In knee 
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patients, an increasing number of comorbidities had no impact on the likelihood to report 
long-standing problems. 
 
 Discussion 
 
Main findings of the study 
Patients with comorbidities undergoing hip and knee replacement surgery reported more 
severe joint problems just before surgery than patients without comorbidities. The largest 
differences in severity of joint problems were reported by patients with liver disease, 
depression and diseases of the nervous system.  These differences in severity of joint 
problems persisted even when considering pain and functional status scores separately. 
Patients with comorbidities reported not only worse functional status but also more pain 
just before surgery, suggesting patients with comorbidities have truly worse joint 
symptoms regardless of any direct influence of comorbidities on the validity of the disease-
specific measure. When looking at the number of comorbidities, the differences increased 
(worsened) with an increasing number of comorbidities. Patients with different 
comorbidities however reported little to no differences in duration of symptoms compared 
to patients without comorbidities. The differences in the likelihood of having long-standing 
problems were small and variable across all 11 comorbidities and the two surgical sites. 
Overall, the findings suggest that some patients with comorbidities may be having surgery 
later in their course of their joint disease and experience greater joint problems just before 
surgery than those without comorbidities.  
The observed differences in severity of joint problems were small but statistically 
significant for all of the 11 different comorbidities. To interpret the size of the difference, a 
possible comparison is with ‘minimally important differences (MID)’, the smallest 
important difference in scores that patients report as beneficial. Suggested MID values are 
five points for both the OHS and OKS [36]. Only hip and knee patients with four or more 
comorbidities reported a minimally important difference in scores compared to patients 
without comorbidities. 
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With regard to the variable impact of comorbidities on duration of symptoms, the 
inconsistency in results may be due to recall bias. Patients were asked, “How long they had 
experienced problems with the hip or the knee on which they were about to have 
surgery?” but patients may have reported the duration of symptoms of a most recent 
episode with a specific level of severity, rather than the overall duration [37].   
What is already known on this topic? 
Differences in symptom severity just before surgery have been suggested to reflect 
inequitable access to healthcare [25].  Little is known about the impact of comorbidities on 
access to surgery. Drawing on the evidence on the variation in access to joint replacement 
surgery according to other factors such as socioeconomic status [25] and geography [8], 
this variation has been explained by delays to surgery due to patient decision-making [38] 
or clinical decision-making [39-42].  
Delays to surgery may be due to patient decision-making such as the patients’ 
unwillingness to undergo surgery or health-seeking behaviour. A number of studies have 
reported differences in patient preferences and expectations for joint replacement surgery 
according to sex, ethnic group and socioeconomic status [38, 43, 44]. For example, some 
patients with comorbidities may decide not to want major surgery, which requires a long 
recovery period. Similarly, elderly people may prefer to delay surgery and manage the pain 
and the limited mobility [45]. Health-seeking behaviour and differences in thresholds for 
pain may also delay seeking clinical advice or having surgery. There is evidence that more 
deprived people tend to accept a higher threshold of chronic pain and functional limitation 
before having surgery [46].  
Delays to surgery may also reflect variation in clinical decision-making about the indications 
for replacement surgery [10, 41]. In two studies with different groups of healthcare 
professionals, comorbidities were reported to be reasons not to recommend patients for 
surgery due to the risks of surgery [42, 47]. In our previous work, we explored the views of 
healthcare professionals along the referral pathway to joint replacement about referring 
and selecting patients with comorbidities for joint replacement surgery [48]. Healthcare 
professionals reported that patients with comorbidities were often not ‘prepared’ for 
surgery due to their comorbidities not being controlled and their surgery were therefore 
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delayed and the patients sent back to GPs. Patients were then left to manage their own 
conditions before being reconsidered for surgery. This delayed access to surgery, as a result 
of the fragmented management of patients with comorbidities across the system, is likely 
to be reflected in the severity of joint problems and duration of these joint problems at the 
point of surgery [49]. 
What this study adds? 
This study is the first to examine the relationship between comorbidities and patient-
reported functional status, pain and duration of joint problems just before surgery in a 
routine representative sample of patients undergoing hip or knee replacement surgery. By 
considering functional status and pain scores separately, it was possible to further 
distinguish the impact of comorbidities on severity of joint problems. Patients with 
comorbidities reported not only worse functional status but also more pain suggesting they 
truly have more severe joint problems before surgery compared to patients without 
comorbidities. A further analysis of the number of comorbidities demonstrated that the 
difference between patients with and without comorbidities increases in importance with 
number of comorbidities.  
This study demonstrates there are differences in severity of joint problems just before 
surgery suggesting some patients with comorbidities are having joint replacement later in 
their joint disease.  Previous research suggests that differences in severity of joint problems 
just before surgery may be due to delays to surgery [25]. There are several plausible 
explanations for such delays. These may be related to patient decision-making such as 
patients’ unwillingness to undergo surgery [38] or clinicians’ differences in decision-making 
[42, 47]. The variation in clinical decision-making may also be linked to the eligibility criteria 
imposed by regional commissioners of healthcare to optimise comorbidities before 
surgery. 
Limitations of this study 
Our final sample represents 71% of all patients who had a hip or knee replacement in the 
NHS. While response rate to the PROMs survey is high, non-recruitment may lead to 
confounders being unevenly distributed between different groups of patients and hospitals 
[50]. To account for this, we controlled for hospital variation. This had a minimal impact on 
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the findings. In addition, there is evidence to suggest that a healthy-surgical patients effect 
is operating such that patients who are considered too high-risk, many of whom will likely 
suffer comorbidities, may not be selected for surgery [11]. As a result, our population may 
represent a healthier hip and knee replacement population with one or more comorbidities 
than a random sample from the general population with a similar comorbidity profile.  
There may also be unmeasured or unobserved confounders that are not accounted for that 
would make our sample relatively less frail. For example, indication for surgery may lead to 
the selection of less frail patients for surgery.  Due to the limitations of the clinical data 
available, it was not possible to account for any selection criteria. Such bias may explain the 
small difference in preoperative severity of joint problems between patients with and 
without comorbidities.  In addition, lack of information on behavioural risk factors such as 
smoking status and BMI meant it was not possible to ascertain whether any of the variation 
in severity of joint problems is due to variation in behavioural risk factors. Clinical data on 
the severity of the 11 comorbidities was also limited.  
The OKS and OHS measures are also not completely disease-specific. Previous studies have 
reported concerns that the OKS and OHS also capture the effects of comorbidity [27-29]. It 
was therefore important that we also looked at pain and functional status OHS/OKS scores 
separately as pain is considered to be more joint-specific.  
There may also be a risk of recall bias. With regards to duration of symptoms there is very 
limited literature on the accuracy of the reporting of symptom duration. Drawing on the 
evidence on the accuracy of retrospective symptom duration in patients presenting with 
lower back pain, symptom duration reporting is often found to be inconsistent [37, 51]. 
This may be due to the lack of clarity on the definitions of symptom duration and the use of 
unreliable questions to elicit information about symptom duration [37, 51].  As such, this 
may partly explain why the findings about the duration of symptoms were inconsistent.   
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 Conclusion 
Patients with comorbidities undergoing hip or knee replacement surgery reported more 
severe joint problems, and not only worse functional status but also more pain, just before 
surgery compared to patients without comorbidities. This suggests that patients with 
comorbidities have truly worse joint problems and it is not simply an effect of comorbidity 
on the disease-specific measure.  The differences in severity of symptoms increased 
(worsened) with the number of comorbidities. Patients with comorbidities reported little to 
no difference in the duration of symptoms which is likely due to patients reporting 
symptoms of a most recent specific level of severity, instead of the overall duration. The 
findings therefore suggest that patients with comorbidities may on average have surgery 
slightly later in the course of their joint disease. Some of these differences could be 
attributable to delays to surgery resulting from variation in patient decision-making or 
clinical decision-making.  
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 Figures and Tables 
Table 1- Pre-operative severity of joint problems (OHS/OKS) according to comorbidity (adjusted according to 
age, sex, ethnicity, SES, and other comorbidities) 
Comorbidity OHS total 
(0 worse and 48 best) 
OKS total 
(0 worse and 48 best) 
Mean 
score 
Adjusted difference 
(95% CI) 
P-value Mean 
score 
Adjusted difference 
(95% CI) 
P-value 
Heart disease      
No 17.7 -  18.4 -  
Yes 16.0 -1.29 (-1.37, -1.21) <0.001 17.6 -1.05 (-1.12, -0.98) <0.001 
High blood pressure      
No 18.2 -  18.9 -  
Yes 16.5 -1.22 (-1.29, -1.17) <0.001 17.8 -0.87 (-0.92, -0.81) <0.001 
Stroke      
No 17.4 -  18.3 -  
Yes 14.5 -1.39  (-1.67, -1.10) <0.001 16.2 -1.15 (-1.40, -0.89) <0.001 
Leg pain due to poor circulation     
No 17.4 -  18.3 -  
Yes 15.3 -1.28  (-1.50, -1.06) <0.001 17.4 -0.83 (-1.05, -0.62) <0.001 
Lung disease      
No 17.7 -  18.6 -  
Yes 15.6 -1.49  (-1.57, -1.41) <0.001 16.7 -1.21 (-1.28, -1.14) <0.001 
Diabetes      
No 17.6 -  18.5 -  
Yes 15.7 -1.31 (-1.41, -1.21) <0.001 16.8 -1.26 (-1.34, -1.18) <0.001 
Kidney disease      
No 17.5 -  18.3 -  
Yes 15.3 -1.06  (-1.19, -0.93) <0.001 17.1 -0.82 (-0.94, -0.71) <0.001 
Diseases of the nervous system     
No 17.5 -  18.4 -  
Yes 14.4 -2.49 (-2.66, -2.31) <0.001 15.5 -2.58 (-2.73, -2.42) <0.001 
Liver disease      
No 17.4 -  18.3 -  
Yes 14.0 -2.29 (-2.65, -1.93) <0.001 16.9 -1.30 (-1.64, -0.97) <0.001 
Cancer       
No 17.4 -  18.3 -  
Yes 16.4 -1.22 (-1.42, -1.03) <0.001 18.6 -0.46 (-0.66, -0.26) <0.001 
Depression       
No 17.5 -  18.4 -  
Yes 14.6 -2.07 (-2.21, -1.93) <0.001 15.3 -1.98 (-2.10, -1.85) <0.001 
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Table 2 – Pre-operative severity of joint problems (OHS/OKS) separated by functional status and pain (adjusted according to age, sex, ethnicity, SES and other comorbidities) 
Comorbidity OHS OKS 
Functional status (0 worst 24 best) Pain (0 worst 24 best) Functional status (0 worse and 28 best) Pain (0 worse 20 best) 
Adjusted difference (95% CI) P-value Adjusted difference (95% CI) P-value Adjusted difference (95% CI) P-value Adjusted difference (95% CI) P-value 
Heart disease        
No -  -  -  -  
Yes -0.68 (-0.72, -0.64) <0.001 -0.61 (-0.65, -0.57) <0.001 -0.70 (-0.74, -0.66) <0.001 -0.35 (-0.38, -0.32) <0.001 
High blood pressure        
No -  -  -  -  
Yes -0.69 (-0.73, -0.66) <0.001 -0.54 (-0.57, -0.50) <0.001 -0.59 (-0.62, -0.55) <0.001 -0.28 (-0.31, -0.26) <0.001 
Stroke         
No -  -  -  -  
Yes -0.81 (-0.96, -0.66) <0.001 -0.57 (-0.72, -0.43) <0.001 -0.84 (-1.00, -0.68) <0.001 -0.30 (-0.41, -0.19) <0.001 
Leg pain due to poor circulation        
No -  -  -  -  
Yes -0.62 (-0.74, -0.50) <0.001 -0.66 (-0.78, -0.55) <0.001 -0.59 (-0.73, -0.46) <0.001 -0.24 (-0.33, -0.15) <0.001 
Lung disease        
No -  -  -  -  
Yes -0.70, (-0.75, -0.66) <0.001 -0.79 (-0.83, -0.75) <0.001 -0.78 (-0.83, -0.74) <0.001 -0.43 (-0.46, -0.40) <0.001 
Diabetes        
No -  -  -  -  
Yes -0.72 (-0.77, -0.67) <0.001 -0.59 (-0.64, -0.53) <0.001 -0.84 (-0.89, -0.79) <0.001 -0.42 (-0.45, -0.38) <0.001 
Kidney disease        
No -  -  -  -  
Yes -0.60 (-0.67, -0.53) <0.001 -0.46 (-0.53, -0.39) <0.001 -0.57 (-0.65, -0.50) <0.001 -0.25 (-0.30, -0.20) <0.001 
Diseases of the nervous system        
No -  -  -  -  
Yes -1.48 (-1.57, -1.39) <0.001 -1.01 (-1.10, -0.91) <0.001 -1.87 (-1.96, -1.77) <0.001 -0.71 (-0.78, -0.65) <0.001 
Liver disease         
No -  -  -  -  
Yes -1.28 (-1.48, -1.08) <0.001 -1.01 (-1.20, -0.82) <0.001 -0.90 (-1.11, -0.69) <0.001 -0.41 (-0.55, -0.26) <0.001 
Cancer        
No -  -  -  -  
Yes -0.72 (-0.83, -0.61) <0.001 -0.50 (-0.61, -0.40) <0.001 -0.35 (-0.48, -0.22) <0.001 -0.11 (-0.20, -0.03) <0.001 
Depression        
No -  -  -  -  
Yes -1.12 (-1.19, -1.04) <0.001 -0.95 (-1.03, -0.88) <0.001 -1.31 (-1.38, -1.23) <0.001 -0.67 (-0.73, -0.62) <0.001 
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Figure 1 - Impact of comorbidities on long-standing joint problems (duration> 5 years) (95% CI) (adjusted 
according to age, sex, ethnicity, SES and other comorbidities) 
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Table 3 – Pre-operative severity of joint problems (OHS/OKS) and likelihood of long-standing problems by number of comorbidities (95% CI, P-value for trend) (adjusted according to age, sex, 
ethnicity and SES)  
Number of 
comorbidities 
Severity of joint problems 
(OHS or OKS) 
(0 worse and 48 best) 
Functional status  
(OHS or OKS) 
(0 worst 24 best) 
Pain 
(OHS or OKS) 
(0 worst 24 best) 
Long-standing joint problems 
(duration > 5 years) 
Mean 
score 
Adjusted difference 
(95% CI) 
P-value Mean 
score 
Adjusted difference 
(95% CI) 
P-value Mean 
score 
Adjusted difference 
(95% CI) 
P-value % Adjusted OR 
(95% CI) 
P-value 
Hip replacement            
0 18.8 Reference  10.6 Reference  8.21 Reference  21.3 Reference  
1 17.4 -1.45 (-1.52, -1.38) <0.001 9.73 -0.79 (-0.83, -0.76) <0.001 7.67 -0.66 (-0.69, -0.62) <0.001 17.3 0.93 (0.91, 0.95) 0.076 
2 16.2 -2.79 (-2.87,-2.70)  9.03 -1.52 (-1.56, -1.47)  7.17 -1.28 (-1.32, -1.23)  16.5 0.98 (0.95, 1.00)  
3 14.9 -4.15 (-4.27, -4.04)  8.31 -2.23 (-2.30, -2.17)  6.58 -1.92 (-1.98, -1.86)  16.1 1.02 (0.98, 1.06)  
4+ 13.3 -5.79 (-5.96, -5.61)  7.42 -3.13 (-3.23, -3.03)  5.89 -2.66 (-2.75, -2.56)  17.5 1.15 (1.09, 1.23)  
Knee replacement            
0 19.5 Reference  12.5 Reference  7.01 Reference  45.7 Reference  
1 18.5 -1.06 (-1.12, -0.99) <0.001 11.7 -0.72 (-0.76, -0.68) <0.001 6.77 -0.34 (-0.37, -0.31) <0.001 42.2 0.95 (0.93, 0.97) 0.663 
2 17.6 -2.16 (-2.24, -2.09)  11.0 -1.50 (-1.51,-1.42)  6.51 -0.70 (-0.73, -0.67)  41.9 0.97 (0.95, 0.99)  
3 16.5 -3.38 (-3.48, -3.28)  10.3 -2.28 (-2.34, -2.22)  6.17 -1.10 (-1.15, -1.06)  41.8 0.98 (0.96, 1.01)  
4+ 15.1 -4.79 (-4.94, -4.64)  9.39 -3.21 (-3.31, -3.11)  5.75 -1.58 (-1.64, -1.51)  41.9 0.99 (0.95, 1.04)  
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 Supplementary Information 
 
 
Supplementary Information 1 – Flow chart  
PROMs  
N (791 369) 
Duplicates removed 
Q1 survey responses (10 762) 
HES episodes (140) 
Linked to HES records 
N (780 462) 
Excluded cases 
Not first surgery (103 395)  
Coding errors (644) 
Revisions (22 132 hips, 13 464 
knees) Analysis Sample 
N (640 832) 
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Supplementary Information 2– Breakdown of OKS and OHS by pain and function questions (P=pain, F=function) 
 
OHS OKS 
1 How would you describe the pain you usually have in your hip? (P) Describe the pain you usually have from your knee? (P) 
2 Have you been troubled by pain from your hip in bed at night? (P) How much trouble do you have washing and drying yourself? (F) 
3 Have you had any sudden, severe pain-' shooting ', 'stabbing', or 
'spasms' from your affected hip? (P) 
 
How much trouble do you have getting in/out car or using public 
transport? (F) 
4 Have you been limping when walking because of your hip? (F) How long can you walk before pain becomes severe? (P) 
5 For how long have you been able to walk before the pain in your hip 
becomes severe (with or without a walking aid)? (P) 
After a meal how painful has it been to stand up from a chair? (P) 
6 Have you been able to climb a flight of stairs? (F) Have you been limping when walking? (F) 
7 Have you been able to put on a pair of socks, stockings or tights? (F) Could you kneel down and get up again? (F) 
8 After a meal (sat at a table), how painful has it been for you to stand 
up from a chair because of your hip? (P) 
Have you been troubled by pain in bed at night? (P) 
9 Have you had any trouble getting in and out of a car or using public 
transportation because of your hip? (F) 
How much has pain from your knee interfered with your normal 
work? (P) 
10 Have you had any trouble with washing and drying yourself (all over) 
because of your hip? (F) 
Have you felt your knee might suddenly give way or let you down? 
(F) 
11 Could you do the household shopping on your own? (F) 
 
Could you do the shopping on your own? (F) 
12 How much has pain from your hip interfered with your usual work, 
including housework? (P) 
Could you walk down a flight of stairs? (F) 
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Supplementary information 3 - Study population characteristics 
Characteristic Hip replacement Knee replacement 
No. of patients 312 079 (48.7) 328 753 (51.3) 
Mean (SD) OHS or OKS  17.4 (8.25) 18.3 (7.87) 
Mean (SD) EQ-5D 0.33 (0.33) 0.39 (0.32) 
Problem for more than five years, n (%) 57 827 (18.5) 141 559 (43.1) 
Age (mean, range) 68 (18-105) 69 (18-102) 
Gender, n (%)  
Male  126 925 (40.7) 140 971 (42.9) 
Female  184 982 (59.3) 187 525 (57.0) 
Missing, not stated  172 257 
Socioeconomic status by quintile group, n (%)  
1 (least deprived) 74 380 (23.4) 69 582 (21.2) 
2 76 164 (24.4) 74 799 (22.8) 
3 55 793 (17.9) 62 851 (19.1) 
4 52 194 (16.7) 60 177 (18.3) 
5 (most deprived) 50 408 (16.2) 58 327 (17.7) 
Missing 3 140 3 017 
Ethnicity, n (%)  
White or White British 271 959 (98.3) 279 159 (94.5) 
Mixed background 546 (0.19) 836 (0.28) 
Asian or Asian British 1 239 (0.45) 10 445 (3.53) 
Black or Black British 1 703 (0.62) 3 347 (1.13) 
Chinese  or other ethnic  1 150 (0.42) 1 706 (0.58) 
Missing 35 482 33 260 
Prevalence of comorbidities, n (%) 
Heart disease 53 277 (17.1) 60 755 (18.5) 
High blood pressure 151 163 (48.4) 187 815 (57.1) 
Stroke 3 227 (1.03) 3 530 (1.07) 
Leg pain due to poor circulation 5 140 (1.65) 4 955 (1.51) 
Lung disease 43 481 (13.9) 51 176 (15.6) 
Diabetes 29 535 (9.46) 44 813 (13.6) 
Kidney disease 16 428 (5.26) 18 000 (5.48) 
Diseases of the nervous system 8 483 (2.72) 9 741 (2.96) 
Liver disease 1 888 (0.60) 1 931 (0.59) 
Cancer 6 354 (2.04) 5 545 (1.69) 
Depression 13 367 (4.28) 14 814 (4.51) 
Count of comorbidity, n (%)   
0 113 479 (36.4) 94 290 (28.7) 
1 107 139 (34.3) 119 012 (36.2) 
2 59 976 (19.2) 75 202 (22.9) 
3  22 929 (7.35) 29 761 (9.05) 
4+ 8 556 (2.74) 10 488 (3.19) 
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7 RESULTS CHAPTER – Safety  
 
The fifth component of the research programme investigated the impact of comorbidities 
on safety outcomes after hip and knee replacement surgery. The research is presented in 
the form of a research paper. Supplementary information can be found at the end of this 
section.  
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 Abstract 
 
Aims 
Increasing numbers of patients with comorbidities are undergoing hip and knee 
arthroplasty. We assessed the impact of different comorbidities on a number of adverse 
outcomes that reflect the safety of hip and knee arthroplasty.  
 
Patients and Methods 
We included 640 832 patients who underwent elective primary hip or knee arthroplasty 
patients between 2009 and 2016. Multivariable logistic analysis was used to estimate the 
impact of 11 different comorbidities on the likelihood of an adverse outcome (minimum of 
one of the following: in-hospital transfers to another consultant, mortality and emergency 
readmissions 30 days after surgery) and on the likelihood of a prolonged hospital length of 
stay (LOS)(> 8 days) after hip or knee arthroplasty adjusted for age, sex, socioeconomic 
status, ethnicity and other comorbidities.  
 
Results 
A total of 28 273 (4.4%) patients had an adverse outcome and 35 334 (5.5%) patients had a 
prolonged LOS.  Presence of heart disease, stroke, diseases of the nervous system and liver 
disease had the largest impact on these outcomes. In hip arthroplasty, the relative odds 
ratio for an adverse outcome ranged from 1.15 (95% CI 1.10, 1.19) for high blood pressure 
to 1.86 (95% CI, 1.67, 2.08) for patients with stroke. The relative odds ratio for a prolonged 
LOS ranged from 1.24 (95% CI 1.20, 1.29) for high blood pressure to 3.05 (95% CI 2.86, 3.26) 
for patients with disease of the nervous system. In knee arthroplasty, the increased risk for 
an adverse outcome ranged from 1.14 (95% CI 1.10, 1.19) for patients with high blood 
pressure to 1.89 (95% CI 1.70, 2.10) for patients with stroke.  The relative odds ratio for a 
prolonged LOS ranged from 1.20 (95% CI 1.16, 1.24) for patients with high blood pressure 
to 2.90 (95% CI 2.73, 3.08) for patients with diseases of the nervous system. The impact of 
comorbidities on adverse outcomes was most pronounced with increasing number of 
comorbidities: patients with three or more comorbidities had a 3 to 4-fold increase in risk 
of adverse outcomes.  
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Conclusion 
The risk of adverse outcomes and a prolonged hospital stay is moderate for patients with 
single comorbidities but if number of comorbidities increases, the risk becomes substantial. 
This finding demonstrates that safety is a key issue in patients with multiple comorbidities.  
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 Introduction 
Increasingly more patients with comorbidities are undergoing hip and knee arthroplasty 
[1]. As populations age, the number of patients with multiple comorbidities will only 
continue to increase. Hip and knee arthroplasty is one of the most effective surgeries and 
its use continues to increase [2-4] but the impact of a variety of individual comorbidities on 
adverse outcomes that reflect the safety of hip and knee arthroplasty has not been fully 
explored. 
Patient safety is a critical issue in elective total joint arthroplasty. Orthopaedic surgery 
patients continue to develop complications and management of these complications 
requires a thorough understanding of the impact of preoperative comorbidities [5]. 
Identification of these risk factors for complications and adequate critical care intervention 
have proven to be instrumental in reducing mortality and morbidity after surgery [6].  
In a previous meta-analysis of 70 papers published up until May 2017, looking at the impact 
of comorbidities on outcomes of hip and knee arthroplasty, comorbidities predominantly 
had an impact on the safety of joint arthroplasty but little impact on its effectiveness. The 
impact on outcomes related to safety (surgical complications, short-term mortality and 
readmissions) however presented an inconsistent picture [7]. The most common measure 
of safety across all 70 studies was surgical complications (85% of studies). While commonly 
investigated, the validity and reliability of the coding of these surgical complications in 
administrative data has been called into question [8-10]. Furthermore, there is a lack of 
consensus on how to best measure surgical complications [11].  Studies investigating safety 
have therefore resorted to looking at other safety outcomes that measure health service 
use [12] and that can act as surrogates for surgical complications, such as short-term 
mortality and readmissions to hospital after surgery.  
The aim of this nationwide study was to investigate the impact of comorbidities on a 
variety of adverse outcomes that reflect safety of hip and knee arthroplasty, using large 
datasets from Hospital Episode Statistics (HES) and the Office for National Statistics (ONS). 
We studied multiple adverse outcomes that reflect the safety of joint arthroplasty such as a 
transfer to another consultant during the admission for the joint arthroplasty, emergency 
readmissions and 30-day mortality, which we presented as a single composite adverse 
outcome as well as looking separately at prolonged length of stay in hospital.   
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 Patients and Methods 
Ethics approval was obtained from the NHS Health Research Authority Ethics committee 
(Ref: 211186). We used outcome data on patients undergoing hip and knee arthroplasty 
between 2009 and 2016 in the English NHS and who participated in the Patient Reported 
Outcome Measures (PROMs) programme. The PROMs programme includes patients 
undergoing elective hip or knee arthroplasty who complete a questionnaire before surgery 
and then again six months after surgery.  Patients’ PROMs data were linked with hospital 
records from Hospital Episodes Statistics (HES), the national dataset for all hospital 
admissions in England, and the Office for National Statistics (ONS) death registry data, the 
national registry for all deaths in England. NHS Digital, the national information and 
technology partner to the health system, linked the HES data to ONS death registry data for 
all PROMS eligible procedures.  
Patients who completed more than one pre-operative questionnaire for the same 
procedure were identified and the closest questionnaire to the date of procedure was 
retained.  The final analysis sample was restricted to the first primary procedure for each 
patient. Subsequent primary procedures and all revision procedures were excluded. This 
left a final sample of 640 832 hip and knee arthroplasty patients.  
Eleven comorbidities were identified from the list of 12 self-reported comorbidities from 
the pre-operative PROMs questionnaires which, in turn, represented a simplified version of 
the 13-item Self-Administered Comorbidity Questionnaire by Katz et al. [13]. Arthritis was 
excluded because it was the reason for surgery rather than a comorbidity. The 11 
comorbidities comprised: heart disease; high blood pressure; problems caused by a stroke; 
leg pain when walking due to poor circulation; lung disease; diabetes; kidney disease; 
nervous system disease; liver disease; cancer and depression. Each comorbidity was 
mapped to its relevant, International Classification of Diseases, Tenth Revision, (ICD-10) 
diagnosis codes in HES data as described in a previous study [14]. The presence of a 
comorbidity was indicated if a mapped code appeared in any HES diagnosis field in any 
hospital admission up to one year prior to a patient’s surgery.  
 
Measures 
The primary outcome for the analysis was a composite measure of safety following hip or 
knee arthroplasty to increase the statistical power and to simplify the reporting of multiple 
outcome measures that relate to safety of joint arthroplasty. Composite measures have 
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also been found to give a more comprehensive view of quality of care [15] and better 
explain hospital-level variation in serious complications and mortality compared to 
individual measures [16].  The primary outcome was defined as a binary variable indicating 
the presence of one or more of the following three indicators of safety: a transfer to 
another consultant during the same hospital admission, mortality and an emergency 
readmission to hospital within 30 days of the procedure. Patients transferred for care 
under a different consultant in the same admission as their hip or knee arthroplasty were 
identified by examining subsequent episodes of care within their hospital admission (see 
supplementary material 2). In HES the unit of care is a single consultant episode of care - 
the total time a patient spends under the care of an individual consultant. Mortality was 
captured using linked ONS death registry data. Emergency readmissions were identified by 
checking for any emergency hospital admission within 30 days of surgery using linked HES 
records for each patient.  
Length of stay (LOS) following surgery was examined as a secondary outcome. A prolonged 
LOS was defined as a LOS greater than eight days as measured from the date of operation 
to the date of hospital discharge or, if available, the date the patient was ready for 
discharge. The threshold of eight days was based on the median LOS for patients whose 
hospital admission included any additional episode of care following the episode of the 
primary procedure. The date the patient was ready for discharge was used in the LOS 
calculation to avoid delays in discharge outside the control of the hospital contributing to a 
prolonged LOS. Further validation work was conducted to ascertain that patients with our 
definition of prolonged LOS were more likely to have complications (OR 4.07, 95% CI 3.94, 
4.20) and that they had higher number of procedures conducted than patients with a 
shorter LOS.  Complications were identified using ICD-10 diagnosis codes (Y40-Y84) – coded 
complications associated with adverse incidents of medical care.  
 
Statistical analysis 
We conducted multivariable logistic regression for the primary (adverse outcomes) and 
secondary outcomes (prolonged LOS) for hip and knee arthroplasty comparing those 
patients with and without each comorbidity. The analyses were adjusted for 
sociodemographic factors (age, sex, ethnicity and socioeconomic status as measured by the 
Index of Multiple Deprivation [17]) and the other comorbidities. Missing values for 
ethnicity, age, sex, and socioeconomic status were imputed with chained equations [18]. 
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Analyses were run for each of the 10 imputed data sets and estimated parameters were 
combined using Rubin’s rules and reported as odds ratios (OR) with 95% confidence 
intervals. The results are presented in forest plots of the 11 comorbidities for hip and knee 
arthroplasty. The impact of multiple comorbidities was examined by repeating the analyses 
using the number of comorbidities.  
We conducted an array of sensitivity analyses.  We looked at the impact of changing the 
definition of prolonged LOS. We also repeated our analyses adjusting for hospital variation 
and preoperative severity of symptoms. All p-values were two-tailed and p-values less than 
0.05 were considered statistically significant. A test-for-trend was conducted for all p-
values (multiple comorbidities). All statistical analysis were carried out using STATA V.15.   
 
 Results 
We included 640 832 patients undergoing a primary hip or knee arthroplasty (312 079 hip 
operations and 328 753 knee operations) between April 2009 and March 2016 in the 
analyses. Patients were on average 68 years of age, female (58%) and were from a White 
ethnic background (>95%) (see Figure 1). Over 65% had at least one comorbidity and high 
blood pressure, heart disease and lung disease were the comorbidities with the highest 
prevalence. High blood pressure and heart disease were the most common comorbidity 
combinations across all groups of patients with multiple comorbidities (2, 3 or 4 
comorbidities) (see supplementary information 1).  
Of these patient populations, 13 374 (4.29%) hip patients and 14 899 (4.53%) knee patients 
had adverse outcomes (i.e. minimum of one or more of transfers to another consultant, 
mortality in 30 days, emergency readmissions in 30 days) (see Table 2). The majority of 
patients who had an adverse outcome, had an emergency readmission in 30 day (57.9%) 
followed by a transfer to another consultant (37.0%). Only 9 (0.03%) patients had all three 
adverse outcomes (see Table 3).  
 
Adverse outcome 
Multivariable analysis of the adverse outcome showed that patients with single 
comorbidities, especially patients with heart disease, stroke, diseases of the nervous 
system and liver disease, were more likely to have adverse outcomes compared to patients 
without comorbidities (see Figure 2). In hip arthroplasty, patients with stroke (OR 1.86, 95% 
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CI 1.67, 2.08), liver disease (OR 1.83, 95% CI 1.55, 2.16), heart disease (OR 1.77, 95% CI 
1.70, 1.84) and diseases of the nervous system (OR 1.69 95% CI 1.56, 1.84) of all 11 
comorbidities were most likely to have an adverse outcome. The least likely to have an 
adverse outcome among those with comorbidities, but still statistically significant, was 
observed in patients with high blood pressure (OR 1.15, 95% CI 1.10, 1.19), and diabetes 
(OR 1.17, 95% CI 1.11, 1.23). In knee arthroplasty, we found patients with stroke (OR 1.89, 
95% CI 1.70, 2.10); diseases of the nervous system (OR 1.79, 95% CI 1.66, 1.93), liver 
disease (OR 1.78, 95% CI 1.51, 2.09) and heart disease (OR 1.64, 95% CI 1.57, 1.70) had the 
highest likelihood among those with comorbidities of an adverse outcome.  Similar to hip 
arthroplasty, patients with high blood pressure (OR 1.14, 95% CI 1.10, 1.19), and diabetes 
(OR 1.22, 95% CI 1.17, 1.27) were the least likely among those with comorbidities to have 
an adverse outcome.  
 
Prolonged LOS 
Multivariable analysis of prolonged LOS in hospital after hip or knee arthroplasty showed 
that all patients with the 11 comorbidities were more likely to have a prolonged LOS than 
patients without comorbidities (see Figure 3). In hip arthroplasty, patients with diseases of 
the nervous system (OR 3.05, 95% CI 2.86, 3.26), liver disease (OR 2.43, 95% CI 2.10, 2.83) 
stroke (OR 2.15, 95% CI 1.96, 2.37) and heart disease (OR 2.13, 95% CI 2.06, 2.21) were 
most likely among patients with comorbidities to have a prolonged LOS. The lowest 
likelihood was seen in patients with high blood pressure (OR 1.24, 95% CI 1.20, 1.29). In 
knee arthroplasty, the highest likelihood of a prolonged LOS among patients with 
comorbidities was seen in patients with diseases of the nervous system (OR 2.90, 95% CI 
2.73, 3.08), stroke (OR 2.21, 95% CI 2.01, 2.41), liver disease (OR 1.95, 95% CI 1.67, 2.27) 
and heart disease (OR 1.94, 95% CI 1.88, 2.01).  Similar to hip arthroplasty, patients with 
high blood pressure (OR 1.20, 95% CI 1.16, 1.24) were the least likely among patients with 
comorbidities to have a prolonged LOS.  
 
Impact of multiple comorbidities 
The risk of adverse outcomes and likelihood of a prolonged LOS increased with the number 
of comorbidities (see Table 4).  In hip arthroplasty, patients with four or more 
comorbidities were five-times as likely (OR 4.63, 95% CI 4.30, 4.99) to have an adverse 
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outcome and were also eight times (OR 8.35, 95% CI 7.80, 8.95) more likely to have a 
prolonged LOS than patients without comorbidities.  In knee arthroplasty, patients with 
four or more comorbidities were four-times as likely (OR 4.09, 95% CI 3.80, 4.39) to have an 
adverse outcome and were also seven times (OR 6.82, 95% CI 6.39, 7.28) more likely to 
have a prolonged LOS.   
 
 Discussion 
This study demonstrates that the presence of a comorbidity in patients undergoing hip or 
knee arthroplasty was associated with a moderately higher risk of adverse outcomes and a 
prolonged hospital stay. This risk increased with the number of comorbidities and was 
considerably higher in patients with three or more comorbidities.  Heart disease, stroke, 
diseases of the nervous system and liver disease were the comorbidities associated with 
the highest relative increase in risk of an adverse outcome and prolonged LOS whereas 
patients with high blood pressure, diabetes and cancer had the lowest relative increased 
risk.  
To our knowledge, this is the first study to focus on the impact of a range of different 
comorbidities and the number of comorbidities on multiple adverse outcomes that reflect 
the safety of hip and knee arthroplasty in a large national sample of patients in England. 
Previous research has predominantly focused on determining the impact of single risk 
factors for surgical complications [19-21]. In this study, we have explored outcomes that 
are associated with adverse outcomes as well as developing a new outcome, the need for a 
transfer to another consultant, in the same admission as the joint arthroplasty.  
Orthopaedic surgeons have to operate on increasingly more complex patients [1]. Often 
these patients have more than one comorbidity [22]. This study suggests that for individual 
comorbidities the increase in the risk of adverse outcomes is relatively small. Only in 
patients with multiple comorbidities does the increased risk become considerable.  These 
findings can assist healthcare professionals in the discussion with patients with 
comorbidities and especially patients with multiple comorbidities about the risks of surgery 
as well as predict the possibility of an adverse outcome and to allocate appropriate 
resources to manage these adverse outcomes. Determining what is an acceptable risk level 
is beyond the scope of this study but any increased risk should be interpreted in the 
context of whether patients benefit overall.  
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Our findings are consistent with other studies looking at short-term outcomes in patients 
with comorbidities undergoing total joint arthroplasty. From our previous systematic 
review the impact of comorbidities on readmissions within 90 days [21, 23-25] and 
mortality within 90 days [26, 27] was highest for patients with liver disease, heart disease, 
stroke and diseases of the nervous system [7].  Similarly, a small study of 802 patients in 
the USA, looking at complications and LOS in patients undergoing elective primary hip and 
knee arthroplasty, reported that patients with congestive heart failure, chronic kidney 
disease, and cirrhosis experienced the majority of the documented major complications 
following joint arthroplasty and were also more likely to have an increased LOS beyond 3 
days [28]. Prolonged hospital LOS can have a negative impact on health service use after 
elective surgery and our findings are consistent with previous studies that have implicated 
comorbidities in high LOS [29, 30]. The finding that adverse outcomes are more likely with 
increasing number of comorbidities corroborates a recent large US study of 516,745 
patients undergoing knee arthroplasty that showed that increasing number of 
comorbidities were associated with longer LOS [30]. 
This study has several limitations. The first relates to the use of a composite measure of 
adverse outcomes. While there are advantages of using composite measures such as 
increasing statistical power and simplifying the reporting of many outcome measures, the 
validity and the interpretability of a measure may be compromised as a result [31]. In 
addition, a composite outcome will not capture the impact of changes in one outcome on 
the other outcomes in the composite measure, for example a reduction in mortality may 
lead to an increase in emergency readmission and as a result the two effects will be 
cancelled out.  It has been suggested that methodological transparency can address some 
of the challenges of using composite measures [32]. Following this guidance, the logic of 
choosing the measure, the aim the measure is trying to achieve, the individual effects on 
each outcome, and risk adjustment of individual measures were all reported.  
The second limitation relates to the observational nature of the study. It is not possible to 
account for all unobserved patient characteristics and it was not possible to explore any 
selection bias. There is likely to be a ‘healthy-surgical patient’ effect such that high-risk 
patients, who are likely to have many comorbidities, are excluded from elective surgery. 
Evidence has suggested that patients with comorbidities are being selected out by 
healthcare professionals along the referral pathways to joint arthroplasty [33]. This has 
been used to explain why patients undergoing knee arthroplasty have lower than expected 
mortality for their age and sex [26]. Due to selection criteria, not being fully available in our 
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dataset we could not account for selection in our analysis.  Furthermore, the data did not 
allow us to stratify comorbidities by severity of disease. 
 
 Conclusion 
In conclusion, our results show that patients with single comorbidities have a moderately 
increased risk of adverse outcomes and a prolonged hospital stay than patients without 
comorbidities. The risk was considerably higher in patients with multiple comorbidities. A 
surgeon must assess the risks and benefits of conducting hip and knee arthroplasty 
especially for more complex patients. These findings can guide this discussion but should 
be interpreted in the context of whether patients with comorbidities benefit overall. 
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 Figures and Tables  
 
Figure 1- Flow chart 
 
 
 
 
  
PROMs  
N (791 369) 
Duplicates removed 
Q1 survey responses (10 762) 
HES episodes (140) 
 
Linked to HES records 
N (780 462) 
Excluded cases 
Not first surgery (103 395)  
Coding errors (644) 
Revisions (22 132 hips, 13 464 
knees) 
Analysis Sample 
N (640 832) 
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Table 1 - Patient characteristics  
 Hip arthroplasty Knee arthroplasty 
No. of patients, n (%) 312 079 (48.7) 328 753 (51.3) 
Age (mean, range) 68 (18-105) 69 (18-102) 
Gender, n (%)  
Male  126 925 (40.7) 140 971 (43.0) 
Female  184 982 (59.3) 187 525 (57.0) 
Missing, not stated  172  257  
Socioeconomic status by quintile group, n (%)  
1 (least deprived) 74 380 (23.4) 69 582 (21.2) 
2 76 164 (24.4) 74 799 (22.8) 
3 55 793 (17.9) 62 851 (19.1) 
4 52 194 (16.7) 60 177 (18.3) 
5 (most deprived) 50 408 (16.2) 58 327 (17.7) 
Missing 3 140  3 017  
Ethnicity, n (%)  
White or White British 271 959 (98.3) 279 159 (94.5) 
Mixed background 546 (0.19) 836 (0.28) 
Asian or Asian British 1 239 (0.45) 10 445 (3.53) 
Black or Black British 1 703 (0.62) 3 347 (1.13) 
Chinese  or other ethnic  1 150 (0.42) 1 706 (0.58) 
Missing 35 482 33 260 
Prevalence of comorbidities, n (%) 
Heart disease 53 277 (17.1) 60 755 (18.5) 
High blood pressure 151 163 (48.4) 187 815 (57.1) 
Stroke 3 227 (1.03) 3 530 (1.07) 
Leg pain due to poor circulation 5 140 (1.65) 4 955 (1.51) 
Lung disease 43 481 (13.9) 51 176 (15.6) 
Diabetes 29 535 (9.5) 44 813 (13.6) 
Kidney disease 16 428 (5.26) 18 000 (5.48) 
Diseases of the nervous system 8 483 (2.72) 9 741 (2.96) 
Liver disease 1 888 (0.60) 1 931 (0.59) 
Cancer 6 354 (2.04) 5 545 (1.69) 
Depression 13 367 (4.28) 14 814 (4.51) 
Count of comorbidity, n (%)    
0 113 479 (36.4) 94 290 (28.7) 
1 107 139 (34.3) 119 012 (36.2) 
2 59 976 (19.2) 75 202 (22.9) 
3  22 929 (7.35) 29 761 (9.05) 
4+ 8 556 (2.74) 10 488 (3.19) 
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Table 2 – Number of patients with adverse outcomes and a prolonged LOS by comorbidity (n(%)) 
Comorbidity Hip arthroplasty Knee arthroplasty 
Adverse outcomes Prolonged LOS  Adverse outcomes Prolonged LOS 
Heart disease    
No 8967 (3.46) 9859 (3.81) 10 165 (3.79) 11 526 (4.30) 
Yes 4407 (8.27) 6850 (12.9) 4734 (7.79) 7099 (11.7) 
High blood pressure    
No 5214 (3.24) 5159 (3.21) 4978 (3.53) 5267 (3.74) 
Yes 8160 (5.40) 11 550 (7.64) 9921 (5.28) 13358 (7.11) 
Stroke    
No 12 962 (4.20) 16 000 (5.18) 14 453 (4.44) 17 880 (5.50) 
Yes 412 (12.8) 709 (22.0) 446 (12.6) 745 (21.1) 
Leg pain due to poor circulation    
No 12 884 (4.20) 16 005 (5.21) 14 468 (4.47) 18 034 (5.57) 
Yes 490 (9.53) 704 (13.7) 431 (8.70) 591 (11.9) 
Lung disease    
No 10 583 (3.94) 12 947 (4.82) 11 701 (4.22) 14 253 (5.13) 
Yes 2791 (6.42) 3762 (8.65) 3198 (6.25) 4372 (8.54) 
Diabetes    
No 11 517 (4.08) 13 869 (4.91) 12 188 (4.27) 14 560 (5.13) 
Yes 1857 (6.29) 2840 (9.62) 2781 (6.21) 4065 (9.07) 
Kidney disease    
No 11 854 (4.01) 14 125 (4.78) 13 321 (4.29) 16 005 (5.15) 
Yes 1520 (9.25) 2584 (15.7) 1578 (8.77) 2620 (14.6) 
Diseases of the nervous system    
No 12 638 (4.16) 15 269 (5.03) 14 004 (4.39 17 013 (5.33) 
Yes 736 (8.68) 1440 (17.0) 895 (9.19) 1612 (16.6) 
Liver disease    
No 13 206 (4.26) 16 470 (5.31) 14 730 (4.51) 18 411 (5.63) 
Yes 168 (8.90) 239 (12.7) 169 (8.75) 214 (11.1) 
Cancer    
No 12 925 (4.23) 16 086 (5.26) 14 510 (4.49) 18 078 (5.59) 
Yes 449 (7.07) 623 (9.80) 389 (7.02) 547 (9.86) 
Depression    
No 12 554 (4.20) 15 787 (5.29) 13 952 (4.44) 17 634 (5.62) 
Yes 820 (6.13) 922 (6.90) 947 (6.39) 991 (6.69) 
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Table 3 – Composite outcome breakdown (and proportion of patients who also have a prolonged LOS> 8 days)  
Outcome combinations 
 
n (%) Outcome combination 
+ LOS > 8 days  
Total number with a composite outcome 28,273   
One outcome only 
1. Transfer to another consultant 10 449 (37.0) 4 187/10 449 (40.1) 
2. Death in 30 days only 634 (2.24) 151/634 (23.8) 
3. Emergency readmission in 30 days only  16 366 (57.9) 1 331/16 366 (8.13) 
Two outcomes only 
1. Transfer to another consultant + Emergency 
readmission in 30 days only 
461 (1.63) 271/461 (58.8) 
2. Transfer to another consultant + death in 30 days 
only 
247 (0.87) 168/247 (68.0) 
3. Emergency readmission in 30 days + death in 30 
days only 
107 (0.38) 18/107 (16.8) 
All three outcomes 9 (0.03) 8/9 (88.9) 
 
 
 
Figure 2- Forest plot for composite adverse outcomes comparing patients with and without comorbidity 
(adjusted according to age, sex, ethnicity, SES, and other comorbidities) 
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Figure 3 - Forest plot for prolonged LOS comparing patients with and without comorbidities (95% CI) (adjusted 
according to age, sex, ethnicity, SES, and other comorbidities) 
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Table 4 – Impact of multiple comorbidities on safety outcomes after hip and knee arthroplasty (95% CI) 
(adjusted according to age, sex, ethnicity, and SES) 
Number of 
comorbidities 
Adverse outcomes Prolonged LOS 
% Adjusted OR 
(95% CI) 
P-value 
 for trend 
% Adjusted OR 
(95% CI) 
P-value 
for trend 
Hip arthroplasty      
0 2.46 Reference  1.94 Reference  
1 3.75 1.36 (1.30,1.43) <0.001 4.19 1.62 (1.54,1.71) <0.001 
2 5.69 1.95 (1.85, 2.06)  8.17 2.84 (2.69, 2.99)  
3 8.73 2.95 (2.77, 2.13)  14.0 4.79 (4.52, 5.08)  
4+ 13.4 4.63 (4.30, 4.99)  22.4 8.35 (7.80, 8.95)  
Knee arthroplasty      
0 2.73 Reference  2.49 Reference  
1 3.78 1.30 (1.24, 1.37) <0.001 4.06 1.39 (1.32,1.46) <0.001 
2 5.49 1.83 (1.74, 1.93)  7.54 2.33 (2.08, 2.53)  
3 8.15 2.69 (2.53, 2.85)  12.5 4.02 (3.81, 4.25)  
4+ 12.2 4.09 (3.80, 4.39)  19.8 6.82 (6.39, 7.28)  
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 Supplementary information 
 
Supplementary information 1- Comorbidity profile by number of comorbidities (n (%)) 
# of 
Comorbidities 
Heart 
disease 
High BP Stroke Circulation Lung 
disease 
Diabetes Kidney 
disease 
Nervous 
system 
disease 
Liver 
disease 
Cancer Depression 
1 16 310 
(7.21) 
152 508 
(67.4) 
504 
(0.22) 
1 075 
(0.48) 
28 060 
(12.4) 
8 552 
(3.78) 
2 470 
(1.09) 
4 597  
(2.03) 
693 
(0.30) 
2 938 
(1.30) 
8 444 
(3.73) 
2 49 510 
(36.6) 
118 334 
(87.5) 
1 696 
(1.25) 
2 482 
(1.84) 
34 107 
(25.2) 
32 470 
(24.0) 
11 120 
(8.23) 
5 758  
(4.26) 
1 130 
(0.80) 
3 948 
(2.92) 
9 801 
(7.25) 
3 32 909 
(62.5) 
49 607 
(94.1) 
2 151  
(4.08) 
3 338 
(6.34) 
21 476 
(40.8) 
22 134 
(42.0) 
12 175 
(23.1) 
4 289  
(8.14) 
1 012 
(1.92) 
2 925 
(5.55) 
6 054 
(11.5) 
4 15 303 
(80.4) 
18 529 
(97.3) 
2 406 
(12.6) 
3 200  
(16,8) 
11 014 
(57.8) 
11 192 
(58.8) 
8 663  
(45.5) 
3 580  
(18.8) 
984 
(5.17) 
2 088 
(11.0) 
3 881 
(20.4) 
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Supplementary information 2 – Treatment specialty of consultants that patients are transferred to (n= 11,128) 
Treatment specialty  Transfer to another consultant 
n (%) 
Trauma or & Orthopaedics  4 151 (37.3) 
Rehabilitation  1 768 (15.9) 
General Medicine 1 163 (10.4) 
Critical care medicine 1 005 (9.02) 
Geriatric medicine 922 (8.27) 
Cardiology 744 (6.68) 
Gastroenterology 366 (3.28) 
General surgery 253 (2.27) 
Intermediate Care  163 (1.46) 
Respiratory Medicine 141 (1.27) 
Other 452 (4.18) 
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Supplementary information 3 - Forest plot of individual outcomes in the composite measure comparing patients with and without comorbidities (adjusted OR, 95% CI) (adjusted according to 
age, sex, ethnicity, SES, and other comorbidities) 
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Supplementary information 4 – Adjusted OR for individual outcomes in the composite adverse outcome by 
number of comorbidities (95% CI) (adjusted according to age, sex, ethnicity and SES) 
 
Number of 
comorbidities 
Transfer to another 
consultant 
Mortality in 30 days Emergency Readmissions 
in 30 days 
% Adjusted OR 
(95% CI) 
% Adjusted OR 
(95% CI) 
% Adjusted OR 
(95% CI) 
Hip arthroplasty      
0 0.85 Reference 0.03 Reference 1.62 Reference  
1 1.38 1.37 (1.26, 1.49) 0.10 2.11 (1.46, 3.08) 2.34 1.35 (1.27, 1.43) 
2 2.46 2.22 (1.05, 2.42) 0.22 3.94 (2.74, 5.68) 3.20 1.76 (1.65, 1.88) 
3 3.97 3.42 (3.11, 3.76) 0.52 8.25 (5.69, 12.0) 4.78 2.58 (2.38, 2.79) 
4+ 6.77 5.76  (5.17, 6.42) 1.10 16.2 (11.0, 23.8) 6.51 3.50 (3.16, 3.86) 
Knee arthroplasty      
0 0.97 Reference 0.05 Reference 1.73 Reference 
1 1.35 1.28 (1.18,1.39) 0.08 1.30 (0.92, 1.83) 2.39 1.31 (1.24, 1.40) 
2 2.20 1.97 (1.81, 2.14) 0.18 2.41 (1.73, 3.35) 3.27 1.74 (1.64, 2.45) 
3 3.42 2.95 (1.70, 3.24) 0.42 5.04 (3.61, 7.04) 4.68 2.45 (2.27, 2.63) 
4+ 5.40 4.62 (4.14, 5.14) 0.96 10.9 (7.68, 15.4) 6.55 3.42 (3.11, 3.75) 
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8 RESULTS CHAPTER– Effectiveness 
 
The fifth component of the research programme investigated the impact of comorbidities 
on the effectiveness of hip and knee replacement surgery. The research is presented in the 
form of a research paper. Supplementary information can be found at the end of this 
section.  
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 Abstract  
 
Background: In some areas of the UK access to hip and knee replacement surgery has been 
restricted to reduce costs. Eligibility criteria has included body mass index and the 
optimisation of pre-existing comorbidities. It is important to therefore understand the 
impact of comorbidities on the effectiveness of hip and knee replacement surgery. 
 
Methods: Our sample included 640 832 patients in England who had an operation between 
2009 and 2016. Eleven different comorbidities were identified from hospital admissions 
data based on ICD-10 diagnosis coding. Primary outcomes were change in the Oxford Hip or 
Knee Score (OHS/OKS) which measures severity of joint problems (pain and function) on a 
scale from 0 (worst) to 48 (best) and EQ-5D a health-related quality of life (HRQoL) 
measure. Linear regression analysis was used with adjustment for age, sex, ethnicity, 
socioeconomic status and other comorbidities.  
 
Findings: Overall, patients with comorbidities reported large improvements in severity of 
joint problems and HRQoL after hip and knee replacement surgery.  Patients with 
comorbidities reported slightly smaller improvements in OKS/OHS (adjusted differences in 
OHS ranged from 0·39 (95% CI 0·27, 0·51) to 0·74 (95% CI 0·31, 1·17) and OKS ranged from 
0·32 (95% CI 0·07, 0·57) to 1.15 (95% CI 0·58, 1·72)) compared to patients without 
comorbidities, except for patients where a comorbidity was high blood pressure, kidney 
disease or cancer who had little to no improvement.  There was limited to no impact of 
comorbidities on HRQoL. The adjusted differences increased with the number of 
comorbidities but remained small.  
 
Conclusions: Patients with comorbidities do benefit from hip and knee replacement 
surgery and the improvements in function are only slightly less than patients without 
comorbidities. This suggests that the negative impact of comorbidities on the outcome of 
hip or knee replacement surgery is small compared to the positive impact of the surgery 
itself. Our findings therefore indicate that restricting access based on the presence of 
comorbidities alone is unjustified.   
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 Introduction  
Since the first hip replacement in 1962 and knee replacement in the early 1970s [1], joint 
replacement surgery has become one of the most successful interventions in medicine [2-
4]. It offers substantial improvement in function and HRQoL in patients suffering with 
osteoarthritis or inflammatory arthritis [5-8]. Despite the success of joint replacement 
surgery, a small number of patients continue to report no improvement in function [9]. A 
European collaborative study of 1327 patients with total hip and knee replacement, found 
that, despite hip and knee replacement being effective in the majority of cases, between 
14% and 36% of patients were found not to have improved or even to be worse 12 months 
after surgery [9].  
In England, some commissioners of healthcare services have recently introduced arbitrary 
eligibility criteria to access hip and knee replacement surgery in a bid to cut spending 
despite their being no clinical or economic justification for any of these criteria [10] and not 
being supported by national clinical guidelines [11]. Examples of eligibility criteria include 
that a patient’s body mass index is lower than 30kg/m2 [12, 13] and that any pre-existing 
medical conditions are optimised [14-16]. Obesity and high body mass index (BMI) are 
rarely an isolated diagnosis and are strongly associated with comorbid conditions (e.g. 
diabetes and heart disease) that are considered to increase the risk of surgical 
complications after joint replacement surgery [17, 18]. An increasing number of patients 
undergoing hip and knee replacement surgery have at least one comorbidity [19].  It is 
therefore important to understand the impact of comorbidities on the effectiveness of 
replacement surgery.  
Increasingly, researchers have measured effectiveness of hip and knee replacement surgery 
by using patient-reported measures such as function, health-related quality of life (HRQoL) 
and patient’s perceptions of the success or failure of their joint replacement. The Patient 
Reported Outcome Measures (PROMs) programme in patients undergoing elective surgery 
in England routinely collects information on disease severity and HRQoL, from patients just 
before surgeryand six months after surgery and provides new opportunities to explore and 
monitor outcomes after joint replacement.  
Our previous work, a systematic review and meta-analysis of 70 studies published up until 
May 2017, found that individual comorbidities had a greater impact on short-term 
outcomes related to safety of joint replacement surgery such as short-term mortality and 
readmission [20]. The impact on longer-term outcomes relating to effectiveness was 
smaller for revision surgery but less clear for patient-reported outcomes such as function 
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and HRQoL. The fifteen studies (five reporting HRQoL) that examined PROMs were 
generally small (<2000 patients) single-centre studies. The availability of national PROMs 
data provides an opportunity to examine the impact of comorbidities on patient-reported 
outcomes that reflect the effectiveness of hip and knee replacement surgery in a large 
national representative group of patients undergoing elective hip or knee replacement 
surgery in the English National Health Service (NHS). 
 
 Methods 
 
Study design and population 
We used data from the National PROMs Programme for elective surgery in England for 
patients undergoing hip or knee replacement surgery between April 2009 and November 
2016. All NHS patients participating in the PROMS programme were given a questionnaire 
to complete before surgery either on admission or at preoperative assessment and then 
sent a follow-up questionnaire 6 months after surgery asking the same questions on the 
severity of their joint problems and HRQoL as well as their general views on the outcome of 
their operation.   
PROMs data were linked at a patient level to data about their hospital admission extracted 
from the Hospital Episode Statistics (HES) for patients treated in NHS providers, and NHS-
funded patients treated in private hospitals and independent sector treatment centres. To 
ensure we only had one record per patient we only included the first primary hip or knee 
surgery and excluded revision surgeries. We also excluded patients who had not returned a 
postoperative questionnaire with complete information on the main outcome and patients 
who had a second primary operation before they completed their postoperative 
questionnaire (see Figure 1).  
 
Instruments and data collection  
Our primary outcomes were the improvement in the Oxford Hip (OHS), Oxford Knee (OKS) 
and EQ-5D scores.  The OHS and OKS produce disease-specific scores that are derived from 
patient responses to 12 questions about pain and limits on physical functioning and 
everyday activities. Responses to each question are measured on a 5-point scale, and 
values associated with each response are added up to produce an overall score with the 
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range 0 (worst) to 48 (best). Both scales have been shown to be internally consistent, 
reliable and to correlate with surgeon-assessed measures of symptoms and disability in 
patients undergoing hip or knee replacement [21, 22]. The EQ-5D was used to measure 
HRQoL and is derived from the EQ-5D profiles. The score ranges from -0.594 (worst) to 1 
(best) with 0 reflecting ‘death’.  
Our secondary outcomes were overall improvement in the hip or knee problem and 
satisfaction with the results of the operation. These outcomes were derived from 
responses to the question: “overall, how are the problems now in the (hip/knee) on which 
you had surgery, compared with before your operation?” and “How would you describe the 
results of your operation?”. Five categories of response for the first question were ‘much 
better’, ‘a little better’, ‘about the same’, ‘a little worse’ and ‘much worse’. Responses were 
grouped to form a binary outcome, taking the value 1 for patients that reported no 
improvement in problems (i.e. same or worse) and 0 for those that reported them to be a 
little or much better. Five categories of responses for describing the results of the 
operation were ‘excellent’, ‘very good’, ‘good’, ‘fair’ and ‘poor’. A binary outcome was 
derived grouping patients into a group who were dissatisfied (described their results as 
‘fair’ or ‘poor’) and ones who were satisfied (described their results as ‘good’, ‘very good’, 
‘excellent’).  
Eleven common comorbidities were defined from HES using an algorithm described in a 
previous study that correspond to the comorbidity categories in the PROMs pre-operative 
questionnaire which included: heart disease; high blood pressure; problems caused by a 
stroke; leg pain when walking due to poor circulation; lung disease; diabetes; kidney 
disease; nervous system disease; liver disease; cancer and depression [23].  HES derived 
comorbidities were used in preference to patient-reported comorbidities to ensure 
comorbidities were consistent with clinical records.   
 
Statistical analysis  
We used multivariable linear regression to explore the relationship between the 11 
different comorbidities and improvement (change scores) in severity of joint problems 
(OHS and OKS) and HRQoL (EQ-5D).  In nonrandomised studies of pre-existing group (e.g. 
patients with and without comorbidities), change scores (postoperative-preoperative) have 
been shown to be less biased than the ANCOVA approach (postoperative scores adjusted 
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for preoperative scores) [24]. This assumes however that without treatment the groups 
have equal change over time [25]. This is plausible in the case of deterioration of joint 
problems over time between patients with and without comorbidities. Regression analysis 
included all 11 comorbidities and adjusted for other confounders such as age, sex, ethnicity 
and socioeconomic status (Index of Multiple Deprivation [25]) and other comorbidities. We 
used multivariable logistic regression to explore the relationship between comorbidities 
and the odds of reporting no improvement in hip or knee problems and being dissatisfied 
with the results of the operation. We also investigated the association between number of 
comorbidities and all outcomes to explore the effect of having multiple comorbidities.  
Descriptive results are presented as means and percentages. Multiple imputation using 
chained equations [26] was used to deal with missing values for ethnicity, age, sex and 
socioeconomic status. Analyses were run on each of the 10 imputed data sets and 
estimated parameters were combined using Rubin’s rules [27]. Regression results are 
presented as adjusted differences and odds ratios (ORs), both with their 95% confidence 
intervals and graphically presented in forest plots. All statistical analysis were carried out 
using STATA V.15. 
 
 Results 
 
Sample characteristics  
Our final sample included 234 432 patients who had a hip replacement and 245 200 
patients who had a knee replacement. The majority of patients were female (60% hips and 
57% knees) with an average age of 69. The majority of patients were of White ethnicity 
(98.7% for hip and 95.7% for the knee). Population characteristics are shown in Table 1. 
The most common comorbidities were high blood pressure, heart disease and lung disease 
for both knee and hip patients. 31% of patients had two or more comorbidities.  Of those 
patients with two comorbidities, 88% of patients had high blood pressure and 37% had 
heart disease. Of those patients with three comorbidities, 95% had high blood pressure, 
64% had heart disease and 42% had diabetes. Of those patients with four or more 
comorbidities, 98% had high blood pressure, 81% had heart disease, 59% had diabetes and 
57% had lung disease (see supplementary information 2).  
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The impact of comorbidities on the improvement in the OHS and OKS and HRQoL 
On average, hip patients reported a 20-point improvement in the OHS and knee patients 
reported a 15-point improvement in the OKS after their hip or knee replacement surgery. 
Similarly, hip patients reported a 0·43-point and knee patients a 0·31-point improvement in 
the EQ-5D score (see Table 2). 
Six months after surgery, patients with comorbidities tended to have slightly less 
improvement in pain and mobility issues in their hip or knee than patients without 
comorbidities. The mean OHS score for patients after surgery was 38·9 and 34·5 for the 
OKS. In hip patients, all comorbidities were associated with a slightly smaller improvement 
in OHS score except for patients with high blood pressure, kidney disease and cancer (see 
Figure 2). For hip replacement, the adjusted differences in the OHS score ranged from 0·40 
(95% CI 0·21, 0·60) for kidney disease to -0·74 (95% CI -1·17, -0·31) for stroke. For knee 
replacement surgery, all patients with comorbidities except high blood pressure, kidney 
disease and cancer were more likely to report a smaller improvement in OKS score.  The 
adjusted differences in the OKS score ranged from 0·32 (95% CI 0·14, 0·51) for kidney 
disease to -1·15 (95% CI -1·72, -0·58) for liver disease.  
Six months after surgery, improvement in general HRQoL scores did not vary significantly 
between patients with and without comorbidities (see Figure 2). For hip replacement 
surgery, only patients with high blood pressure (0·02, 95% CI 0·01, 0·02) and kidney disease 
(0·02, 95% CI 0·01, 0·02) had more improvement in HRQoL than patients without 
comorbidities but the difference was very small. Similarly, for knee replacement surgery, 
only patients with high blood pressure (0·01, 95% CI 0·00, 0·01), kidney disease (0·01, 95% 
CI 0·00, 0·01) and disease of the nervous system (0·01, 95% CI 0·00, 0·01) had more 
improvement in HRQoL than patients without comorbidities but again the difference was 
marginal.  
 
The impact of comorbidities on satisfaction with the results of the operation 
Patients with comorbidities were more likely to report being less satisfied with the results 
of their operation compared to patients without comorbidities (see Figure 3). The 
percentages describing their results as ‘fair’ or ‘poor’ were 7·35% for hip patients and 
15·6% for knee patients. In hip patients, all patients with comorbidities, except patients 
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with kidney disease and liver disease, were more likely to report being less satisfied with 
the results of their operation. The adjusted OR in hip patients ranged from 0·69 (95% CI 
0·65, 0·75) for depression to 1·02 (95% CI 0·95, 1·09) for kidney disease.  In knee patients, 
all patients with comorbidities, except for patients with kidney disease and cancer were 
more likely to be less satisfied with the results of their operation. In knee patients the 
adjusted OR ranged from 0·75 (95% CI 0·65, 0·85) for liver disease to 1·01 (95% CI 0·95, 
1·05) for kidney disease.  
 
The impact of comorbidities and reporting overall improvement in hip or knee problem 
Patients with comorbidities were less likely to report overall improvement in their hip or 
knee problems compared to patients without comorbidities (see Figure 2). The percentages 
reporting no overall improvement after their operation was 4·52% for hip patients and 
11·3% for knee patients.  In hip replacement, all patients with comorbidities, except for 
patients with liver disease and cancer, were more likely to report no improvement after 
surgery. The adjusted OR in hip patients ranged from 0·65 (95% CI 0·59, 0·70) for patients 
with depression to 1·05 (95% CI 0·97, 1·15) for kidney disease. Similar to reports of 
dissatisfaction, the highest likelihood was reported in patients with depression and disease 
of the nervous system (OR 0·67, 95% CI 0·60, 0·74).  In knee replacement, patients with 
comorbidities, except high blood pressure, kidney disease and cancer, were more likely to 
report no improvement after surgery. The adjusted OR in knee patients ranged from 0·66 
(95% CI 0·57, 0·76) for liver disease to 1·02 (95% CI 0·92, 1·12) for cancer with the highest 
reports in patients with liver disease and depression (OR 0·73, 95% CI 0·69, 0·77). In both 
hip and knee patients, kidney disease patients were less likely to report no overall 
improvement in their hip or knee problem after their operation.  
 
Multiple comorbidities  
Patients with multiple comorbidities were more likely to report a smaller improvement in 
OHS and OKS than patients with no comorbidities (see Figure 4).  The likelihood of 
reporting satisfaction with the results of the operation and no overall improvement in the 
hip or knee problems also decreased (worsened) considerably with increasing number of 
comorbidities (see Figure 5).  Hip patients with four or more comorbidities had a smaller 
improvement in the OHS (adjusted difference -0·91, 95% CI -1·19, -0·64), a slightly larger 
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improvement in HRQoL (0·01, 95% CI 0·00, 0·02) and were more than twice less likely to be 
satisfied (OR 0·41, 95% CI 0·38, 0·45) and report overall improvement (OR 0·41, 95% CI 
0·37, 0·45) in their hip compared to patients with no comorbidities.  Knee patients with 
four or more comorbidities had a smaller improvement in OHS (adjusted difference -1·42, 
95% CI -1·67, -1·17), no difference in HRQoL (0·00, 95% CI -0·01, 0·01) and were twice less 
likely to be satisfied (OR 0·48, 95% CI 0·45, 0·51) and to report overall improvement (OR 
0·47, 95% CI 0·44, 0·51) in their hip compared to patients with no comorbidities. 
 
 Discussion 
In our study, substantial improvements in severity of joint problems and HRQoL after hip or 
knee replacement surgery were reported regardless of comorbidity. When examining 
differences between patients with and without comorbidities, patients with comorbidities 
reported slightly smaller improvements in joint problems but a similar HRQoL after hip or 
knee replacement surgery than patients without comorbidities. Patients with comorbidity 
also reported less satisfaction and less overall improvement in hip or knee severity of joint 
problems after surgery. These differences in improvement in severity of joint problems 
were more pronounced in patients with multiple comorbidities.  
While there is a small impact of comorbidities on improvement in severity of joint problems 
six months after the joint replacement, the differences need to be interpreted within the 
context of the change in the overall scores. If we compare against the ‘Minimal Important 
Change’, the minimum change in health status in a single patient that is perceived by 
patients as beneficial, the overall change in both the OKS and OHS and EQ-5D in both 
patients with or without comorbidities was much higher than the minimum change [28, 
29].   
In contrast, when we investigated differences between patients with and without 
comorbidities and compared against the ‘Minimal Important Difference (MID)’, the 
difference in health gain between two independent groups that a patient perceives as 
beneficial, the differences are much smaller than the suggested MID values of five points 
for the OHS and OKS [28], and 0.08 for the EQ-5D [30]. Even in patients with multiple 
comorbidities, the differences are much smaller than the MID. It is important to note 
however, that the number of patients with multiple comorbidities is relatively small as the 
current practice of selecting patients for joint replacement would make patients with 
multiple comorbidities ineligible for surgery [31]. As a result, the findings suggest patients 
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with comorbidities do benefit significantly from hip and knee replacement surgery and only 
slightly less compared to patients without comorbidities.  
Previous research on the impact of comorbidities on severity of joint problems and HRQoL 
after hip and knee replacement surgery has been inconclusive and relied on single-centre 
studies with small sample sizes [32, 33]. These smaller studies with fewer than 500 patients 
predominantly found no significant differences [32, 33] but studies with larger samples 
(>1000 patients) with longer follow-up times (>2 years) reported an impact of 
comorbidities on improvement in functional impairment [34, 35]. Our study of almost half a 
million patients from a nationwide representative sample of patients demonstrates that 
comorbidities have a marginal impact on the improvement in severity of joint problems 
and no impact on the improvement in HRQoL after joint problems compared to patients 
without comorbidities.   
Even if the differences in improvement between patients with and without comorbidities in 
severity of joint problems and HRQoL at the individual comorbidity level were marginal, 
patients with comorbidities were less likely to report overall improvement and satisfaction 
with the results of their operation. A previous study investigating the use of single-item 
questions on patient satisfaction demonstrates that single transitional items such as 
questions about the satisfaction with the results of the operation and the extent of the 
overall improvement had low correlations with disease-specific severity measures and 
generic HRQoL suggesting such questions may be offering different insights [36]. 
Furthermore, previous studies have reported contradictory findings and reported no 
evidence of an impact of comorbidities on patient satisfaction [37-39]. This study therefore 
highlights the importance of also measuring severity of symptom and HRQoL to examine 
differences rather than relying only on single item questions such as patient satisfaction 
with the outcome of the surgery.   
This study has several limitations. The first relates to potential selection bias. Firstly, 
patients undergoing hip and knee replacement surgery are more likely to be healthy than in 
the general population as patients considered too high risk such as patients with 
comorbidities may not be selected for hip or knee replacement surgery [31]. Selection for 
surgery is likely to be based on risk factors that we have no data for or that we capture very 
poorly. Due to clinical data being limited it was not possible to account for any selection 
criteria. Similarly, only patients that returned a postoperative questionnaire were included 
and a previous study found that non-responders were more likely to be severe cases and 
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have more comorbidities [40]. These selection biases may lead to an underestimation of 
the differences in outcomes between patients with and without comorbidities. 
The second limitation relates to the availability of data on potential confounders. There 
was a lack of information on other risk factors such as BMI, smoking status and on the 
severity of the comorbidities. We did however have information about comorbidities that 
are associated with obesity such as diabetes, heart disease and high blood pressure. 
Furthermore, a previous study of 2180 patients, which compared patients with normal 
weight against patients with a BMI>25kg/m2, reported that functional outcomes after knee 
replacement surgery were not influenced by BMI [41]. 
 
 Conclusion 
In summary, our findings suggest that the impact of comorbidities on outcomes is very 
small compared to the overall benefits of the hip or knee replacement surgery itself. 
Patients with comorbidities reported on average large improvements in joint problems and 
HRQoL. When compared to patients without comorbidities, patients with comorbidities 
reported slightly smaller improvements in their joint problems but no difference in HRQoL. 
Patients with comorbidities were less likely to report overall improvement and to be 
satisfied with the results of their operation compared to patients without. This study 
suggests that patient with comorbidities benefit greatly from hip and knee replacement 
surgery and therefore any restriction of access to hip and knee replacement surgery based 
on the presence of comorbidity alone is unjustified.   
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 Figures and Tables 
 
Figure 1 - Flow chart 
 
  
PROMs  
N (791 369) 
Duplicates removed 
- Q1 survey responses (10 762) 
- HES episodes (140) 
 
Linked to HES records 
N (780 462) 
Excluded cases 
- Subsequent procedures (103 395)  
- Coding errors (644) 
- Revisions (22 132 hips, 13 464 
knees) 
- Q2 survey incomplete (141 346) 
- Second primary operations  (19 
Analysis Sample 
N (479 632) 
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Table 1 - Study population characteristics 
Characteristic Hip replacement Knee replacement 
No. of patients 234 432 245 200 
Age (mean, range) 69 (18-101) 70 (18-102) 
Gender, n (%)  
Male  94 545 (40·3) 105 150 (42·9) 
Female  139 734 (59·7) 139 821 (57·1) 
Missing, not stated  153  229 
Socioeconomic status by quintile group, n (%)  
1 (least deprived) 58 162 (24·8) 54 117 (22·1) 
2 58 824 (25·1) 57 572 (23·5) 
3 40 769 (17·4) 45 840 (18·7) 
4 37 903 (16·2) 43 397 (17·7) 
5 (most deprived) 36 331 (15·5) 41 880 (17·1) 
Missing 2 443 2 394 
Ethnicity, n (%)  
White or White British 205 512 (98·7) 211 737 (95·7) 
Mixed background 304 (0·15) 532 (0·24) 
Asian or Asian British 653 (0·31) 5 764 (2·61) 
Black or Black British 966 (0·46) 2 102 (0·95) 
Chinese  or other ethnic  745 (0·36) 1 071 (0·48) 
Missing 26 252  23 994  
Prevalence of comorbidities, n (%) 
Heart disease 39 594 (16·9) 44 914 (18·3) 
High blood pressure 114 373 (48·8) 139 931 (57·1) 
Stroke 2 423 (0·99) 3 723 (1·59) 
Leg pain due to poor circulation 3 723 (1·59) 3 686 (1·50) 
Lung disease 30 989 (13·2) 36 672 (15·0) 
Diabetes 21 621 (9·22) 32 247 (13·5) 
Kidney disease 11 916 (5·08) 12 992 (5·30) 
Diseases of the nervous system 5 723 (2·44) 6 735 (2·75) 
Liver disease 1 147 (0·49) 1 219 (0·50) 
Cancer 4 633 (1·98) 4 167 (1·70) 
Depression 8 288 (3·54) 9 549 (3·89) 
Count of comorbidity, n (%)   
0 86 104 (36·7) 71 472 (29·2) 
1 81 505 (34·8) 89 798 (36·6) 
2 44 789 (19·1) 55 636 (22·7) 
3  16 352 (6·98) 21 225 (8·66) 
4+ 5 682 (2·42) 7 069 (2·88) 
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Table 2 – Unadjusted net change (Post-Pre) for OHS, OKS and EQ-5D and number of patients reporting being 
satisfied and an overall improvement in their joint problem.   
 Improvement in 
OHS/OKS 
Mean (SD) 
Improvement in EQ-5D 
Mean (SD) 
Patients reporting 
being satisfied  
n (%) 
Patients reporting 
overall improvement 
n (%) 
Hips Knees Hips  Knees Hips  Knees Hips Knees 
Comorbidity 
 
        
Heart disease 20·4 
(10·6) 
15·1 
(10·4) 
0·433 
(0·346) 
0·303 
(0·334) 
35 088 
(90·5) 
36 137 
(81·7) 
37 279  
(94·2) 
39 011 
(86·9) 
High blood 
pressure 
20·9 
(10·4) 
15·7 
(10·1) 
0·441 
(0·342) 
0·314 
(0·331) 
102 969 
(91·7) 
115 353  
(83·7) 
108 676 
(95·0) 
123 832  
(88·5) 
Stroke 19·8 
(11·1) 
14·4 
(10·8) 
0·434 
(0·353) 
0·305 
(0·351) 
1898 
(87·3) 
1902 
(80·2) 
2051  
(91·9)  
2064 
(85·2) 
Leg pain due to 
poor circulation 
20·1 
(10·9) 
14·9 
(10·5) 
0·422 
(0·360) 
0·293 
(0·333) 
3228 
(88·6) 
2946 
(81·2) 
3464  
(93·0) 
3185  
(86·4) 
Lung disease 20·6 
(10·9) 
15·2 
(10·4) 
0·435 
(0·350) 
0·309 
(0·340) 
27 398 
(90·1) 
29 158 
(80·7) 
29 073 
(93·8) 
31 594  
(89·1) 
Diabetes 20·4 
(10·7) 
14·7 
(10·6) 
0·437 
(0·348) 
0·309 
(0·342) 
19 214 
(90·6) 
25 347 
(79·8) 
20 278  
(93·8)  
27 460  
(85·2) 
Kidney disease 21·0 
(10·5) 
15·8 
(10·4) 
0·432 
(0·355) 
0·322 
(0·334) 
10 648 
(91·3) 
10715 
(83·8) 
11 304 
(94·9) 
11 527 
(88·7) 
Diseases of the 
nervous system 
20·2 
(10·9) 
15·2 
(10·8) 
0·433 
(0·351) 
0·317 
(0·350) 
5325 
(80·6) 
5000 
(89·1) 
5311 
(92·8) 
5740 
(85·2) 
Liver disease 20·8 
(11·1) 
14·2 
(10·4) 
0·445 
(0·358) 
0·286 
(0·347) 
1010 
(89·6) 
920 
(76·3) 
1072 
(93·5) 
986 
(80·9) 
Cancer 20·9 
(10·4) 
15·6 
(10·1) 
0·431 
(0·337) 
0·303 
(0·327) 
4156 
(91·5) 
3453 
(84·4) 
4411 
(95·2) 
3714 
(89·3) 
Depression 20·6 
(11·1) 
14·9 
(10·6) 
0·434 
(0·367) 
0·313 
(0·361) 
7221 
(88·5) 
7353 
(77·9) 
7696 
(92·9) 
7950 
(83·3) 
 
Number of comorbidities 
 
   
    
0 
21·3 
(9·91) 
15·9 
(10·0) 
0·424 
(0·327) 
0·306 
(0·320) 
79 672 
(92·7) 
60 714 
(86·2) 
83 024  
(96·4) 
64 197  
(89·8) 
1 
21·1 
(10·2) 
15·8 
(10·1) 
0·436 
(0·338) 
0·314 
(0·326) 
74 267 
(92·7) 
75 268 
(85·1) 
77 965  
(95·7) 
80 410  
(89·6) 
2 
20·7 
(10·5) 
15·4 
(10·3) 
0·439 
(0·346) 
0·310 
(0·334) 
40 010 
(91·0) 
45 376 
(82·7) 
42 389  
(94·6) 
48 800  
(87·7) 
3 
20·3 
(10·9) 
15·0 
(10·6) 
0·441 
(0·351) 
0·311 
(0·342) 
14 322 
(89·6) 
16 659 
(79·8) 
15 258 
(93·3) 
18 152  
(85·5) 
4+ 
19·9 
(11·3) 
14·4 
(10·9) 
0·434 
(0·362) 
0·307 
(0·357) 
4855 
(87·3) 
5369 
(77·3) 
5211 
 (91·7) 
5837  
(82·6)  
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Figure 2  – Severity of joint problems and HRQoL for patients with and without comorbidities after hip and knee 
replacement (adjusted for age, sex, ethnicity, SES and other comorbidities) 
 
 
Figure 3 – Adjusted OR for satisfaction and improvement comparing patients with and without comorbidities 
after hip and knee replacement (adjusted for age, sex, ethnicity, SES and other comorbidities) 
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Figure 4 - Severity of joint problems and HRQoL by number of comorbidities (95% CI) (adjusted for age, sex, 
ethnicity, SES and other comorbidities) 
 
 
 
Figure 52- Satisfaction and overall improvement by number of comorbidities (95% CI) (adjusted for age, sex, 
ethnicity, SES and other comorbidities) 
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 Supplementary Information  
 
Supplementary information 1- Comorbidity profile 
Comorbidity Comorbidity sub-category n (%) 
Heart disease Ischemic heart disease 48 555 (57.0) 
Cardiac arrhythmias 38 492 (45.5) 
Valvular disease 9 377 (11.0) 
Congestive heart failure 7 566 (8.91) 
Stroke Ischemic stroke 2 156 (46.3) 
Transient Ischemic Attack 745 (16.0) 
Subarachnoid haemorrhage 52 (1.10) 
Other Stroke 1 806 (38.8) 
Leg pain due to poor 
circulation  
Peripheral vascular diseases 3 861 (52.1) 
Vascular implants 2 214 (29.9) 
Aortic diseases 1 844 (24.9) 
Gangrene 105 (1.4) 
High BP Primary hypertension 235 890 (92.7) 
Secondary hypertension 4 323 (1.7) 
Diseases of the nervous 
system  
 
Epilepsy 4 912 (39.4) 
Parkinsonism 2 779 (22.3) 
Dementia 1 713 (13.7) 
Neuropathies 1 004 (8.10) 
Demyelinating diseases 790 (6.31) 
Other nervous system (e.g. paralysis, huntington's disease) 1 534 (12.3) 
Lung disease Asthma 47 728 (70.5) 
COPD 20 574 (30.4) 
Pulmonary heart diseases 1 661 (2.50) 
Other lung disease (e.g. due to external agents) 1 024 (1.51) 
Diabetes Non-insulin-dependent diabetes 51 787 (96.1) 
Insulin-dependent diabetes 2 290 (4.20) 
Other 597 (1.10) 
Kidney disease Chronic renal failure 21 122 (84.8) 
Glomerular disease 3 177 (12.7) 
Acute renal failure 1 191 (4.71) 
Liver disease Cirrhosis 583 (24.6) 
Alcoholic liver disease 401 (16.9) 
Hepatitis  361 (15.2) 
Hepatic failure 37 (1.60) 
Any other liver disease 1 123 (47.4) 
Cancer Cancer without metastasis 6 934 (78.8) 
Lymphoma 1 708 (19.4) 
Metastatic cancer 921 (10.5) 
Depression Depression 16 322 (91.5) 
Depression linked to anxiety and stress 1 721 (9.60) 
Other depression (linked to schizophrenia and BAD) 15 (0.10) 
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Supplementary information 2- Comorbidity profile by number of comorbidities n (%) 
# of 
Comorbidities 
Heart 
disease 
High BP Stroke Circulation Lung 
disease 
Diabetes Kidney 
disease 
Nervous 
system 
disease 
Liver 
disease 
Cancer Depression 
1 12 575 
(7.30) 
117 710 
(68.7) 
371 
(0.20) 
805 
(0.46) 
20 291 
(11.8) 
6 331 
(3.70) 
1 871  
(1.09) 
3 296  
(1.92) 
437 
(0.20) 
2 235 
(1.30) 
5 380 
(3.10) 
2 37 623 
(37.5) 
88 589 
(88.2) 
1 248 
(1.20) 
1 889 
(1.80) 
24 850 
(24.70) 
24 166 
(24.1) 
8 394  
(8.36) 
4 024  
(4.01) 
716 
(0.70) 
2 991 
(2.90) 
6 360 
(6.30) 
3 23 933 
(63.7) 
35 564 
(94.6) 
1 482  
(3.90) 
296 
(6.60) 
15 220 
(40.5) 
15 840 
(42.1) 
8 753  
(23.3) 
2 883  
(7.67) 
636 
(1.69) 
2 144 
(5.70) 
3 780 
(10.1) 
4 10 377 
(81.4) 
12 441 
(97.6) 
1 555 
(12.1) 
2 219  
(17.4) 
7 299  
(57.2) 
7 531 
(59.1) 
5 890  
(46.2) 
2 255  
(17.7) 
577 
(4.53) 
1 430 
(11.2) 
2 317 
(18.2) 
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9 DISCUSSION 
This programme of research seeks to investigate the access to and safety and effectiveness 
of hip and knee replacement surgery for patients with a variety of comorbidities.  In the 
following section, I summarise the main findings of my PhD research, move on to discuss 
the policy implications of the findings for the health system and the overall strengths and 
limitations of the programme. Finally, I consider the future research opportunities.  
 
9.1 Summary of main findings  
In the UK, there are indications that access to elective hip and knee replacement surgery is 
being restricted by commissioners of health services in a bid to cut spending budgets. 
Restrictions have included eligibility criteria such as the optimisation of comorbidities 
before surgery. This programme of research set out to determine if there are any 
inequalities in access to hip and knee replacement as well as the safety and effectiveness of 
hip and knee replacement for patients with comorbidities. There were three main 
components to this programme of research: a literature review, methodological work and 
empirical work.  
 
 Literature review: existing literature on access and outcomes   
Before analysing the data, I sought to understand the literature on the relationship 
between comorbidities and access to and outcomes of, hip and knee replacement surgery. 
My systematic review and meta-analysis (RP1) focused on the impact on outcomes of 
surgery rather than access to surgery. This was because the literature on access was limited 
and heterogeneous. This is likely due to the lack of consensus on what constitutes access to 
healthcare and on how to measure it. Under any useful definition, access is difficult to 
quantify [133]. The literature identified in the systematic search on access was 
incorporated into the research paper on access (RP4).  
 
My systematic review demonstrates that patients with comorbidities are more likely to be 
readmitted and to suffer a higher short-term mortality but there is little evidence that 
patients benefit significantly less in terms of HRQoL, function and pain compared to 
patients without comorbidities. Furthermore, it highlighted two gaps in the literature. First, 
the more common and familiar comorbidities are widely investigated - only six studies 
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focused on patients with diseases of the nervous system whereas over 30 studies I 
reviewed investigated outcomes in patients with diabetes. Second, the majority of the 
literature on outcomes after hip and knee replacement surgery measured the risk of 
surgical complications (85% of studies) but very few measured patient-reported outcomes - 
only five studies reported on HRQoL outcomes and only two studies reported on pain. 
 
 
 Methodological work 
I then undertook an innovative piece of methodological work to explore the agreement 
between the two sources of data on comorbidity: patient-reported and administrative-data 
derived comorbidities (RP3).  This is the first study to investigate the agreement between 
these two datasets. I demonstrated that patients can give accurate information about the 
presence of comorbidities, if the description in the patient questionnaire is precise, if the 
disease is familiar to most patients, and if the disease has a significant impact on their life. 
These results highlight the importance of validating patient questionnaires that ask patients 
about the presence of comorbidities before they are used for research and service 
evaluation projects.  
Based on this work, I had to decide what measure I would use to identify comorbidities. 
The decision was to use the PROMs comorbidity categories to group together the individual 
comorbidities, but to identify the individual comorbidities using a combination of 
comorbidity indices in administrative data.  This was because it allowed for a comparison 
with a combination of already existing ICD-10 diagnosis based comorbidity indices in 
administrative data and ensured that I captured as many comorbidities as possible 
including those that were not captured accurately by patient-report.  
 
 Empirical Work 
 
9.1.3.1 Access  
Before embarking on the quantitative examination of inequalities in access to joint 
replacement surgery, I sought to understand the referral pathway for patients with 
comorbidities (RP2). My qualitative study found that different types of professionals across 
the system managed patients with comorbidities differently and that there are 
disagreements about whose role and responsibility it is to prepare patients with 
comorbidities for surgery. As a result, when patients with comorbidities were considered 
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unfit for surgery, patients were referred back to their GP where they were left to learn how 
to improve the self-management of their conditions. A barrier may therefore be operating 
at the referral pathway level such that patients with comorbidities are getting ‘lost in the 
system’ and their surgery delayed.  
To explore inequalities in access quantitatively, I compared the severity and duration of 
joint problems just before surgery between patients with and without comorbidities (RP4).  
If there were differences in access, we might expect to see differences in the severity of 
joint problems and in the duration of problems between patients with and without 
comorbidities just before surgery.  The exploration of severity of joint problems just before 
surgery showed a consistent picture. Patients with comorbidities reported more severe 
preoperative hip or knee symptoms compared to patients without comorbidities.  To 
further explore the severity of joint problems and to account for the possibility that 
comorbidities directly influence joint disease-specific measures, pain and functional status 
scores were investigated separately. I hypothesised that pain is more ‘joint-specific’ than 
functional status and is therefore less likely to be linked to comorbidities. Patients with 
comorbidities reported more severe pain suggesting that they truly have worse joint 
problems. In addition, the more comorbidities a patient had, the worse the reported 
severity of joint problems just before surgery. These results support the findings of the 
qualitative study (RP2) that patients with comorbidities may be having surgery later in the 
course of their joint disease.  
With regards to duration of joint problems, the impact of different comorbidities was less 
consistent across hip and knee patients and being observed in 6 out of 11 comorbidities in 
hip patients and 2 out of 11 in knee patients.   This inconsistency may be due to patients 
having reported the duration of symptoms of the most recent episode of a specific level of 
severity rather than the overall duration suggesting questions about duration of symptoms 
may be unclear and therefore unreliable.  
 
9.1.3.2 Outcomes 
The investigation of outcomes focused on measuring safety (RP5) and effectiveness (RP6) 
of hip and knee replacement surgery. Healthcare professionals need to consider both the 
safety risks and the benefits of joint replacement surgery before referring or selecting 
patients for surgery. Compared to patients without comorbidities, patients with single 
comorbidities had a slightly increased risk of adverse outcomes and a prolonged hospital 
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stay, but for patients with three or more comorbidities the study showed that the risk was 
considerably higher (RP5).  In contrast, the study of the impact of comorbidities on 
effectiveness of hip and knee replacement surgery, in line with the findings from my 
systematic review, found that patients with comorbidities, measured by improvement in 
severity of joint problems and HRQoL, did benefit overall from hip and knee replacement 
surgery, and only slightly less than patients without comorbidities. Together these two 
papers on safety and effectiveness (RP5 and RP6) suggest that the impact of comorbidities 
is small compared to the overall benefit of hip and knee replacement surgery.   
 
9.1.3.3 Multiple comorbidities  
I also explored the impact of having multiple comorbidities on access to and safety and 
effectiveness of hip and knee replacements surgery. Increasingly more patients are 
presenting with multiple comorbidities and little is known about the impact of multiple 
comorbidities on access to and outcomes of joint replacement surgery. The most common 
conditions in patients with multiple comorbidities were high blood pressure, heart disease, 
diabetes and lung disease. The preoperative severity of joint problems decreased 
(worsened) with increasing number of comorbidities. The risk of adverse outcomes and less 
improvement in severity of joint problems and HRQoL increased (worsened) with 
increasing number of comorbidities. Specifically, patients with three or more comorbidities 
appear to have a clinically important increased risk in adverse outcomes. Nevertheless, 
despite this increase risk of adverse outcomes, patients with multiple comorbidities 
continued to report large improvements in severity of joint problems and quality of life 
after surgery.  
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9.2  Policy implications for clinical practice and the health system 
The next section discusses the policy implications for clinical practice and the NHS derived 
from the findings of this research.  
 
 Before surgery: access and the referral pathway  
One of the aims of this thesis was to investigate whether there were any inequalities in 
access for patients with LTCs.  The quantitative and qualitative empirical work on access 
suggested there are. Compared to patients without comorbidities, patients with 
comorbidities reported more severe preoperative joint problems, suggesting patients with 
comorbidities may be having surgery later in their joint disease. The qualitative study 
revealed that there may be inequalities in access due to patients being considered 
ineligible for surgery because of their comorbidities. Patients with comorbidities whose 
conditions were not ‘optimised’ for surgery had their operations delayed and were sent 
back to their GPs. Patients were then left to learn how to improve the self-management of 
their comorbidities before being reconsidered for surgery. This finding suggested that 
patients with comorbidities may therefore be receiving their hip or knee replacement 
surgery later (or not at all, if they fail to improve their conditions themselves). Together 
these findings demonstrate that inequalities in access do exist for patients with 
comorbidities.  
The current approach to resolving these inequalities has been to develop guidelines and 
procedures to prepare patients with comorbidities for surgery [134, 135]. This assumes, 
however, that all comorbidities can be ‘optimised’ or controlled as is the case with 
conditions such as diabetes or hypertension. This is not the case for comorbidities such as 
Parkinson’s disease, heart failure or COPD.  Comorbidities should therefore not be 
considered as a homogenous group.   
In the UK and the USA, enhanced recovery protocols have been introduced (consisting of a 
multimodal programme before, during and after surgery) to improve outcomes for patients 
undergoing joint replacement surgery. Before surgery, this programme involves patient 
education about what to expect from the surgery, preoperative fasting and carbohydrate 
loading, detecting and correcting anaemia and pre-emptive analgesia [136]. Very little of 
this programme directly addresses the optimisation of patients with comorbidities. In the 
USA, orthopaedic surgeons have also developed a programme called Strong for Surgery 
that addresses the care provided to maximise patients’ health before elective surgery by 
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working with surgeons in the clinics. This programme includes a review of nutrition, 
smoking cessation, glycaemic control and medication use [134]. This relates to the 
management of comorbidities such as diabetes, high blood pressure, heart disease and 
stroke. Further research however is needed to evaluate these programmes and determine 
which interventions work best to optimise patients’ health before surgery [135].   
Currently, guidelines on how to prepare patients with comorbidities for surgery in the UK 
are limited [137]. The few guidelines that exist focus on the immediate perioperative 
period rather than the period between consultation and the procedure. Guidelines 
specifically relate to the management of anaesthetic risk related to comorbidities in 
preparation for surgery. Guidelines are also predominantly based on single diseases with a 
focus on comorbidities that can be controlled such as diabetes and hypertension [138-141]. 
There is very little literature on preparing patients with multiple comorbidities for surgery. 
This may be due to the small  number of studies examining the impact of multiple 
comorbidities on surgical risks and other outcomes [137].  
 
 After surgery: short-term (safety) and long-term (effectiveness) outcomes 
The focus on better preparing patients with comorbidities for surgery, however, is based on 
the belief that patients with comorbidities will have poorer outcomes after surgery. My 
research shows that even if patients with comorbidities have an increased risk of short-
term adverse outcomes they benefit significantly from hip and knee replacement surgery. 
Even patients with multiple comorbidities who have a substantial increased risk of adverse 
outcomes in the short-term benefitted considerably on average.   
Healthcare professionals need to consider the risks and benefits of surgery so they can 
make an informed decision about recommending patients for surgery [142]. The 
appropriate balance between avoiding complications and providing access to care, 
however, is difficult to determine.  This research shows that a decision to operate on 
patients with comorbidities is a commitment to managing complications should they arise. 
Managing complications requires additional time and resources leading to the introduction 
of eligibility criteria for total joint arthroplasty which then have the effect of delaying or 
denying the operation to patients. In England, commissioners of healthcare have imposed 
eligibility criteria such as BMI of less than 30kg/m2 and the optimisation of comorbidities 
before surgery with the aim of reducing costs [143]. The concerns about high BMI relate to 
its association with comorbidities such as diabetes, high blood pressure and heart disease.  
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My research has also demonstrated however, that compared to patients without 
comorbidities, patients with comorbidities benefit just as much in terms of improvements 
in function, pain and HRQoL.  Limiting access to joint replacement surgery would be 
therefore denying pain relief and functional improvement to patients as well as indirectly 
increasing costs of care associated with advanced hip or knee arthritis. 
A study exploring the balance of risk of complications and benefits of joint replacement 
surgery compared the impact of BMI-based eligibility criteria on avoiding complications or 
death against how many patients would have been denied access to a complication-free 
joint replacement. The study reported that the blanket eligibility criterion of having a BMI 
of less than 30kg/m2 was only marginally better than flipping a coin and should not 
determine surgical eligibility. On a population-level, this policy would therefore reduce the 
overall number of complications but would also deny access to join replacement to a much 
larger number of patients who would not have suffered complications [144].  
The question of whether any blanket criteria on the presence of comorbidities is acceptable 
or equitable is difficult to answer. Patients might prefer to have the choice to assume any 
risk whereas surgeons may consider such a trade-off acceptable if they do not have the 
resources or support to handle any potential complications. NICE clinical guidelines on 
osteoarthritis have recommended that “patient-specific factors (including age, sex, 
smoking, obesity and comorbidities) should not be barriers to referral for joint surgery”. My 
findings add to the evidence supporting the NICE guidelines that such restrictive eligibility 
criteria for patients with comorbidities are unjustified and may be creating inequities in 
access to joint replacement surgery [19].  Further study however is needed to explore the 
appropriate balance between the risks and benefits of undertaking joint replacement 
surgery in patients with comorbidities and therefore whether these inequalities are 
inequitable.  
As part of its Elective Care Transformation Programme (2017-2019), the NHS is currently 
considering the revision and creation of new standardised eligibility criteria for hip and 
knee replacement surgery across England in order to reduce the variation in access [145]. 
This programme aims to support local commissioners and clinicians in changing how 
patients are referred to secondary care, to make better use of resources, and to reduce the 
wait for hospital treatment (the 18-week target). The findings of my research could inform 
this discussion about standardised eligibility criteria for patients in need of hip or knee 
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replacement surgery and provide the evidence that any restrictions on the basis of the 
presence of comorbidities alone is unjustified.  
 
 
9.3 Strengths and Limitations 
The strengths and limitations of specific methods and analytical approaches have been 
discussed in each chapter but this section will focus on overarching strengths and 
limitations.  
 
 Strengths  
 
9.3.1.1 Methodological approach 
One of the key strengths of this thesis was the use of both qualitative and quantitative 
(RP4) research methods (RP2). The qualitative study allowed for an in-depth exploration of 
the complexity of the health system and to capture the perspectives of providers and 
organisations [146].  Specifically, the qualitative study gave a better understanding of the 
patient journey through the health system for a hip or knee replacement and the roles of 
healthcare professionals in this system. This insight was essential to explore the possible 
reasons for any differences in access for patients with comorbidities. The quantitative study 
did not have data on selection criteria and could not account for unobserved confounders 
such as indication for surgery so the insight from the qualitative interviews with healthcare 
professionals on the referral and selection of patients with comorbidities was invaluable. 
The finding that some patients with comorbidities may be getting ‘lost in the system’ and 
their operations delayed was supported by the quantitative findings on access.  Much of 
the discussion around the impact of comorbidities on access and the possible explanation 
for any inequalities in access would have been lost if only a quantitative approach was 
used.  
 
9.3.1.2 Linked patient-level data 
Another major strength of this thesis was the use of linked national patient-level data. The 
NHS itself is an ideal forum to explore inequalities in health and access due to the available 
patient-level data. I used both patient-reported (PROMs) data to include the patient 
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perspective as well as routine administrative hospital data.  Data linkage provided an 
opportunity to study outcomes other than survival, complications and readmissions and to 
look at outcomes which are a reflection of how patients experience their outcomes.  The 
PROMs survey has a response rate of over 70%, meaning that I did not have access to data 
on all hip or knee replacement surgeries in England, but I did have a large (>500,000 
patients) representative nationwide sample (see further details in Appendix J).  
 
 Limitations  
There were three main limitations to this thesis: the approach to measuring access, the 
healthy-surgical patient effect and the assumption that comorbidities have no impact on 
disease-specific measures. 
 
9.3.2.1 Measuring Access  
As discussed in the introduction, it is not possible to directly observe access to joint 
replacement surgery. I therefore measured access indirectly using a population standard 
approach which measures variation in ‘realised access’.  The main limitation of this 
approach, however is that it cannot explain all the variation.  It is not possible to determine 
whether the rest of the variation is due to random variation or unmeasured or unobserved 
demand or supply factors [32].  
Access to health services as discussed in the introduction is multifaceted and the 
complexity of what constitutes access was demonstrated in my qualitative study. Access 
goes further than the utilisation of healthcare services and limiting the definition of access 
to the use of health services will therefore not fully account for the variation in access.  
Future research on access to joint replacement surgery should therefore attempt to 
simultaneously consider other factors that influence ‘potential access’ such as the 
structural features of the health system (e.g. availability of service) and features of the 
individuals (e.g. ability to seek, ability to pay and patient willingness to undergo surgery) 
[147]. This comprehensive approach will make it possible to truly judge whether there are 
inequities in access and whether the demand is aligned with supply.  This more 
comprehensive view of access has been called for especially due to the increasing 
prevalence of patients with more than one LTC. The emphasis currently is on patients to 
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self-manage their LTCs. Any future concept of access should therefore incorporate patient-
centred perspectives into population-level approaches [148].   
In addition, to explore the determinants of ‘realised access’ I hypothesised that if there 
were differences in access, we might expect to see differences in severity of joint problems 
and duration of these just before the joint replacement surgery. This assumes that 
osteoarthritis is a progressive disorder – the longer you have the disorder the more severe 
the symptoms are. However, there may be other explanations for having more severe joint 
problems just before surgery such as simply having a more severe form of joint disease 
such that the disease progresses more rapidly.  
My approach to access however is also a strength of this study as it demonstrates what can 
be inferred about access from PROMs data. In the wider literature, quantitative studies 
using similar methods to understand access have been limited about what they can 
conclude from using a population standard approach to measuring access. It is for this 
reason that I also used qualitative methods to understand the complexity of the pathway to 
accessing joint replacement surgery.  
 
9.3.2.2 The healthy-surgical patient effect 
Whilst the data used in this research were of a representative sample of patients 
undergoing hip and knee replacement surgery in England, there is still evidence of selection 
bias.  The literature suggests that there is a ‘healthy-surgical patient effect’ such that the 
most severe patients, many of whom will likely suffer comorbidities, are unlikely to be 
eligible for hip and knee replacement surgery and are therefore not selected for surgery 
[50]. As such, the hip and knee replacement patient population with one or more 
comorbidities is likely to represent a healthier population than a random sample from the 
general population with a similar comorbidity profile.  
In addition, this study, similar to other observational studies has the limitation of not being 
able to account for all unmeasured or unobserved confounders such as indication for 
surgery. Skilled clinicians use their expert judgement to decide whether to select a patient 
for surgery and this judgement includes an assessment of the severity of the condition or 
the frailty of the patient.  In addition, patients may have other unmeasured characteristics 
that would make them relatively less frail. This would lead to an underestimation of the 
difference between patients with and without comorbidities [149].  Due to clinical data 
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being unavailable and the lack of consensus on indication for surgery, such confounding 
was not accounted for.  A randomised trial would be required to address this limitation.  
The limited clinical data on any selection criteria and severity of comorbidities prevented 
any exploration of this ‘healthy-surgical patient’ effect. Clinical data on severity of 
comorbidities would have allowed the stratification of the impact of comorbidities on 
outcomes according to the severity of the comorbidity. Understanding comorbidity severity 
is key to understanding the difference between suitability for surgery and unjustifiably 
restricting access on the basis of concerns about adverse outcomes and decreased benefit 
[150].   
 
9.3.2.3 Disease-specific measures and comorbidity 
One of the challenges of interpreting disease-specific measures was disentangling the 
impact of comorbidity on the disease-specific measure itself (RP4).  Previous research in 
both hip and knee patients have reported concerns that comorbidities do influence the 
OHS and OKS, which provides evidence that the OHS/OKS may not be fully ‘joint-specific’ 
[151, 152].  This concern has also been reported in studies of patients with COPD, asthma, 
heartburn and ulcers aiming to measure the extent to which comorbidity influences 
disease-specific quality of life measures and generic quality of life instruments. These 
studies demonstrated that comorbidities had a direct impact on the disease-specific 
measures albeit to a smaller degree than on the generic measure [153-155]. This has 
significant impact on the estimation of true effects of hip and knee replacement surgery 
and should be considered in the design of studies looking at comorbidities and using 
disease-specific as well as generic quality of life measures.  
To account for this direct influence of comorbidities on the OHS/OKS I investigated the 
impact of comorbidities on the two dimensions of severity of joint problems, functional 
status and pain, separately. I hypothesised that pain is more joint-specific compared to 
mobility. For example, questions such as “Have you been able to climb a flight of stairs?” or 
“Could you do the household shopping on your own?” could also elicit a negative response 
in patients with respiratory problems or who are frail.  I therefore investigated the impact 
of the 11 comorbidities on the OHS/OKS functional status and pain scores separately.  This 
analysis demonstrated that compared to patients without comorbidities, patients with 
comorbidities reported not only worse functional status but also more severe pain. This 
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suggests that any direct influence of comorbidities on the OHS/OKS is small compared to 
the overall impact of comorbidities on the severity of the joint problems.   
 
 Further limitations 
 
9.3.3.1 Data  
Data limitations prevented further explorations of known important confounders and 
outcomes. Ideally, I would have wanted to include BMI as a confounder but BMI data was 
not available in HES. I could have used a proxy measure of patients with a reported 
diagnosis of obesity (ICD-10 code: E669) but this has only recently started to be coded 
reliably in HES. This would not have greatly altered the results however as BMI is on the 
causal pathway of several comorbidities included in this programme of work (e.g. diabetes, 
high blood pressure, heart disease).  
Several large national studies in the UK using National Joint Registry (NJR) and Clinical 
Practice Research Datalink (CPRD) data have looked at the impact of high BMI [18, 156] and 
demonstrated that despite slightly increased risks of complications, large improvements in 
outcomes were observed irrespective of BMI [18, 157]. Similarly, a meta-analysis of 17 
studies published before January 2017 found only a small impact of obesity on 
postoperative pain and surgical complications [158].  
It would have been helpful also to have had access to the HES Accident & Emergency (A&E) 
and the Adult Critical Care HES datasets in addition to the Inpatient Admissions data. 
Accident & Emergency data would have allowed me to look more closely at emergency 
visits after surgery and the reason for the emergency visit. The quality of the A&E dataset 
has been questioned however [159]. Adult Critical Care data would have allowed for an 
exploration of patients needing different levels of critical care such as intensive care 
(unplanned) and high dependency care (planned).  It was possible to derive an indicator for 
entering critical care from the Inpatient Admissions data but there were too few critical 
care admissions (N=732/0.15%) compared to expected figures reported by ICNARC 
suggesting coding of critical care may be unreliable [160].  
I also did not look at specific surgical complications after hip or knee replacement surgery 
because of the coding limitations of secondary diagnoses (ICD-10) and procedure codes in 
HES (RP5). There is a lack of consensus on how to measure surgical complications and 
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adverse events in administrative data. In the USA, the Agency for Healthcare Research and 
Quality (AHRQ) developed Patient Safety Indicators (PSIs) to screen for problems that 
patients experience as a result of their care (e.g. postoperative sepsis, respiratory failure, 
sepsis, infections, haemorrhage) in administrative data [161]. The reliability of the coding of 
these PSIs have however, been called into question [162-164]. In the UK the accuracy of the 
coding of secondary diagnoses (comorbidities) and procedure codes (complications) have 
been found to be unreliable and therefore the rates of complications based on these codes 
are likely to be underestimated [165].  As a result, like most studies, I measured adverse 
outcomes that reflect health service use such as 30-day readmission, 30-day mortality and 
transfers to another consultant, as surrogates for surgical complications. 
 
9.3.3.2 Identifying comorbidities 
After analysing the agreement between PROMs and HES-derived comorbidities (RP3), I had 
to decide which measure of comorbidities to use in the subsequent results chapters (RP 4-
6).  I decided on using a combination of comorbidity indices to identify the presence of 
comorbidities in HES rather than just using one comorbidity index (e.g. Charlson 
Comorbidity Index or the Elixhauser) because I wanted to include as many ICD-10 codes to 
capture as many comorbidities as possible. Individual comorbidity indices are only designed 
to calculate a final score for comorbidity adjustment.  
The PROMs comorbidity categories were used to group together the individual types of 
comorbidities. The PROMs survey comorbidity categories were originally chosen based on 
the work of Bayliss et al [44]. Bayliss et al searched the literature to determine the health 
conditions that were most frequently assessed in measuring comorbidity, were important 
to patients and then subsequently pre-tested the instrument for clarity with patients.  
It was therefore decided to use the list of 11 PROMS comorbidity categories but to identify 
the presence of the comorbidity in HES. Each comorbidity was mapped to its relevant ICD-
10 codes as described in RP3 (see also Appendix I). The impact of using different definitions 
of comorbidities is beyond the scope of this thesis but further work needs to be conducted 
to understand the impact of using different definitions on the likelihood of having adverse 
outcomes or reporting improvement in severity of joint problems and HRQoL after surgery.  
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9.4 Opportunities for future research 
In this section I describe areas which I believe are opportunities for future research based 
on the findings here and on the literature in other disease areas and health systems.  
 
9.4.1.1 Future research on access to hip or knee replacement surgery 
Due to the limitations of this programme of work on access, further work is needed to 
understand the profile of patients who are in need of a hip or knee replacement but who 
do not end up receiving a hip or knee replacement. Future work could study patients with 
osteoarthritis in primary care and investigate who does or does not receive a hip or knee 
replacement surgery. This would require the use of GP data (e.g. CPRD data) to identify 
patients with osteoarthritis in primary care and follow them through to secondary care by 
linking the GP data to PROMs or NJR data. This data linkage could also allow further 
investigation of duration of symptoms and validate the patient-reported duration of 
symptoms by looking at the time from the osteoarthritis diagnosis to the date of the 
surgery.  
Such work would also benefit from a larger qualitative study in multiple areas of England 
with not only healthcare professionals but also patients to further explore the impact of 
comorbidities on the referral pathways to joint replacement surgery. Further 
understanding and the added perspective from patients will help describe the specific 
barriers at the system level that may lead to patients with comorbidities getting ‘lost in the 
system’.    
 
9.4.1.2 Future research on the impact of comorbidities on disease-specific measures 
One of the limitations of this thesis was the impact of comorbidities on joint-specific 
measures which made interpretation of such measures challenging. Comorbidities may 
compromise the specificity of such measures, including the OHS/OKS and the WOMAC 
[166], which were originally designed to exclude the effects of comorbidities. Further work 
is needed to ascertain the extent to which comorbidities influence these measures, such as 
the OHS/OKS score, and how to interpret their influence.  
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9.4.1.3 Future research on patient safety after hip or knee replacement surgery 
In the PROMs dataset, patients were also asked to report any postoperative adverse events 
such as wound complications. I did not investigate these outcomes as further work is 
needed to ascertain the reliability of using patient-reported adverse events as opposed to 
adverse events derived from administrative or clinical data. A systematic review of 55 
studies exploring the links between patient experience, clinical safety and effectiveness 
outcomes has found that, in general, there is less evidence available on safety compared to 
effectiveness in research using patient reports of their care [167]. There is evidence to 
suggest that patients could be used as partners in identifying poor and unsafe practice and 
that they could help enhance effectiveness and safety of surgery [168, 169].  Previous 
studies exploring patients’ ability to identify medical errors or adverse events in hospital 
have shown positive associations between patient-reported adverse events and records of 
events in medical records [168, 169]. The reliability of patient-reported adverse events has 
also been explored in oncology [170].  
A previous study in England in hip and knee replacement surgery has looked at the impact 
of BMI on the PROMS patient-reported complications and readmissions but these 
outcomes have not been validated against hospital records [156]. Further work using 
patient-reported complications could elucidate whether these outcomes could be used as 
indicators of unsafe practices after hip or knee replacement surgery.  
 
9.4.1.4 Future research on the impact of multimorbidity on access to and outcomes of hip 
and knee replacement surgery 
Multimorbidity, the presence of one or more comorbidities, is one of the major challenges 
facing our health system [171]. There is a lack of  research on delivering healthcare for 
patients with multimorbidity and thus guidance is primarily on single comorbidities as is the 
case for hip and knee replacement surgery [172]. There is evidence that care for patients 
with multimorbidity is fragmented as the healthcare system is geared towards the single-
disease paradigm and super-specialism [173].   Managing resources to provide care for 
patients with multimorbidity is therefore challenging for healthcare professionals [174, 
175].  
My research, while focusing on individual comorbidities, has found that a significant 
number of patients have more than one comorbidity - 29% (91 461) of patients undergoing 
a hip replacement and 35% (115 451) of patients undergoing a knee replacement.  This 
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highlights the challenges posed to the NHS by the increasing burden of multimorbidity. My 
research has started to explore the effects of having more than one comorbidity and has 
demonstrated that with increasing number of comorbidities, pre-operative severity of joint 
problems increased (worsens) (RP4), improvement in severity of joint problems after 
surgery decreased (worsens) (RP6) and the likelihood of adverse outcomes (RP5) increased. 
The qualitative study (RP2) also highlighted the challenge for healthcare professionals to 
provide care for patients with more than one comorbidity. Further study is needed 
however, to explore how often specific combinations of comorbidities occur compared 
with what can be expected based on chance alone. It would also be important to consider 
how to classify severity of disease with single comorbidities and multiple conditions. 
Current approaches to severity classification are not adequate to address multimorbidity 
[150]. Once this is determined, it would be useful to evaluate the impact of the most 
common combinations of comorbidities on access to and outcomes of hip and knee 
replacement surgery.  
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10 CONCLUSION 
An increasing number of patients undergoing hip and knee replacement surgery have one 
or more comorbidities. This thesis demonstrates that there is variation in access to and 
safety and effectiveness of hip and knee replacement surgery when comorbidity is present. 
Access for patients with comorbidities appears to be complicated by the fragmented 
management of patients with comorbidities along the orthopaedic referral pathway and 
leads to patients being ‘lost in the system’. This was supported by the finding that 
compared to patients without comorbidities, patients with comorbidities reported worse 
functional status and more severe pain just before surgery, and that they are therefore 
likely to have had surgery later in the development of their joint disease. With respect to 
outcomes, patients with comorbidities had a moderately increased risk of adverse 
outcomes after surgery but continued to benefit from the hip and knee replacement 
almost as much as patients without comorbidity. A single comorbidity has a small impact 
but multiple comorbidities have an impact that may be clinically important. The findings 
from this programme of research therefore suggest that the restriction of access to joint 
replacement surgery based on the presence of comorbidities alone is unjustified.  
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12 APPENDICES 
 
12.1 Appendix A – Conference presentations 
As part of my PhD I have attended and presented (oral and poster presentations) at several 
conferences as outlined below. 
 
Research Paper Conference 
RP1 – Systematic Review - PROMs Conference 2017 (Oral) 
- Health Service Research UK Conference 2017 (Oral)  
RP2 – Qualitative Study - Health Service Research UK Conference 2018 (Poster)  
- Society for Social Medicine & Population Health 2018 
(Poster walk) 
RP3 –Methodological piece  - PROMs Conference 2018 (Oral) 
RP4 - Access - American Public Health Association Conference 2018 
(Poster walk) 
- European Public Health Conference 2018 (Poster walk) 
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12.2 Appendix B – Training 
As part of the PhD studentship funded by the NIHR CLAHRC North Thames, I have 
undertaken training in research methods relevant to my PhD study as outlined below.  
 
Research Paper Training 
RP1 – Systematic Review - Reviewing the Literature course at LSHTM  
RP2 – Qualitative Study - Qualitative Methodologies course at LSHTM 
- Qualitative interviewing and analysis course at Oxford 
University 
- NViVo course at LSHTM 
RP3-6  - Statistical Methods in Epidemiology course at LSHTM 
- Introduction to Hospital Episode Statistics at UCL 
- Introduction to Quality of Life and Other Patient 
Reported Outcomes Theory, Measurement, and 
Applications 
 
 
  
 190 
 
12.3 Appendix C – Supplementary Information RP1  
 
Supplementary Information 1 – Search string 
1  knee replacement.mp. or exp knee arthroplasty/  
2  hip replacement.mp. or exp hip arthroplasty/  
3  knee arthroplasty.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
4  hip arthroplasty.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
5  exp Arthroplasty, replacement/  
6  exp hip surgery/ or hip surgery.mp.  
7  exp knee surgery/ or knee surgery.mp.  
8  1 or 3 or 7  
9  2 or 4 or 6  
10  8 and 9  
11  8 or 9 or 10  
12  11 or 5  
13  Humans/  
14  exp Comorbidity/  
15  charlson comorbidity index.mp.  
16  elixhauser comorbidity index.mp.  
17  exp Cardiovascular Diseases/  
18  exp Hypertension/  
19  exp Stroke/  
20  exp Peripheral Vascular Diseases/  
21  exp Lung Diseases/  
22  exp Diabetes Mellitus/  
23  exp Kidney Diseases/  
24  exp Nervous System Diseases/  
25  exp Liver Diseases/  
26  exp Neoplasms/  
27  exp Depression/  
28  exp Diabetes Complications/  
31  underlying diagnosis.mp.  
32  comorbidit*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
33  14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 
27 or 28 or 29 or 30 or 31 or 32  
34  exp Postoperative Complications/  
35  exp Treatment Outcome/  
36  exp "Quality of Life"/  
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Supplementary Information 2 – Description of selected studies (n = 70) 
Study Data  Patient Sample Comorbid Conditions Outcomes 
Country Years of 
data 
Data source Type of 
surgery 
Primary or 
Revision 
surgery 
Sample 
Size 
Ackland 
(2011) 
UK 2004-2005 Single-site THA and TKA Primary & 
Revision 
526 Chronic Kidney disease 
 
Infection, Pain, Postoperative morbidity 
Adams 
(2013) 
USA 2001-2009 Joint registry TKA Primary 40,491 Controlled diabetes All-cause rehospitalizations, Deep 
Infection, Deep vein thrombosis, 
Revisions 
Aggarwal 
(2013) 
USA 2007-2011 Single-site THA and TKA Primary & 
Revision 
323 Atrial Fibrillation Readmission rate 
Amusat 
(2014) 
Canada NS Multi-site TKA Primary 405 Diabetes without impact on 
routine activities, Kidney Disease 
Overall health (HUI3) -6m post-
operative, WOMAC function, WOMAC 
pain 
Ayers 
(2005) 
USA NS Single-site TKA Primary 165 Lower extremity (PVD, venous 
insufficiency) 
Mean change in Physical Function (SF-
36) 12mths post surgery, Mean change 
in Physical Function (WOMAC) 12mths 
post surgery 
Belmont 
(2016) 
USA 2011-2012 Multi-site TKA Revision 1754 Cardiac disease, COPD, 
CVA/Stroke, Diabetes, 
Hypertension 
Readmissions within 30 days 
Bolognesi 
(2008) 
USA 1988-2003 Administrative 
data 
THA and TKA Primary & 
Revision 
2,249,427 Diabetes DVT, Died, Infection 
Browne 
(2014) 
USA 2006-2008 Administrative 
data 
THA and TKA Primary 497,222 Depression Infection, Pulmonary embolism 
Buller 
(2015) 
USA 1990-2007 Administrative 
data 
THA and TKA Primary 8,379,490 Chronic pulmonary disease, CAD, 
Depression, Diabetes, 
Hypertension 
Adverse Events (wound complication , 
postoperative shock, postoperative 
bleeding, acute postoperative infection, 
acute postoperative anemia, acute renal 
failure, acute myocardial infarction, 
pulmonary embolism, induced mental 
disorder, pneumonia, pulmonary 
insufficiency, DVT, intubation and 
transfusion of blood) 
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Chan (2005) UK 2000-2003 Single-site THA NS 1,297 Diabetes Deep Infection, Deep vein thrombosis 
Clement 
(2013) 
UK NS Single-site TKA Primary 2,389 Depression, Diabetes, Heart 
disease, High blood pressure, 
Kidney disease, Lung disease, 
Neurological diseases, Vascular 
disease 
Post-operative OKS at 12mths, post-
operative SF-12 at 12mths 
Cohen 
(2005) 
USA 1986-2002 Single-site THA and TKA Primary 122 Liver cirrhosis Death, Major complications 
Courtney 
(2017) 
USA 2011-2014 Multi-site THA and TKA Primary 169,406 Cardiac disease, Diabetes, History 
of stroke, Preoperative creatinine 
>1.5mg/dL 
30 day complications (SSI, pneumonia, 
respiratory, pulmonary embolism, DVT, 
stroke, cardiac arrest, renal failure, UTI, 
sepsis, septic shock), 30 day 
readmissions 
Deegan 
(2014) 
USA 2004-2011 Single-site THA and TKA NS 779 Chronic Kidney Disease Death, Infections, Revisions 
Deleuran 
(2015) 
Denmark 1995-2001 Administrative 
data 
THA and TKA Primary 109,522 Liver cirrhosis Deep prosthetic infection, Intraoperative 
complications, Mortality within 30 days 
Readmission within 30 days, Revision in 
one year 
Dowsey 
(2009) 
Australia 1998-2005 Single-site TKA Primary 1,214 Cardiovascular disease, Diabetes, 
Respiratory diseases 
Deep Infection 
Erkocak 
(2016) 
USA 2000-2012 Single-site THA and TKA NS 1077 Chronic Renal failure Surgical site infections, In-hospital 
mortality 
Gandhi 
(2009) 
Canada 1998-2006 Single-site TKA NS 1,460 Diabetes, Hypertension DVT within 3 months 
Gaston 
(2007) 
UK 1998-2006 Single-site THA Primary 1,744 Cerebrovascular disease, CHF, 
COPD, Diabetes 
Mortality within 3mths after admission 
Huddleston 
(2009) 
USA 2002-2004 Multi-site TKA NS 2,033 Diabetes Adverse events (deep infections, 
necrosis, nerve injury, dislocation, 
cardiovascular complication, 
periprosthetic fracture, Revision, UTI, 
DVT, Pneumonia, Death) 
Hunt  
(2013) 
UK 2003-2011 Joint registry THA NS 409,096 CHF, PVD, CVD, Chronic Pulmonary 
disease, Diabetes without 
90-day mortality 
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complications, Renal disease, 
Cancer, Dementia 
Hunt  
(2014) 
UK 2003-2011 Joint registry TKA NS 467,779 CHF, PVD, CVD, Chronic Pulmonary 
disease, Diabetes without 
complications, Renal disease, 
Cancer, Dementia 
45-day mortality 
Inacio 
(2016) 
Australia 2001-2012 Administrative 
data 
THA NS 30820 Liver disease, CHF, Renal disease, 
Parkinson’s disease, Dementia, 
Chronic airway disease, Solid 
tumour without metastasis  
90-day mortality, 1-year mortality 
Iorio  
(2012) 
USA 2004-2009 Single-site THA and TKA Primary 1,529 Diabetes Infection 
Jain  
(2005) 
USA 1988-2000 Administrative 
data 
THA and TKA 
and shoulder 
arthroplasty 
Primary 959,839 Diabetes, Hypertension Complications (infections, wound 
infections, pulmonary embolism, 
thromophlebitis, vascular complications, 
other) 
Jamsen 
(2013) 
Finland 1998-2008 Joint registry THA and TKA Primary 96,754 Cancer, CHD, Depression, 
Diabetes, Hypertension (without 
CVD), Pulmonary disease 
Risk of Revision surgery 
Jamsen 
(2014) 
Finland 1998-2009 Administrative 
data + Joint 
registry 
THA and TKA Primary 3,428 Parkinson’s disease Infection at 1 year, Mortality > 1 year 
Revisions in 0-2 years postoperative 
Jamsen 
(2015) 
Finland 1998-2009 Administrative 
data + Joint 
registry 
THA and TKA Primary 4,526 Alzheimer’s disease Mortality after 10 years, Rate of surgical 
site infection, Risk of Revision 
Jorgensen 
(2015a) 
Denmark 2010-2012 Multi-site THA and TKA Primary 8,757 Cardiovascular disease, Pulmonary 
disease 
90-day readmission 
Jorgensen 
(2015b) 
Denmark 2010-2012 Multi-site THA and TKA Primary 8,055 Diabetes Type II "Diabetes-related morbidity" (cardiac 
arrhythmias, acute congestive heart 
failure, MI, prosthetic or wound 
infections, renal insufficiency, cerebral 
attacks, pneumonia, UTI>4days, 
dysregulated blood glucose, other 
infections), 90-day readmission 
Judge 
(2012) 
UK 1993-1995 Multisite THA NS 282 Diabetes SF-36 Physical functioning 
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Kapoor 
(2010) 
USA 2003-2006 Administrative 
data 
THA and TKA Primary 316,671 COPD, CAD, Cerebrovascular 
disease, Diabetes 
Venous Thromboembolism 
Kapoor 
(2013) 
USA 2002-2009 Administrative 
data 
THA and TKA Primary & 
Revision 
24,051 COPD, CAD, Cerebrovascular 
disease, Diabetes 
Venous Thromboembolism 
Karam 
(2015) 
USA 2000-2011 Single-site THA and TKA Primary & 
Revision 
26,415 Cancer Deep vein thrombosis, Mortality 
Overall in-hospital complications, 
Periprosthetic joint infection 
Keswani 
(2016) 
USA 2011-2013 Multi-site THA and TKA Revision 10,112 Disseminated cancer, Cardiac 
disease, Diabetes, Renal disease, 
Stroke, Hypertension, Pulmonary 
disease 
30-day readmissions 
Kildow 
(2017) 
USA 2005-2012 Multi-site THA NS 61,778 Diabetes DVT- 30 days, Prosthetic Joint infection - 
90 days, THA Revision - 2-years 
Kuo  
(2017) 
Taiwan 2009-2012 Single-site TKA Primary 615 Chronic Kidney Disease 30-day readmissions 
Lee  
(2017) 
Korea 2004-2013 Single-site TKA Primary 3,049 Diabetes, Hypertension 90-day readmission 
Liao 
(2016) 
Taiwan 2004-2008 Administrative 
data 
THA NS 2,426 Cardiovascular disease, CVA, 
Chronic Kidney disease, COPD, 
Hypertension 
1-year mortality, 30-day readmissions 
Marchant 
(2009) 
USA 1988-2005 Administrative 
data 
THA and TKA Primary & 
Revision 
1,030,013 Controlled diabetes DVT, Died, Infection 
Martinez 
(2013) 
Spain 2001-2008 Administrative 
data 
THA and TKA Primary 373,131 Diabetes In-hospital mortality 
Mazoch 
(2009) 
USA 2004-2012 Single-site THA and TKA Revision 130 Diabetes All complications, Infection 
McCleery 
(2010) 
UK 1985-2008 Joint registry TKA NS 59,288 Renal failure Early infection (<90 days), Late Revision 
Meding 
(2003) 
USA 1987-1999 Single-site TKA Primary 5,220 Diabetes Deep Infection, DVT, Knee Society Pain 
score - 1yr 
Menendez 
(2016) 
USA 2002-2011 Multi-site THA and TKA Primary 6,054,344 Multiple Myeloma In-hospital mortality, SSI, 
Thromboembolic events 
Miric 
(2014a) 
USA 2005-2010 Joint registry TKA Primary 41,852 Chronic Renal Disease DVT, Mortality (anytime), Mortality 
within 90 days, Readmission within 90 
days, Revision,  
SSI deep 
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Miric 
(2014b) 
USA 2006-2010 Joint registry THA Primary 20,720 Chronic Kidney Disease DVT, Mortality (anytime), Mortality 
within 90 days, Readmission within 90 
days, Revision (any), SSI (any) 
Moon 
(2008) 
Korea 1995-2004 Single-site TKA Primary 1,581 Diabetes Deep joint infection, DVT, Knee Society 
Score – function, Knee Society Score – 
Pain, Overall complications 
Pedersen 
(2010) 
Denmark 1996-2005 Joint registry THA Primary 57,575 Diabetes Overall Revisions 
Perez 
(2014) 
Spain NS Single-site TKA NS 736 Depression SF-36 Physical component scores, 
WOMAC score 
Radkte 
(2016) 
Germany 2011-2012 Single-site THA Primary 498 Cancer, Depression, Diabetes Periprosthetic joint infection 
Rajamaki 
(2015) 
Finland 2009-2011 Single-site THA and TKA Primary 134 Glucose metabolism abnormalities Persistent Pain 
Rasouli 
(2016) 
USA 2009-2009 Single-site THA and TKA Primary & 
Revision 
1,969 Depression Surgical complications 
Robertson 
(2012) 
UK 1989-2002 Single-site TKA NS 734 Diabetes Knee Society knee score year 1 
Sanders 
(2012) 
UK 2006-2010 Administrative 
data 
THA and TKA Primary 414,985 Cancer, Diabetes, Heart Failure, 
Hypertension, Liver disease, PVD, 
Renal failure, Respiratory disease, 
Stroke 
In-hospital mortality, Readmission 
Seol  
(2017) 
South 
Korea 
2007-2015 Multi-site THA and TKA Primary 143 Liver Cirrhosis Infections, Medical complications 
Sikora-Klak 
(2017) 
USA 2012-2014 Single-site THA and TKA Primary 2,914 Diabetes 90-day readmission 
Singh 
(2014a) 
USA 1993-2005 Joint registry TKA Primary 
and 
Revision 
8,672 Depression Knee status: much better  2- years 
Singh 
(2009) 
USA 1993-2005 Joint registry THA Revision 2,687 Depression Moderate-Severe ADL limitation - 2 
years 
Moderate-severe pain - 2 years 
Singh 
(2014b) 
USA 1993-2005 Joint registry TKA Primary & 
Revision 
7,139 Cerebrovascular disease Moderate-Severe ADL limitation - 2 
years 
Moderate-severe pain - 2 years 
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Singh 
(2013a) 
USA 1993-2005 Joint registry THA Primary & 
Revision 
8,394 COPD, Diabetes, Heart disease, 
PVD, Renal disease 
Moderate-severe pain at 2 years 
Singh 
(2013b) 
USA 1993-2005 Joint registry TKA Primary 7,139 
 
Diabetes without complications Moderate-severe ADL limitation 2 -years 
Singh 
(2013c) 
USA 1993-2005 Joint registry TKA Primary 8,672 COPD, Depression, Diabetes, Heart 
disease, PVD, Renal disease 
Moderate-severe pain at 2 years 
Singh 
(2014) 
USA 1993-2005 Joint registry TKA Revision 1,533 Depression Moderate-severe pain at 2 years 
Stundner 
(2013) 
USA 2000-2008 Administrative 
data 
THA and TKA Primary 1,212,493 Depression In-hospital mortality, Major 
complications, Sepsis, Venous 
Thromboembolism 
Tiberi 
(2014) 
USA 2000-2012 Single-site THA and TKA NS 230 Liver cirrhosis Infections within 90 days, Mortality most 
recent follow-up, Mortality within 90 
days, Readmissions 90 days, Revision 
surgery during follow up 
Vannini 
(1984) 
Italy 1969-1979 Single-site THA NS 1,227 Diabetes Post-surgery infections 
Wang 
(2013) 
China 2003-2011 Single-site TKA NS 245 CHD, Diabetes, Hypertension DVT 
Warth 
(2015) 
USA 2006-2012 Administrative 
data 
THA and TKA Primary 74,300 Chronic Renal disease Overall complications 
Zhao  
(2014) 
China 2011-2013 Single-site TKA NS 358 Diabetes, Hypertension DVT within 14 days 
 
Note. NS = not stated; THA = Total Hip Arthroplasty; TKA = Total Knee Arthroplasty; PVD = Peripheral Vascular Disease; COPD = Chronic Obstructive Pulmonary Disorder; 
CAD = Coronary Artery Disease ; CHD = Coronary Heart Disease ; CHF = Coronary Heart Failure; CVA/CVD = Cerebrovascular Accident/Disease; SF-36= Short-form 36; 
WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; OKS = Oxford Knee Score; SF-12 = Short-form 12; SSI = Surgical Site Infection; DVT = Deep Vein 
Thrombosis; UTI = Uterine Infection; MI = Myocardial Infarction.  
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Supplementary Information 3 - Quality appraisal of included 70 studies 
Study 
Patient Selection Comparability Outcome Assessment 
Overall 
quality 
score 
 
Cohort 
Representative? 
Patients drawn 
from same 
community? 
Presence of 
comorbidities 
verified? 
Outcome not 
present at 
the start? 
Cohort drawn 
from multiple 
communities? 
Controlled 
for age and 
sex? 
Controlled for 
SES and 
Ethnicity? 
Outcome of 
interest clearly 
defined? 
Follow-up 
long 
enough? 
Follow-up 
adequate? 
Ackland (2011) Yes Yes Yes Yes No No No Yes NS No 6 
Adams (2013) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
Aggarwal (2013) Yes Yes Yes Yes No Yes No Yes NS No 8 
Amusat (2014) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Ayers (2005) No Yes Yes Yes No Yes No Yes Yes No 8 
Belmont (2016) Yes Yes Yes Yes Yes Yes No No Yes Yes 9 
Bolognesi (2008) Yes Yes Yes Yes Yes Yes Yes No NS No 9 
Browne (2014) Yes Yes Yes Yes Yes Yes Yes (ethnicity) No NS No 8 
Bulle (2015) Yes Yes Yes Yes Yes Yes No No NS No 7 
Chan (2004) Yes Yes Yes Yes No Yes No Yes Yes Yes 10 
Clement (2013)  Yes Yes Yes Yes No No No Yes Yes Yes 8 
Cohen (2005) Yes Yes Yes Yes No No No Yes Yes No 7 
Courtney (2017) Yes Yes Yes Yes Yes Yes Yes (ethnicity) No Yes Yes 10 
Deegan (2014) Yes Yes Yes Yes No Yes No Yes Yes Yes 10 
Deleuran (2015) Yes Yes Yes Yes Yes Yes No No Yes Yes 9 
Dowsey (2009) Yes Yes Yes Yes No Yes No Yes Yes Yes 10 
Ekocak (2016) Yes Yes Yes  Yes No No No No Yes Yes 6 
Gandhi (2009) Yes Yes Yes Yes No Yes No Yes Yes No 9 
Gaston (2007) Yes Yes Yes Yes No Yes No Yes Yes Yes 10 
Huddleston (2009) Yes Yes Yes Yes Yes Yes Yes (ethnicity) No Yes Yes 10 
Hunt (2013) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
Hunt (2014) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
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Inacio (2016)  No Yes Yes Yes Yes Yes No No  Yes Yes 8 
Iorio (2012) Yes Yes Yes Yes No No No Yes NS No 6 
Jain (2005) Yes Yes Yes Yes Yes Yes Yes No NS No 9 
Jamsen (2013) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
Jamsen (2014) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
Jamsen (2015) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
Jorgensen (2015a) Yes Yes Yes Yes Yes No No Yes Yes Yes 9 
Jorgensen (2015b) Yes Yes Yes Yes Yes No No Yes Yes Yes 9 
Judge (2012) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Kapoor (2010) No Yes Yes Yes Yes Yes No No NS Yes 7 
Kapoor (2013) No Yes Yes Yes Yes Yes Yes No Yes Yes 10 
Karam (2015) Yes Yes Yes Yes No No No Yes Yes Yes 8 
Keswani (2016) Yes Yes Yes Yes Yes Yes No No Yes Yes 9 
Kildow (2017) No Yes Yes Yes Yes No No No Yes Yes 6 
Kuo (2017) No Yes Yes Yes No Yes No Yes Yes Yes 9 
Lee (2017) No Yes Yes Yes No Yes No Yes Yes Yes 9 
Liao (2016) No Yes Yes Yes Yes Yes No No Yes Yes 8 
Marchant (2009) No Yes Yes Yes Yes Yes Yes (SES) No Yes Yes 9 
Martinez (2013) No Yes Yes Yes Yes Yes No No Yes Yes 8 
Mazoch (2009) Yes Yes Yes Yes No 1 No Yes NS Yes 8 
McCleery (2010) Yes Yes Yes Yes Yes Yes No No Yes Yes 9 
Meding (2003) Yes Yes Yes Yes No No No Yes Yes No 7 
Menendez (2016) Yes Yes Yes Yes Yes Yes Yes (ethnicity) No Yes Yes 10 
Miric (2014a) Yes Yes Yes Yes Yes Yes Yes (ethnicity) Yes Yes Yes 12 
Miric (2014b) Yes Yes Yes Yes Yes Yes Yes (ethnicity) Yes Yes Yes 12 
Moon (2008) Yes Yes Yes Yes No No No Yes Yes Yes 8 
Pedersen (2010) Yes Yes Yes Yes Yes Yes No Yes Yes Yes 11 
Perez (2014) Yes Yes Yes Yes No No No Yes Yes Yes 8 
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Radkte (2016) No Yes Yes Yes No No No Yes Yes Yes 7 
Rajamaki (2015) Yes Yes Yes Yes No Yes No Yes Yes No 9 
Rasouli (2016) Yes Yes Yes Yes No Yes No Yes Yes Yes 10 
Robertson (2012) Yes Yes Yes Yes No Yes No Yes Yes Yes 10 
Sanders (2012) Yes Yes Yes Yes Yes Yes Yes (SES) No Yes Yes 10 
Seol (2017) Yes Yes Yes Yes Yes No No Yes NS Yes 8 
Sikora-Klak (2017) No Yes Yes Yes No No No Yes Yes No 6 
Singh (2014a) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Singh (2009) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Singh (2014b) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Singh (2013a) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Singh (2013b) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Singh (2013c) Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Singh (2014)  Yes Yes Yes Yes Yes Yes No Yes Yes No 10 
Stundner (2013) Yes Yes Yes Yes Yes Yes Yes (ethnicity) No Yes Yes 10 
Tiberi (2014) Yes Yes Yes Yes No No No Yes Yes Yes 8 
Vannini (1984) Yes Yes Yes Yes No No No Yes Yes Yes 8 
Wang (2013) No Yes Yes Yes No Yes No Yes No Yes 8 
Warth (2015) Yes Yes Yes Yes Yes No No No Yes Yes 7 
Zhao (2014) No Yes Yes Yes No Yes No Yes No Yes 8 
Note: SES = Socioeconomic Status 
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Supplementary Information 4 – Sensitivity Analysis  
Comorbidities  All Studies High Quality Studies (Quality score ≥11) 
# of studies # of patients OR 95% lower CI 95% upper CI # of studies # of patients OR 95% lower CI 95% upper CI 
Surgical Complications 
Cancer 1 <100,000 1.33 1.09 1.62 0     
Depression 3 >1M 1.08 0.94 1.24 0     
Diabetes 7 >1M 1.12 1.01 1.25 0     
Diseases of the Nervous System 0     0     
Heart Disease 3 >1M 1.25 0.95 1.65 0     
High blood pressure 2 >1M 1.03 0.96 1.11 0     
Kidney Disease 3 <1M 1.97 1.84 2.10 0     
Liver disease 3 <1M 3.55 0.99 12.72 0     
Lung disease 2 >1M 1.35 0.84 2.15 0     
Poor circulation 0     0     
Stroke 2 <1M 1.40 1.03 1.90 0     
Venous Thromboembolism 
Cancer 2 >1M 2.30 1.35 3.92 0     
Depression 2 >1M 1.15 1.02 1.30 0     
Diabetes 12 >1M 1.26 0.92 1.72 1 <100,000 0.84 0.60 1.17 
Diseases of the Nervous System 0     0     
Heart Disease 3 <1M 1.07 0.95 1.20 0     
High blood pressure 3 <10,000 1.19 0.79 1.80 0     
Kidney Disease 2 <100,000 1.09 0.73 1.64 2 <100,000 1.09 0.73 1.64 
Liver disease 0     0     
Lung disease 2 <1M 1.29 1.08 1.55 0     
Poor circulation 0     0     
Stroke 2 <1M 1.07 0.73 1.57 0     
Surgical site infections 
Cancer 3 >1M 1.43 0.60 3.41 0     
Depression 3 >1M 1.54 0.64 3.69 0     
Diabetes 12 >1M 1.90 1.32 2.74 1 <100,000 1.31 0.92 1.86 
Diseases of the Nervous System 2 <10,000 1.00 0.50 2.01 2 <10,000 1.00 0.50 2.01 
Heart Disease 1 <10,000 1.92 0.40 9.20 0     
High blood pressure 0     0     
Kidney Disease 6 <1M 1.27 0.97 1.66 2 <100,000 1.06 0.75 1.50 
Liver disease 3 <1M 2.46 1.46 4.12 0     
Lung disease 1 <10,000 0.89 0.22 3.55 0     
Poor circulation 0     0     
Stroke 0     0     
Readmissions 
Cancer 2 <1M 1.29 1.14 1.46 0     
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Depression 0     0     
Diabetes 9 <1M 1.15 1.11 1.19 1 <100,000 1.08 1.00 1.16 
Diseases of the Nervous System 0     0     
Heart Disease 7 <1M 1.68 1.28 2.19 0     
High blood pressure 5 <1M 1.10 0.95 1.28 0     
Kidney Disease 7 <1M 1.62 1.31 2.01 2 <100,000 1.34 1.16 1.56 
Liver disease 3 <1M 1.79 1.36 2.35 0     
Lung disease 5 <1M 1.33 1.11 1.58 0     
Poor circulation 1 <1M 1.35 1.19 1.53 0     
Stroke 5 <1M 1.53 1.38 1.71 0     
Short-term mortality 
Cancer 5 >1M 1.22 0.80 1.87 0     
Depression 1 >1M 0.53 0.32 0.88 0     
Diabetes 4 >1M 1.26 1.15 1.38 0     
Diseases of the Nervous System 3 <1M 1.67 1.20 2.32 0     
Heart Disease 5 >1M 2.96 1.95 4.48 0     
High blood pressure 2 <1M 1.17 1.02 1.35 0     
Kidney Disease 7 >1M 1.83 0.94 3.55 2 <100,000 0.73 0.42 1.26 
Liver disease 3 <1M 2.32 1.43 3.77 0     
Lung disease 4 >1M 1.21 1.03 1.43 0     
Poor circulation 3 >1M 1.50 1.08 2.10 0     
Stroke 4 >1M 2.18 1.42 3.33 0     
Function 
Cancer 0     0     
Depression 4 <100,000 1.69 1.26 2.28 0     
Diabetes 5 <100,000 1.14 0.96 1.35 0     
Diseases of the Nervous System 1 <10,000 1.05 0.73 1.52 0     
Heart Disease 1 <10,000 1.24 1.01 1.52 0     
High blood pressure 1 <10,000 0.99 0.86 1.13 0     
Kidney Disease 2 <10,001 1.58 0.46 5.44 0     
Liver disease 1 <10,000 0.68 0.35 1.32 0     
Lung disease 2 <10,000 1.27 0.49 3.29 0     
Poor circulation 2 <10,000 0.93 0.36 2.42 0     
Stroke 1 <10,000 1.32 1.02 1.71 0     
Quality of Life 
Cancer 0     0     
Depression 2 <10,000 1.20 0.70 2.05 0     
Diabetes 3 <10,000 1.01 0.61 1.68 0     
Diseases of the Nervous System 1 <10,000 1.11 0.79 1.55 0     
Heart Disease 1 <10,000 1.49 1.24 1.78 0     
High blood pressure 1 <10,000 1.00 0.88 1.14 0     
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Kidney Disease 1 <10,000 0.92 0.55 1.55 0     
Liver disease 1 <10,000 0.36 0.20 0.65 0     
Lung disease 2 <10,000 1.26 1.02 1.57 0     
Poor circulation 2 <10,000 1.15 0.80 1.64 0     
Stroke 0     0     
Pain 
Cancer 0  
   0     
Depression 3 <100,000 1.22 0.79 1.87 0     
Diabetes 6 <100,000 1.01 0.66 1.54 0     
Diseases of the Nervous System 0     0     
Heart Disease 2 <100,000 1.16 0.88 1.52 0     
High blood pressure 0     0     
Kidney Disease 4 <100,000 1.17 0.81 1.70 0     
Liver disease 0     0     
Lung disease 2 <100,000 1.17 0.93 1.46 0     
Poor circulation 2 <100,000 1.26 0.98 1.61 0     
Stroke 1 <10,000 1.41 0.97 2.04 0     
Revisions 
Cancer 1 <100,000 0.84 0.33 2.16 1 <100,000 0.84 0.33 2.16 
Depression 1 <100,000 1.40 1.09 1.81 1 <100,000 1.40 1.09 1.81 
Diabetes 4 >1M 1.28 1.02 1.59 3 <1M 1.17 1.06 1.30 
Diseases of the Nervous System 2 <100,000 1.00 0.70 1.42 2 <100,000 1.00 0.70 1.42 
Heart Disease 1 <100,000 1.18 1.06 1.30 1 <100,000 1.18 1.06 1.30 
High blood pressure 1 <100,000 1.11 1.02 1.21 1 <100,000 1.11 1.02 1.21 
Kidney Disease 4 <1M 1.10 0.92 1.30 2 <100,000 0.99 0.77 1.28 
Liver disease 2 <1M 1.96 1.16 3.30 0     
Lung disease 1 <100,000 1.12 1.00 1.26 2 <100,000 1.12 1.00 1.26 
Poor circulation 0  
   0     
Stroke 0  
   0     
Long-term mortality 
Cancer 2 <100,000 1.57 1.19 2.07 0     
Depression 0     0     
Diabetes 3 >1M 0.97 0.82 1.13 0     
Diseases of the Nervous System 3 <100,000 1.92 1.48 2.48 2 <10,000 1.67 1.24 2.25 
Heart Disease 1 <100,000 1.72 1.44 2.06 0     
High blood pressure 1 <10,000 1.30 0.78 2.17 0     
Kidney Disease 5 <100,000 1.65 1.27 2.15 2 <100,000 1.24 0.84 1.83 
Liver disease 3 <100,000 3.40 1.17 9.86 0     
Lung disease 2 <10,000 1.38 1.05 1.80 0     
Poor circulation 0     0     
Stroke 2 <100,000 2.05 1.14 3.66 0     
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12.4 Appendix D – Ethics approval 
 
 Ethics approval 
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 Confidentiality Advisory Group (CAG) approval 
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 Health Research Authority approval 
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12.5 Appendix E – Participant Information Sheet 
 
Participant Information Sheet 
 
We would like to invite you to take part in our research study. Before you decide whether 
you would like to, please read this information so you know what the study is about and 
what taking part would involve.  
Study Title 
The access to and outcomes of elective joint replacement surgery for patients with long-
term conditions: a study using Patient Reported Outcomes Measures data and 
administrative data 
 
What is the study about? 
One of the biggest challenges currently facing the NHS is the increase in the number of 
patients living with long- term conditions. The latest estimates from 2010 suggest that 
around 15 million people in England have a long-term condition. Long-term conditions, 
such as diabetes or heart disease, are conditions that are of long duration and are 
incurable. Patients with long-term conditions tend to use health services often. They 
account for at least 50% of General Practitioner appointments, outpatient appointments 
and inpatient stays.  
Studies have shown that factors such as age, gender, ethnicity and socioeconomic status 
have an impact on the likelihood of accessing healthcare interventions such as surgery and 
on the outcomes, post-surgery. Less attention however, has been given to understanding 
the impact of long-term conditions on access to and outcomes of surgery.   
 
What does the study involve? 
This study aims to investigate the access to, and outcomes of, hip and knee replacement 
surgery for patients with long-term conditions using data that is already collected on 
patients in the NHS in England (Patient Reported Outcome Measures data and 
administrative data such as Hospital Episodes Statistics) and will include conducting 
interviews with healthcare professionals.  Healthcare professionals, who have the 
responsibility of referring and selecting patients for hip and knee replacement surgery, will 
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be interviewed in order to understand their views on selecting and referring patients with 
long-term conditions. This study seeks to understand the process by which patients are 
referred or selected for surgery and what influences this decision and how this might differ 
for patients with long-term conditions. The findings of this study will inform the analysis of 
the data on access to hip and knee replacement surgery and will be published.  
Who is carrying out this study? 
The study is part of a PhD project, led by Belene Podmore, based at the London School of 
Hygiene and Tropical Medicine and at the Royal College of Surgeons of England.  She will be 
supported by a team of researchers who specialise in joint replacement surgery and in 
healthcare quality improvement. The study is funded by the NIHR CLAHRC North Thames.  
 
What would taking part involve? 
We would like you to take part in a one-to-one interview with the lead researcher. 
Interviews will take place at a time and place that suits you and we anticipate that they will 
last a minimum of 30 minutes. The interview will involve discussing your views, opinions 
and experiences of referring and selecting patients for hip and knee replacement surgery 
and how this decision is made. With your permission, I will audiotape your views to ensure 
I have recorded them accurately.  If you do take part, you don’t have to answer all the 
questions and you can end the interview at any time. Your participation is voluntary, so you 
can opt out at any time.  
 
What are the possible benefits of taking part?  
This study will help health professionals to improve the care provided to patients with long-
term conditions. It’s an opportunity to talk about your views on an important aspect of 
policy, namely access to healthcare services. At the same time you will be contributing to 
research of national importance which will have an impact on how services are provided, in 
the future, to patients with long-term conditions to optimise patient outcomes.  
 
What are the possible disadvantages and risks of taking part? 
The possible disadvantages of taking part relate to issues of confidentiality but anything 
you tell me will remain strictly confidential and any views or comments we use in writing-
up the study will remain anonymous. All the audio recordings will be transcribed by a 
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professional transcribing company which has experience of working with confidential 
information. The recordings once transcribed will be destroyed and the data will be 
anonymised. All transcriptions will be securely stored for the period of the project 
(December 2018) and only the research team will have access to the data.  
 
What do I do if I am interested in taking part? 
If you are interested in taking part we would be grateful if you could reply to the 
introductory email that has been sent indicating you would be happy to be contacted about 
the study. Following this, one of the research team will phone you to talk to you about 
whether you would like to take part in an interview and answer any questions you may 
have about the study.  
 
If you have any questions or would like to know more, please contact: 
Belene Podmore  
London School of Hygiene and Tropical Medicine 
15-17 Tavistock Place 
London WC1H 9SH 
Phone: 07881596310      
E-mail: Belene.Podmore@lshtm.ac.uk 
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12.6 Appendix F – Consent Form 
 
Study Title: The access to and outcomes of elective joint replacement surgery for patients 
with long-term conditions: a study using Patient Reported Outcomes Measures data and 
administrative data 
 
Please read all the following statements and initial those you agree with in the box to the 
right and then sign your name at the end.  
 
1. I confirm that I have read the information sheet dated 25/07/2016 (version 1) for the 
above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason. 
3. I agree to the interview being audio recorded and I understand that this audio 
recording will be transcribed by a professional transcribing company and then 
destroyed.  
4. I understand that all information I give during the interview will be strictly 
confidential and that all the results will be anonymised and nothing will be attributed 
directly to me. 
5. I am willing for other members of the project research team to have access to my 
responses. 
6. I agree to take part in the above study. 
 
 
 
            
Name of Participant  Date    Signature 
 
            
Name of Person  Date    Signature 
taking consent 
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12.7 Appendix G – Interview topic guides 
 
Topic Guide – Orthopaedic Surgeons 
 
Clarification of details 
- NHS grade 
- Number of years practicing/Years of experience 
- Type of hospital  
- Specialty 
 
Contextual Factors 
 
1. Can you tell me who the patients are that are typically referred to you? 
a. E.g. elderly, young with sports injuries, gender, socioeconomic status 
b. How severe are their symptoms? 
2. Where are the patients typically referred from? 
a. E.g. musculoskeletal services, GPs, other?  
b. How long have they been waiting to see you?  
3. In your opinion what percentage of patients are inappropriately referred and why? 
a. What would you regard as an appropriate referral? What is your 
conversion rate? 
Assessment/Selection 
1. When a patient is referred to you for hip surgery run me through what you do next. 
a. assessment, diagnosis, selection for surgery 
b. Is it any different for patients with knee patients? 
2. What factors do you take into account in your assessment of the patient before 
selecting them for surgery? 
a. severity of symptoms, duration of symptoms, quality of life 
b. Can you talk through a couple of typical hip and knee patients?  
c. Is it different for hip and knee patients? Do you take into account different 
factors? 
Long-term Conditions 
1. Do you take into account any Long-term conditions (for example diabetes, Heart 
disease) that patients may have when selecting patients for surgery? If so, why?  
a. Are LTCS important to take into account? 
b. Hip vs knee patients 
2. What the most common LTCs/comorbidities you see? 
a. Can you talk through the last patient you had who had a comorbidity? 
3. Are there specific LTCs that you think are especially important to take into 
account? 
a. controlled vs. uncontrolled LTCs, severity of LTCs 
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Other Factors 
1. At what point do you give the go ahead for the patient to undergo surgery? 
2. Are there any other factors that influence your decision to go ahead with surgery? 
a. E.g. hospital pressures, financial pressures, other healthcare professionals, 
social environment of the patient.  
3. How do patients respond when they get selected for surgery? 
 
Topic Guide – GPs 
 
Clarification of details 
- Profession – Partner or salaried  
- Number of years practicing/Years of experience 
- What type of GP practice (size of GP practice)  
 
Contextual Factors 
 
1. How often do you see new patients with hip or knee pain?  
a. E.g. daily, weekly, monthly 
b. prevalence of hip vs. knee pain 
2. What kind of patients are they usually? What is a typical patient? 
a. E.g. elderly, young with sports injuries, gender, socioeconomic status 
3. Do they come specifically for their hip and knee pain or is it a secondary to another 
issue? 
Referral Process 
1. When a patient presents with hip or knee pain run me through what you do next. 
a. Assessment 
b. Diagnosis 
c. Referral: where do you send the patients in the first instance? 
d. At what point do you refer patients to be considered for surgery? 
e. Do you do things differently if it is a problem of the Hip vs. the knee? 
2. What factors do you take into account in your assessment of the patient before 
referring them? 
a. Can you talk through a couple of typical hip or knee patients? 
b. severity of symptoms, duration of symptoms, quality of life  
c. Is it different for hip vs knee patients? 
d. In your opinion what are the most important factors? 
Long-term Conditions 
1. Do you take into account any Long-term conditions (for example diabetes, Heart 
disease) that patients may have in your referral for assessment to surgery? If so, 
why?  
a. Hip vs knee patients 
b. Are LTCS important to take into account? 
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2. Are there specific LTCs that you think are especially important to take into 
account? 
a. controlled vs. uncontrolled LTCs, severity of LTCs 
 
Other factors 
1. Are there any other factors that influence your decision to refer? 
a. E.g. practice pressures, financial pressures 
2. How do patients respond when they get referred for assessment for surgery?  
 
Topic Guide – Intermediate care professionals 
 
Clarification of details 
- Profession  
- Number of years practicing/Years of experience 
 
Contextual Factors 
 
1. How often do you see new patients with hip or knee pain?  
a. E.g. daily, weekly, monthly 
b. prevalence of hip vs. knee pain 
2. What kind of patients are they usually? What is a typical patient? 
a. E.g. elderly, young with sports injuries, gender, socioeconomic status 
 
Referral Process 
1. When a patient presents with hip or knee pain run me through what you do next. 
a. Assessment 
b. Diagnosis 
c. Referral: where do you send the patients? 
d. At what point do you refer patients to be considered for surgery? 
e. Do you do things differently if it is a problem of the Hip vs. the knee? 
2. What factors do you take into account in your assessment of the patient before 
referring them? 
a. severity of symptoms, duration of symptoms, quality of life  
b. Is it different for hip vs knee patients? 
c. In your opinion what are the most important factors? 
Long-term Conditions 
1. Do you take into account any Long-term conditions (for example diabetes, Heart 
disease) that patients may have in your referral for assessment to surgery? If so, 
why?  
a. Hip vs knee patients 
b. Are LTCS important to take into account? 
2. What are the most common LTCs/Comorbidities do you see? 
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a. Can you talk through the last patient you had who had a comorbidity? 
3. Are there specific LTCs that you think are especially important to take into 
account? 
a. controlled vs. uncontrolled LTCs, severity of LTCs 
 
Other factors 
1. Are there any other factors that influence your decision to refer? 
a. E.g. service pressures, financial pressures 
2. How do patients respond when they get referred to orthopaedic surgeons for 
assessment for surgery?  
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12.8 Appendix H – Identifying comorbidities in administrative datasets 
 
 Introduction 
Comorbidity, is the presence of additional diseases in relation to an index disease in one 
individual, and needs to be measured, as the additional diseases will have an impact on the 
index disease or any health intervention. This is why, in epidemiology, comorbidity needs 
to be measured to account for confounding and to understand how it interacts with the 
outcome and the natural history of the outcome [1]. 
Administrative datasets are large datasets used in health services for administrative 
purposes such as reimbursement for health service or insurance payments. Due to the 
complexity of these large databases, comorbidity indices have been developed to identify 
comorbidities and quantify their impact on the outcome.  This is why these comorbidity 
Indices are used widely for risk adjustment and risk prediction modelling in administrative 
datasets. 
The most common comorbidity indices are the Charlson and the Elixhauser comorbidity 
indices. Each comorbidity index includes different comorbidities but they usually include 
conditions that cannot also be complications of care.  Each index or set of indices was also 
originally developed to predict a certain outcome such as to predict 1-year mortality 
(Charlson) or length of stay, hospital charges and in-hospital mortality (Elixhauser). The 
comorbidities included are defined using the International Classification of Disease (ICD) 
codes that are used in administrative data to record diagnoses. The majority of the indices 
have been developed for use in version 9 of the ICD and not for the most recent version 10. 
The majority of the studies comparing indices were carried out in the United States and in 
Canada using Medicare and Medicaid data [2]. 
Due to the variability in the comorbidities included in the indices and in the outcomes that 
they were developed to predict, researchers have been forced to modify them so that they 
are more suitable to the study population in which they are interested. As a result, there 
are many modifications of the Charlson and Elixhauser comorbidity indices and it is 
important to understand how they all differ and what their limitations are. 
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 Assessing the properties of comorbidity indices 
 
Validity 
As there is no gold standard for ‘true comorbidity’, researchers use the assumption that 
‘true comorbidity’ is correlated with worse health outcomes, healthcare utilisation and 
costs. Therefore, to test the validity of comorbidity indices, the index is assessed by how 
well it predicts those outcomes which indirectly determine how well the comorbidity index 
can control for confounding.   
There are several measures of validity but the most common is the improvement in the 
variance, R2. For dichotomous outcomes, there are measures of discrimination and 
calibration. Measures of discrimination compare the predicted outcome with the actual 
outcome (e.g. the C statistic) which goes from 0 to 1.  [3].  
Reliability 
Reliability relies on the ability to be able to reproduce the same results in the same set of 
data. In that sense computerised indices are reliable in the sense that they come from 
administrative datasets, but reliability also depends on the accuracy of the information 
stored in the dataset. Accuracy, in turn, depends on how accurately the coded information 
was gathered from medical or pharmacy records. The reliability of the code-based 
comorbidity indices are often not measured directly but inferred from other research 
studies addressing coding accuracy [3]. 
 
 Types of Diagnosis-based Indices  
 
The Charlson Comorbidity Index (CCI) 
The CCI was created by Charlson et al. in 1987 and was developed using chart review to 
predict 1-year mortality in a cohort of 604 patients admitted to a medical service at New 
York during 1 month in the year 1984 [4]. The index includes a list of 19 conditions with 
each condition assigned a weight of 1, 2, 3 or 6 based on adjusted hazard ratios for each 
comorbid conditions. A total score is then calculated from the sum of the weighted scores 
[4]. The CCI is the most widely used comorbidity index and has been validated in a variety 
of patient populations and used to predict a variety of outcomes [5-11]. Many adaptations 
of the CCI have been developed for use with ICD-9 or ICD-10 codes in administrative 
databases.  
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Deyo CCI 
The Deyo CCI is an adaptation of the CCI which is the most commonly used adaptation of 
the CCI [2]. This adaptation uses the ICD-9 codes corresponding to 17 comorbid conditions 
[12]. Several studies have specifically evaluated the ability of the Deyo CCI to predict 
outcomes such as 1-year mortality, length of stay or costs [11, 13, 14]. A systematic review 
in 2012 found that the Deyo CCI showed low abilities to predict short-term mortality but 
behaved very similarly to other adaptations for long-term mortality [2].  In 2004, the Deyo 
CCI was adapted for the use with ICD-10 codes and this adaptation performed similarly to 
the original ICD-9 version in predicting in-hospital mortality [14].  
 
Romano CCI 
Another adaptation of the CCI is the Romano CC which was formerly known as the 
Dartmouth-Manitoba CCI. Compared to the Deyo CCI the Romano adaptation includes 
broader definitions encompassing more ICD-9-CM codes for peripheral vascular diseases, 
complicated diabetes and malignancy [15, 16]. 
Several studies have compared the Romano and Deyo adaptations of the CCI and found 
them to be very similar [8, 17, 18].  The Romano adaptation of the Charlson index however 
had better predictive performance than the majority of the indices for long-term mortality 
[2].   
 
D’Hoore CCI  
D’Hoore et al. created a CCI adaptation using only the first three digits of ICD-9 coding 
without clinical modification (CM) (which includes procedural codes and additional 
morbidity details) as many institutions outside the US use ICD-9 codes without CM [5]. 
D’Hoore claims that the CM digits of the ICD-9 codes can lead to inconsistencies, so they 
have created a simpler and more reliable adaptation. The D’Hoore index has been found to 
have a high ability to predict in-hospital mortality in populations with a principle diagnosis 
of myocardial infarction, ischemic heart disease and bacterial pneumonia, but does not 
have the same ability to predict for stroke and congestive heart failure [19].  
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Ghali CCI  
The Ghali adaptation built further on the Deyo’s adaptation to create a shorter study-
specific index which includes only five comorbidities. The comorbidities included have been 
selected based on whether they have been found to be associated with in-hospital 
mortality. The study-specific weights for each comorbidity were then derived from multiple 
logistic regression analyses on the study sample used for the development of the index [7]. 
The Ghali CCI performs better than the Deyo CCI in predicting in-hospital mortality but 
when compared to the original CCI it did not perform well [20].  
 
Quan CCI 
The Quan adaptation was developed in 2006 by adapting the Deyo CCI coding to the ICD-10 
coding and adding to the selection of codes for each comorbidity, by using experts’ 
knowledge to assess the validity of the ICD-10 codes [21].  In 2011 the Quan index was 
updated and used study-specific weights in a similar method to Ghali’s and demonstrated a 
better ability to predict in-hospital mortality and 1-year mortality than the original Quan 
CCI [22]. 
In comparison to other CCI adaptations, the Quan index is similar to the Romano 
adaptation in predicting short-term and long-term mortality [2] 
 
Elixhauser (El) 
The original Elixhauser comorbidity index is an index made up of 30 comorbidities defined 
using ICD-9-CM codes. The comorbidities were included because they were significant 
predictors of LOS and hospital charges and were explicitly not complications of care. Many 
of the comorbidities were associated with in-hospital mortality but as a group, they were 
not significant. The disadvantage of the original EI is there is no weighting system to 
provide a single score [23].  
Several studies have validated the EI and many have then gone on to modify the EI [21, 24, 
25]. In predicting in-hospital mortality, all EI versions demonstrated acceptable to excellent 
predictive ability. Another study found that the ICD-9-CM version performed better than 
the ICD-10 version. Another EI version using study-derived regression coefficients had 
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similar results to models using the EI which included all comorbidities. An EI version with 
only 21 comorbidities was significantly associated with mortality [25].   
A number of studies have compared EI to other comorbidity indices and have 
demonstrated that various versions of the EI predicted mortality outcomes better than the 
various adaptations of the CCI [20]. Some studies however, found no difference between 
the two. Several studies demonstrated that combining data sources such as inpatient and 
outpatient data resulted in even better predictive ability. 
 
 Other sources of data 
 
Medications-based Indices  
Other sources of administrative data are pharmacy databases. As a result, comorbidity 
indices have been developed for use in these datasets; it has been claimed that they are 
more accurate and complete than diagnosis-based databases.  One of the indices 
developed is the Chronic Disease Scores (CDS) which was developed in 1992 using 
medications data to identify comorbidities. Using a population-based pharmacy database a 
panel of experts, starting from a selected base of medications, created disease categories 
and then assigned weights [26]. The original CDS included 17 diseases but was 
subsequently expanded to 28 and weighting was applied based on regression models [27].  
The RxRisk and RxRisk-V is a risk assessment instrument which was developed using 
outpatient pharmacy data to identify chronic diseases and predict future healthcare costs. 
The score includes 57 adult and paediatric weighted disease categories and drug classes 
[28]. 
The Medication-based Disease Burden Index (MDBI) was developed as an alternative to the 
chronic disease score. This score had a weak correlation with the CCI and CDS and has only 
a moderate ability to predict readmission and 6-month mortality [29].  
Overall medication-based indices demonstrated a better ability than diagnosis-based 
indices to predict health utilization outcomes such as prescription medication use, total 
costs, disease burden and hospital utilisation.  EI, however, demonstrated better ability to 
predict physician visits. Medication and diagnosis-based indices demonstrated similar 
abilities to predict hospital readmission and length of stay, hospitalisation, spending and 
costs [20].  
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Self-report vs. administrative data 
Comorbidity indices calculated from administrative data have also been validated against 
scores derived from self-reported data. Several studies have specifically compared the 
performance of a CCI adaptation derived from self-reported data with the same index 
derived from administrative data or chart review. They found that self-reported data and 
administrative data adaptations had similar ability to predict various outcomes [30, 31]. 
One study found that the levels of agreement varied according to comorbid conditions and 
varied from poor to substantial agreement [32].  
Chart review vs. administrative data 
Comorbidity indices calculated from administrative data have also been validated against 
scores derived from chart review. A systematic review in 2010 compared chart-review and 
CCI adaptations derived from administrative data [33].  They found that CCI scores 
calculated from administrative data were consistently lower than those derived from chart 
review, and agreement between the two sources was poor to fair. Further studies have 
found that agreement varied greatly according to the comorbidity [34]. Another found that 
the two comorbidities correlated well [35]. 
 
 Application of Comorbidity Indices 
 
Approaches to selecting comorbidities 
Studies using comorbidity indices have selected comorbidities based on a mix of looking at 
the prevalence of the diagnoses, comparisons to existing indices and the seeking of expert 
opinion [2]. For example Desai et al. [36]  reviewed the medical literature, expert opinion 
and then looked at the preliminary analysis of the data and considered conditions which 
had a prevalence of >2%. Fleming et al. looked at the prevalence of disease and compared 
it with the Charlson index and was influenced by the desire to focus on chronic rather than 
acute conditions [37]. Others simply combined the conditions listed in the Elixhauser and 
the Deyo adaptation of the Charlson index excepting those conditions thought to be 
related to the main diagnosis [38, 39] 
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Look back periods 
The length of the look back period to identify comorbidities has been found to influence 
the performance of both the Charlson and Elixhauser [34]. A study found that by adding 
inpatient and outpatients claims in the 12 months before the index hospitalisation the 
Charlson and Elixhauser performed better [40]. In another study looking at 1-year mortality 
and readmissions, a 1 year lookback period gave the best fit for 1-year mortality and a 
longer lookback period gave the best fit for readmissions [41]. 
 
 Limitations of comorbidity indices 
One of the clear advantages to using comorbidity indices is that it allows us to use 
administrative datasets for population-based research. Population-based research provides 
us with more accurate estimates of prevalence or incidence and may be more generalizable 
and relevant to policy decision making. Administrative datasets are also less subject to 
patient-related recall bias and selection and nonresponse bias [42]. Practically, 
administrative datasets are also much cheaper than primary data collection. Finally, linkage 
of administrative databases allows for long-term follow-up of the patient journey and its 
outcomes which is increasingly important in integrated care research [43].  
While there are clear advantages of using, comorbidity indices there are also clear 
disadvantages, which need to be considered of using comorbidity indices, in particular, 
diagnosis-based indices. These also include variable coding practices and the accuracy and 
completeness of the data.   
One of the disadvantages of diagnosis-based indices includes a variability in ICD coding 
practices which can lead to under-reporting of chronic conditions in secondary diagnosis 
[33].  A study has found that acute clinical conditions are more accurately documented 
than comorbidities and this varies across different types of hospitals [44]. Some 
researchers argue therefore that chart review is a better source of data on comorbidities 
than administrative dataset, but research has shown that chart review focuses more on the 
history of comorbid conditions rather than more active conditions [45].   
Another problem with coding is that there is often not a clear difference between 
diagnoses of comorbidities at the point of admission to hospital and complications arising 
during the hospital stay. Treating complications as comorbidities can overestimate the 
performance of the comorbidity index at predicting a worse outcome [46]. In addition, if 
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you want to adjust for hospital outcome than you cannot adjust for complications as they 
are partly a result of hospital care [2]. However, a study found that the impact of 
misinterpreting complications as comorbidities in surgical procedures is minor [47].  There 
is also the possibility that diagnoses are sometimes recorded as present when in actual fact 
they are recorded in a bid to rule them out (they are negative). Such misinterpretation is 
only possible to identify if it is possible to look at admissions before and after that index 
admission. The use of diagnostic-type codes which allow for the distinction between 
primary diagnoses and post-admission comorbidities may prevent any misinterpretation 
[33].  
Another limitation is the completeness of the data as this can lead to more inaccuracies. A 
study found that sensitivity in capturing specific diagnoses in administrative datasets with 
five diagnosis fields reduced by an average 13% compared to a record with 25 fields [48].  
Another disadvantage is that certain CCI adaptations can only be used with specific ICD 
versions (e.g. Deyo CCI with ICD-9-CM and the Quan CCI with ICD-10). In addition, there is a 
lot of variation in ICD-10 versions than ICD-9 versions which further limits the applications 
of these diagnosis-based indices. It is therefore important to consider the ICD version used 
in the administrative data before selecting the CCI index. [20] 
Schneeweiss et al. also argue that comorbidity scores only modestly improve on age 
adjustment despite comorbidity indices being more comprehensive.  This may be because 
in summarising a complex construct such as comorbidity in one summary score, numerous 
assumptions are made and therefore inevitability underestimates the magnitude of 
confounding. Having one summary score however is very useful in adjusting for 
confounders but it does depend on the accuracy and completeness of the data.  
Unfortunately, the completeness depends on the accuracy in the data collection and 
recording processes.  [3]. 
It is also important to note that the prognoses of many comorbidities (such as AIDS) have 
dramatically changed in the last decade. This will have an impact on the current weights 
assigned to certain comorbidities which is why studies recommend, if possible, to derive 
study-based weights rather than relying on the weights derived by the original comorbidity 
indices [43]. 
 
 223 
 
 Conclusion  
In conclusion, of the diagnosis-based measures, the Elixhauser seems to be better than the 
CCI in predicting both short and long-term mortality. Of the CCI adaptations it seems the 
Romano adaptation has been demonstrated to be better at predicting various outcomes 
compared to other adaptations of the CCI index [2, 20]. Overall comorbidity indices are 
better at predicting long-term mortality compared to short-term mortality and this may be 
because in patients with serious acute conditions comorbidities are usually underreported 
[2].  
Evidence suggests that other factors can further improve the performance of these indices. 
For example using a combination of both inpatient and outpatient, data improves the 
performance of the comorbidity indices. Similarly, the length of the look back period also 
influences the performance of comorbidity indices. Almost all studies found that deriving 
study-specific weights for both the EI and the CCI adaptations greatly improved their 
performance at predicting outcomes [20].  
While pharmacy data is considered to be of better quality and more reliable it is often not 
very accessible as is the case in this study. There is also a big disadvantage of using 
pharmacy data in that the comorbidities included are limited to those which are treated 
with medications [20].  
Overall, while there are clearly indicators which have been shown to perform better than 
others it is important to consider the source of the data being used, the study population 
and the outcomes of interest before selecting the most appropriate comorbidity indices. 
  
 224 
 
 References 
1. Degroot, V., Beckerman, H., Lankhorst, G., et al., How to measure comorbiditya 
critical review of available methods. Journal of Clinical Epidemiology, 2003. 56(3): p. 221-
229 DOI: 10.1016/s0895-4356(02)00585-1. 
2. Sharabiani, M. T. A., Aylin, P., and Bottle, A., Systematic review of comorbidity 
indices for administrative data. Medical Care, 2012. 50(12): p. 1109-1118 DOI: 
http://dx.doi.org/10.1097/MLR.0b013e31825f64d0. 
3. Schneeweiss, Sebastian and Maclure, Malcolm, Use of comorbidity scores for 
control of confounding in studies using administrative databases. International Journal of 
Epidemiology, 2000. 29(5): p. 891-898 DOI: 10.1093/ije/29.5.891. 
4. Charlson, M. E., Pompei, P., Ales, K. L., et al., A NEW METHOD OF CLASSIFYING 
PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND 
VALIDATION. Journal of Chronic Diseases, 1987. 40(5): p. 373-383 DOI: 10.1016/0021-
9681(87)90171-8. 
5. Dhoore, W., Sicotte, C., and Tilquin, C., RISK ADJUSTMENT IN OUTCOME 
ASSESSMENT - THE CHARLSON COMORBIDITY INDEX. Methods of Information in Medicine, 
1993. 32(5): p. 382-387. 
6. Melfi, C., Holleman, E., Arthur, D., et al., SELECTING A PATIENT CHARACTERISTICS 
INDEX FOR THE PREDICTION OF MEDICAL OUTCOMES USING ADMINISTRATIVE CLAIMS 
DATA. Journal of Clinical Epidemiology, 1995. 48(7): p. 917-926 DOI: 10.1016/0895-
4356(94)00202-2. 
7. Ghali, W A, Hall, R E, Rosen, A K, et al., Searching for an improved clinical 
comorbidity index for use with ICD-9-CM administrative data. Journal of clinical 
epidemiology, 1996. 49: p. 273-8. 
8. Cleves, M. A., Sanchez, N., and Draheim, M., Evaluation of two competing methods 
for calculating Charlson's comorbidity index when analyzing short-term mortality using 
administrative data. Journal of Clinical Epidemiology, 1997. 50(8): p. 903-908 DOI: 
10.1016/s0895-4356(97)00091-7. 
9. Harse, J. D. and Holman, C. D. J., Charlson's Index was a poor predictor of quality of 
life outcomes in a study of patients following joint replacement surgery. Journal of Clinical 
Epidemiology, 2005. 58(11): p. 1142-1149 DOI: 10.1016/j.jclinepi.2005.02.017. 
10. Norena, M., Wong, H., Thompson, W. D., et al., Adjustment of intensive care unit 
outcomes for severity of illness and comorbidity scores. Journal of Critical Care, 2006. 
21(2): p. 142-150 DOI: 10.1016/j.jcrc.2005.11.011. 
11. Hollenbeak, C. S., Stack, B. C., Daley, S. M., et al., Using comorbidity indexes to 
predict costs for head and neck cancer. Archives of Otolaryngology-Head & Neck Surgery, 
2007. 133(1): p. 24-27 DOI: 10.1001/archotol.133.1.24. 
12. Deyo, R A, Cherkin, D C, and Ciol, M A, Adapting a clinical comorbidity index for use 
with ICD-9-CM administrative databases. Journal of clinical epidemiology, 1992. 45: p. 613-
9. 
 225 
 
13. Wang, P. S., Walker, A., Tsuang, M., et al., Strategies for improving comorbidity 
measures based on Medicare and Medicaid claims data. Journal of Clinical Epidemiology, 
2000. 53(6): p. 571-578 DOI: 10.1016/s0895-4356(00)00222-5. 
14. Sundararajan, Vijaya, Henderson, Toni, Perry, Catherine, et al., New ICD-10 version 
of the Charlson comorbidity index predicted in-hospital mortality. Journal of clinical 
epidemiology, 2004. 57: p. 1288-94 DOI: 10.1016/j.jclinepi.2004.03.012. 
15. Roos, L. L., Sharp, S. M., Cohen, M. M., et al., RISK ADJUSTMENT IN CLAIMS-BASED 
RESEARCH - THE SEARCH FOR EFFICIENT APPROACHES. Journal of Clinical Epidemiology, 
1989. 42(12): p. 1193-1206 DOI: 10.1016/0895-4356(89)90118-2. 
16. Romano, P. S., Roos, L. L., and Jollis, J. G., FURTHER EVIDENCE CONCERNING THE 
USE OF A CLINICAL COMORBIDITY INDEX WITH ICD-9-CM ADMINISTRATIVE DATA. Journal 
of Clinical Epidemiology, 1993. 46(10): p. 1085-1090 DOI: 10.1016/0895-4356(93)90106-b. 
17. Ghali, W. A., Hall, R. E., Rosen, A. K., et al., Searching for an improved clinical 
comorbidity index for use with ICD-9-CM administrative data. Journal of Clinical 
Epidemiology, 1996. 49(3): p. 273-278 DOI: 10.1016/0895-4356(95)00564-1. 
18. Nuttall, Martin, van der Meulen, Jan, and Emberton, Mark, Charlson scores based 
on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing 
urological cancer surgery. Journal of clinical epidemiology, 2006. 59: p. 265-73 DOI: 
10.1016/j.jclinepi.2005.07.015. 
19. Dhoore, W., Bouckaert, A., and Tilquin, C., Practical considerations on the use of 
the Charlson comorbidity index with administrative data bases. Journal of Clinical 
Epidemiology, 1996. 49(12): p. 1429-1433 DOI: 10.1016/s0895-4356(96)00271-5. 
20. Yurkovich, M., Avina-Zubieta, J. A., Thomas, J., et al., A systematic review identifies 
valid comorbidity indices derived from administrative health data. Journal of Clinical 
Epidemiology, 2015. 68(1): p. 3-14 DOI: http://dx.doi.org/10.1016/j.jclinepi.2014.09.010. 
21. Quan, H., Sundaratajan, V., Halfon, P., et al., Coding algorithms for defining 
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care, 2005. 43 DOI: 
10.1097/01.mlr.0000182534.19832.83. 
22. Quan, H. D., Li, B., Couris, C. M., et al., Updating and Validating the Charlson 
Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using 
Data From 6 Countries. American Journal of Epidemiology, 2011. 173(6): p. 676-682 DOI: 
10.1093/aje/kwq433. 
23. Elixhauser, A, Steiner, C, Harris, D R, et al., Comorbidity measures for use with 
administrative data. Medical care, 1998. 36: p. 8-27. 
24. Zhu, H. F. and Hill, M. D., Stroke - The Elixhauser Index for comorbidity adjustment 
of in-hospital case fatality. Neurology, 2008. 71(4): p. 283-287 DOI: 
10.1212/01.wnl.0000318278.41347.94. 
25. van Walraven, Carl, Austin, Peter C, Jennings, Alison, et al., A modification of the 
Elixhauser comorbidity measures into a point system for hospital death using 
administrative data. Medical care, 2009. 47: p. 626-33 DOI: 
10.1097/MLR.0b013e31819432e5. 
 226 
 
26. Von Korff, Michael, Wagner, Edward H., and Saunders, Kathleen, A chronic disease 
score from automated pharmacy data. Journal of Clinical Epidemiology, 1992. 45(2): p. 197-
203 DOI: http://dx.doi.org/10.1016/0895-4356(92)90016-G. 
27. Clark, D. O., Von Korff, M., Saunders, K., et al., A chronic disease score with 
empirically derived weights. Med Care, 1995. 33(8): p. 783-95. 
28. Fishman, P. A., Goodman, M. J., Hornbrook, M. C., et al., Risk adjustment using 
automated ambulatory pharmacy data: the RxRisk model. Med Care, 2003. 41(1): p. 84-99 
DOI: 10.1097/01.mlr.0000039830.19812.29. 
29. George, Johnson, Vuong, Tam, Bailey, Michael J, et al., Development and Validation 
of the Medication-Based Disease Burden Index. Annals of Pharmacotherapy, 2006. 40(4): p. 
645-650 DOI: 10.1345/aph.1G204. 
30. Roos, Leslie L., Sharp, Sandra M., Cohen, Marsha M., et al., Risk adjustment in 
claims-based research: The search for efficient approaches. Journal of Clinical 
Epidemiology, 1989. 42(12): p. 1193-1206 DOI: http://dx.doi.org/10.1016/0895-
4356(89)90118-2. 
31. Susser, Stephanie R., McCusker, Jane, and Belzile, Eric, Comorbidity information in 
older patients at an emergency visit: self-report vs. administrative data had poor 
agreement but similar predictive validity. Journal of Clinical Epidemiology, 2008. 61(5): p. 
511-515 DOI: http://dx.doi.org/10.1016/j.jclinepi.2007.07.009. 
32. Ronksley, Paul E., Tsai, Willis H., Quan, Hude, et al., Data enhancement for co-
morbidity measurement among patients referred for sleep diagnostic testing: an 
observational study. BMC Medical Research Methodology, 2009. 9(1): p. 1-9 DOI: 
10.1186/1471-2288-9-50. 
33. Leal, J. R. and Laupland, K. B., Validity of ascertainment of co-morbid illness using 
administrative databases: A systematic review. Clinical Microbiology and Infection, 2010. 
16(6): p. 715-721 DOI: http://dx.doi.org/10.1111/j.1469-0691.2009.02867.x. 
34. Zhang, J X, Iwashyna, T J, and Christakis, N A, The performance of different 
lookback periods and sources of information for Charlson comorbidity adjustment in 
Medicare claims. Medical care, 1999. 37: p. 1128-39 DOI: 
http://dx.doi.org/10.1097/00005650-199911000-00005. 
35. Jang, S. H., Chea, J. W., and Lee, K. B., Charlson comorbidity index using 
administrative database in incident PD patients. Clin Nephrol, 2010. 73(3): p. 204-9. 
36. Desai, M. M., Bogardus, S. T., Jr., Williams, C. S., et al., Development and validation 
of a risk-adjustment index for older patients: the high-risk diagnoses for the elderly scale. J 
Am Geriatr Soc, 2002. 50(3): p. 474-81. 
37. Fleming, S. T., Pearce, K. A., McDavid, K., et al., The development and validation of 
a comorbidity index for prostate cancer among Black men. J Clin Epidemiol, 2003. 56(11): p. 
1064-75. 
38. Gagne, J. J., Glynn, R. J., Avorn, J., et al., A combined comorbidity score predicted 
mortality in elderly patients better than existing scores. J Clin Epidemiol, 2011. 64(7): p. 
749-59 DOI: 10.1016/j.jclinepi.2010.10.004. 
 227 
 
39. Thombs, B. D., Singh, V. A., Halonen, J., et al., The effects of preexisting medical 
comorbidities on mortality and length of hospital stay in acute burn injury: evidence from a 
national sample of 31,338 adult patients. Ann Surg, 2007. 245(4): p. 629-34 DOI: 
10.1097/01.sla.0000250422.36168.67. 
40. Li, P., Kim, M. M., and Doshi, J. A., Comparison of the performance of the CMS 
Hierarchical Condition Category (CMS-HCC) risk adjuster with the Charlson and Elixhauser 
comorbidity measures in predicting mortality. BMC Health Serv Res, 2010. 10: p. 245 DOI: 
10.1186/1472-6963-10-245. 
41. Preen, D. B., Holman, C. D., Spilsbury, K., et al., Length of comorbidity lookback 
period affected regression model performance of administrative health data. J Clin 
Epidemiol, 2006. 59(9): p. 940-6 DOI: 10.1016/j.jclinepi.2005.12.013. 
42. Romano, P. S., Roos, L. L., Luft, H. S., et al., A comparison of administrative versus 
clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient 
Outcomes Research Team. J Clin Epidemiol, 1994. 47(3): p. 249-60. 
43. Needham, D. M., Scales, D. C., Laupacis, A., et al., A systematic review of the 
Charlson comorbidity index using Canadian administrative databases: a perspective on risk 
adjustment in critical care research. Journal of Critical Care, 2005. 20(1): p. 12-9. 
44. Quan, H., Li, B., Saunders, L. D., et al., Assessing validity of ICD-9-CM and ICD-10 
administrative data in recording clinical conditions in a unique dually coded database. 
Health Serv Res, 2008. 43(4): p. 1424-41. 
45. Humphries, K. H., Rankin, J. M., Carere, R. G., et al., Co-morbidity data in outcomes 
research: are clinical data derived from administrative databases a reliable alternative to 
chart review? J Clin Epidemiol, 2000. 53 DOI: 10.1016/s0895-4356(99)00188-2. 
46. Schneeweiss, S. and Maclure, M., Use of comorbidity scores for control of 
confounding in studies using administrative data bases. International Journal of 
Epidemiology, 2000. 29(5): p. 891-898 DOI: 10.1093/ije/29.5.891. 
47. Roos, L L, Stranc, L, James, R C, et al., Complications, comorbidities, and mortality: 
improving classification and prediction. Health services research, 1997. 32: p. 229-38; 
discussion 239-42. 
48. Romano, Patrick S. and Mark, David H., Bias in the Coding of Hospital Discharge 
Data and Its Implications for Quality Assessment. Medical Care, 1994. 32(1): p. 81-90. 
 228 
 
12.9 Appendix I – Supplementary Information RP3 - Mapping of comorbidities  
PROMs chronic 
disease category 
Chronic disease 
Subcategories 
ICD-10 Code ICD-10 definition RCS CI Quan CCI Elixhauser* Backward 
coding 
Cancer  Lymphoma C81.x-C85.x Malignant neoplasms x x x  
C88 Malignant neoplasms x x x  
C90.0 Malignant neoplasms x x x  
C90.2 Malignant neoplasms x x x  
C90-C97 Malignant neoplasms x x   
C96.x Malignant neoplasms x x x  
Metastatic cancer C77–C80 Malignant neoplasms x x x  
Solid Tumour without 
metastasis 
C00.x-C26.x Malignant neoplasms x x x  
C30.x-C34.x Malignant neoplasms x x x  
C37.x-C41.x Malignant neoplasms x x x  
C43 Malignant neoplasms x x x  
C45.x-C58.x Malignant neoplasms x x x  
C60.x-C76.x Malignant neoplasms x x x  
C97.x Malignant neoplasms x x x  
Depression Depression F32.x Depressive episode   x  
F33 Recurrent depressive disorder   x  
F34.1 Dysthymia   x  
Depression linked to 
anxiety and stress 
F41.2 Mixed anxiety and depressive disorder   x  
F43.2 Adjustment disorders   x  
Other depression F20.4 Post-schizophrenic depression   x  
F31.3-F31.5 Bipolar affective disorder, current episode mild or moderate depression, severe 
depression without psychotic symptoms, severe depression with psychotic symptoms 
  x  
Diabetes Insulin-dependent 
diabetes 
E10 Insulin-dependent diabetes mellitus 
x    
Non-insulin-dependent 
diabetes 
E11 Non-insulin-dependent diabetes mellitus 
x x x  
Other  E12 Malnutrition-related diabetes mellitus x x x  
E13 Other specified diabetes mellitus x x x  
E14 Unspecified diabetes mellitus x x x  
Heart disease  Cardiac arrhythmias I441-I443 Atrioventricular block, second degree, Atrioventricular block, complete, Other and 
unspecified atrioventricular block 
  x  
I456 Pre-excitation syndrome   x  
I459 Conduction disorder, unspecified   x  
I47-I49 Paroxysmal tachycardia, Atrial fibrillation and flutter, Other cardiac arrhythmias   x  
R00.1 Bradycardia, unspecified   x  
R00.8 Other and unspecified abnormalities of heart beat   x  
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PROMs chronic 
disease category 
Chronic disease 
Subcategories 
ICD-10 Code ICD-10 definition RCS CI Quan CCI Elixhauser* Backward 
coding 
R000 Tachycardia, unspecified   x  
T82.1 Mechanical complication of cardiac electronic device   x  
Z45.0 Adjustment and management of cardiac pacemaker   x  
Z95.0 Presence of cardiac pacemaker   x  
Congestive heart failure  I09.9 Rheumatic heart disease, unspecified  x x  
I11.0 Hypertensive heart disease with (congestive) heart failure  x x  
I13.0 Hypertensive heart and renal disease with (congestive) heart failure x x x  
I13.2 Hypertensive heart and renal disease with both (congestive) heart failure and renal 
failure 
 x x  
I255 Ischaemic cardiomyopathy x x x  
I42 Cardiomyopathy x    
I42.0 Dilated cardiomyopathy x x x  
I42.5-I42.9 Other restrictive cardiomyopathy, Alcoholic cardiomyopathy, Cardiomyopathy due to 
drugs and other external agents, Other cardiomyopathies, Cardiomyopathy, 
unspecified 
x x x  
I42.6 Alcoholic cardiomyopathy x  x  
I43 Cardiomyopathy in diseases classified elsewhere x x x  
I50 Heart failure x x x  
I517 Cardiomegaly x    
Ischemic heart diseases I21 Acute myocardial infarction x x   
I22 Subsequent myocardial infarction x x   
I23 Certain current complications following acute myocardial infarction x x   
I252 Old myocardial infarction x    
I258 Other forms of chronic ischaemic heart disease    x 
I259 Chronic ischaemic heart disease, unspecified    x 
I20 Angina Pectoris    x 
I251 Atherosclerotic heart disease    x 
Valvular disease Q23.O-Q23.3 Congenital stenosis of aortic valve, Congenital insufficiency of aortic valve, Congenital 
mitral stenosis, Congenital mitral insufficiency 
 x x  
Z95.2 Presence of prosthetic heart valve  x x  
Z95.4 Presence of other heart-valve replacement  x x  
A52.0 Cardiovascular syphilis  x x  
I05.x-I08.x Rheumatic mitral valve diseases,  Rheumatic aortic valve diseases, Rheumatic tricuspid 
valve diseases, Multiple valve diseases 
 x x  
I09.1 Rheumatic diseases of endocardium, valve unspecified  x x  
I09.8 Other specified rheumatic heart diseases  x x  
I34-I39 Nonrheumatic mitral valve disorders, Nonrheumatic aortic valve disorders, 
Nonrheumatic tricuspid valve disorders, Pulmonary valve disorders, Endocarditis, 
 x x  
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PROMs chronic 
disease category 
Chronic disease 
Subcategories 
ICD-10 Code ICD-10 definition RCS CI Quan CCI Elixhauser* Backward 
coding 
valve unspecified, Endocarditis and heart valve disorders in diseases classified 
elsewhere 
High BP Primary hypertension I10.x Essential (primary) hypertension   x  
Secondary hypertension  I11 Hypertensive heart disease x  x  
I15 Secondary hypertension   x  
Kidney disease  Acute renal failure N171* Acute renal failure with acute cortical necrosis x    
N172* Acute renal failure with medullary necrosis x    
N179* Acute renal failure, unspecified    x 
Chronic renal failure I12.0 Hypertensive renal disease with renal failure  x x  
I13.1 Hypertensive heart and renal disease with renal failure  x x  
N18 Chronic kidney disease x x x  
N19 Unspecified kidney failure x x x  
Z49 Care involving dialysis x    
Z49.0-Z49.2 Preparatory care for dialysis, Extracorporeal dialysis, Other dialysis x x x  
Z94.0 Kidney transplant status x x x  
Z99.2 Dependence on renal dialysis x x x  
N19 Unspecified Kidney failure    x 
Glomerular diseases N01 Rapidly progressive nephritic syndrome x    
N03 Chronic nephritic syndrome x    
N03.2–N03.7 Rapidly progressive nephritic syndrome x x   
N05 Unspecified nephritic syndrome x    
N05.2–N05.7 Unspecified nephritic syndrome  Diffuse membranous glomerulonephritis ,  Diffuse 
mesangial proliferative glomerulonephritis,  Diffuse endocapillary proliferative 
glomerulonephritis,  Diffuse mesangiocapillary glomerulonephritis  
x x   
N07 Hereditary nephropathy, not elsewhere classified x    
N08 Glomerular disorders in diseases classified elsewhere x    
Other renal disease N25 Disorders resulting from impaired renal tubular function x    
N289 Disorder of kidney and ureter, unspecified    x 
Secondary hypertension  I12 Hypertensive renal disease x  x  
I13 Hypertensive heart and renal disease x  x  
Leg pain due to 
poor circulation 
Aortic diseases I70 Atherosclerosis x x x  
I71 Aortic aneurysm and dissection x x x  
I72 Other aneurysm and dissection x    
I790 Aneurysm of aorta in diseases classified elsewhere  x x  
Gangrene R02 Gangrene, not elsewhere classified x    
Peripheral vascular 
diseases  
I73 Other peripheral vascular diseases     
I731 Thromboangitis obliterans [Buerger] x x x  
I738 Other specified peripheral vascular diseases x x x  
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PROMs chronic 
disease category 
Chronic disease 
Subcategories 
ICD-10 Code ICD-10 definition RCS CI Quan CCI Elixhauser* Backward 
coding 
I739 Peripheral vascular disease, unspecified x x x  
I770 Arteriovenous fistula, acquired x    
I771 Stricture of artery x x x  
I792 Peripheral angiopathy in diseases classified elsewhere  x x  
Vascular implants Z95.8 Presence of other cardiac and vascular implants and grafts x x x  
Z95.9 Presence of cardiac and vascular implant and graft, unspecified x x x  
Liver disease  Alcoholic liver disease  K70 Alcoholic liver disease x  x  
K70.0 Alcoholic fatty liver x x x  
K70.1 Alcoholic hepatitis  x x   
K70.2 Alcoholic fibrosis and sclerosis of liver x x   
K70.3 Alcoholic cirrhosis of liver x x x  
K70.4 Alcoholic hepatic failure x x   
K70.9 Alcoholic liver disease, unspecified x x x  
Cirrhosis I85.9 Oesophageal varices without bleeding x x x  
I85.0 Oesophageal varices with bleeding x x x  
I86.4 Gastric varices x x x  
I98.2 Oesophageal varices without bleeding in diseases classified elsewhere x x x  
K71.7 Toxic liver disease with fibrosis and cirrhosis of liver x x x  
K74 Fibrosis and cirrhosis of liver  x x  
Hepatic failure K71.1 Toxic liver disease with hepatic necrosis x x x  
K72.0* Acute hepatic failure      
K72.1 Chronic hepatic failure x x x  
K72.9 Hepatic failure, unspecified x x x  
K72.x Hepatic failure, not elsewhere classified   x  
Hepatitis B18 Chronic viral hepatitis x x x  
K71.3-K71.6 Toxic liver disease with chronic persistent hepatitis, chronic lobular hepatitis,  chronic 
active hepatitis 
x x x  
K73 Chronic hepatitis, not elsewhere classified  x x  
K754 Autoimmune hepatitis    x 
Other K76 Other diseases of liver x    
R162 Hepatomegaly with splenomegaly, not elsewhere classified x    
Z94.4 Liver transplant status x x x  
Lung disease Asthma J45-46 Asthma x x x  
COPD J40-42 Bronchitis x x x  
J43 Emphysema x x x  
J44 COPD x x x  
Pulmonary heart diseases I26 Pulmonary embolism x  x  
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PROMs chronic 
disease category 
Chronic disease 
Subcategories 
ICD-10 Code ICD-10 definition RCS CI Quan CCI Elixhauser* Backward 
coding 
I278 Other specified pulmonary heart diseases x x x  
I279 Pulmonary heart disease, unspecified x x x  
Other lung disease (e.g. 
due to external agents) 
J47 Bronchiectasis     
J60-J67 Lung diseases due to external agents x x x  
J684 Chronic respiratory conditions due to chemicals, gases, fumes and vapours x x x  
J701 Chronic and other pulmonary manifestations due to radiation x x x  
J703 Chronic drug-induced interstitial lung disorders x x x  
J841 Other interstitial pulmonary diseases with fibrosis    x 
J920 Pleural plaque with presence of asbestos    x 
Nervous System Dementia F00.x–F03.x Dementia in Alzheimer disease, Vascular dementia,  Dementia in other diseases 
classified elsewhere, Unspecified dementia 
x x   
F051 Delirium superimposed on dementia x x   
G30 Alzheimer disease x x   
G31 Other degenerative diseases of nervous system, not elsewhere classified x    
G31.1 Senile degeneration of brain, not elsewhere classified x x   
G31.2 Degeneration of nervous system due to alcohol x  x  
G31.8 Other specified degenerative diseases of nervous system x  x  
G31.9 Degenerative disease of nervous system, unspecified x  x  
G32.x Other degenerative disorders of nervous system in diseases classified elsewhere   x  
Demyelinating disease G35 Multiple sclerosis   x  
G36 Other acute disseminated demyelination   x  
G37 Other demyelinating diseases of central nervous system   x  
Epilepsy G40 Epilepsy   x  
G41 Status epilepticus   x  
R56 Convulsions, not elsewhere classified   x  
Neuropathies G600 Hereditary motor and sensory neuropathy    x 
G629 Polyneuropathy    x 
G610 Guillain-Barré syndrome    x 
G618 Other inflammatory polyneuropathies    x 
G619 Inflammatory polyneuropathy, unspecified    x 
Parkinsonism G20.x-G22.x Parkinson disease, secondary parkinsonism, parkinsonism in diseases classified 
elsewhere 
  x  
G25.4 Drug-induced chorea   x  
G25.5 Other chorea   x  
G249 Dystonia, unspecified    x 
G250 Essential tremor    x 
A810 Creutzfeldt-Jakob disease  x    
G04.1 Tropical spastic paraplegia   x  
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PROMs chronic 
disease category 
Chronic disease 
Subcategories 
ICD-10 Code ICD-10 definition RCS CI Quan CCI Elixhauser* Backward 
coding 
Other nervous system (e.g. 
paralysis, huntington's 
disease) 
G10.x-G13 Huntingdon disease, Hereditary ataxia, spinal muscular atrophy and related 
syndromes, Systemic atrophies primarily affecting central nervous system in diseases 
classified elsewhere 
  x  
G11.4 Hereditary spastic paraplegia x  x  
G80.1 Spastic diplegic cerebral palsy   x  
G80.2 Spastic hemiplegic cerebral palsy   x  
G82.x Paraplegia and tetraplegia x  x  
G83 Other paralytic syndromes x    
G83.0-G83.4 Diplegia of upper limbs,  Monoplegia of lower limb, Monoplegia of upper limb, 
Monoplegia, unspecified, Cauda equina syndrome 
x  x  
G83.9 Paralytic syndrome, unspecified   x  
G93.1 Anoxic brain damage, not elsewhere classified   x  
G93.4 Encephalopathy, unspecified   x  
R47.0 Dysphasia and aphasia   x  
G700 Myasthenia    x 
G933 Postviral fatigue syndrome    x 
Stroke Transient Ischemic Attack  G45 Transient cerebral ischaemic attacks and related syndromes x x   
Ischemic stroke I69.2 Sequelae of other nontraumatic intracranial haemorrhage x x   
G46 Vascular syndromes of brain in cerebrovascular diseases (I60-I67+)  x x   
H34.0 Transient retinal artery occlusion  x   
I61 Intracerebral haemorrhage x x   
I62 Other nontraumatic intracranial haemorrhage  x x   
I63 Cerebral infarction x x   
I64 Stroke, not specified as haemorrhage or infarction x x   
I65 Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction  x x   
I66 Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction x x   
I69.1 Sequalae of intracerebral haemorrhage x x   
I69.3 Sequelae of cerebral infarction x x   
I69.4 Sequelae of stroke, not specified as haemorrhage or infarction x x   
G81.x Hemiplegia x  x  
Subarachnoid 
Haemorrhage  
I60 Subarachnoid haemorrhage  x x   
I69.0 Sequalae of subarachnoid haemorrhage x x   
Other stroke I67 Other cerebrovascular diseases x x   
I68 Cerebrovascular disorders in diseases classified elsewhere x x   
I69.8 Sequelae of other and unspecified cerebrovascular diseases x x   
Note : * ICD-10 codes not mapped from the Elixhauser Comorbidity Index: AIDS/HIV , Peptic Ulcer Disease, Pulmonary Circulation  disorders, Hypothyroidism, Coagulopathy, Obesity, Weight loss, Fluid and 
electrolyte disorders, Blood loss anaemia, Deficiency Anaemia, Alcohol abuse,  Drug abuse, Psychoses.
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12.10 Appendix J – Data application, linkage, cleaning, and derivation of 
indicators 
The following section describes the process of applying for data from NHS Digital and the 
data linkage process conducted by NHS Digital. Detail about the data cleaning process such 
as the removal of duplications is also described as well as the derivation of indicators.  
 
  Data application process 
The data application process was long and arduous (see table 1). The data application was 
submitted at the end of April 2016 and data was not received until May 2017.  
An application was submitted to NHS Digital as well as the Office for National Statistics 
(ONS) via NHS Digital. Due to the data being potentially patient-identifiable ethics approval 
from the Health Research Authority (HRA) was requested. Approvals were needed from the 
HRA Research Ethics Service (RES) and the HRA Confidentiality Advisory Group (CAG). The 
applications to the HRA were submitted in July 2016.  Meanwhile, to access ONS data every 
researcher needed to be an ONS Approved Researcher. A separate application was 
submitted to ONS for approved researcher status, which involved training. All approvals 
were received by October 2016. Further queries regarding the fair processing statement, 
the role of the funder and the storage of the data at the Royal College of Surgeons of 
England and other NHS Digital delays led to data not being received until May 2017.   
 
Table 3 – Data application process 
Steps Application Date submitted 
1 NHS digital data application 
- Further approvals needed: HRA approval, 
Ethics approval, CAG approval, ONS 
approval, ONS approved researcher status 
May 2016 
2 HRA Research Ethics and CAG application July 2016 
3 ONS Approved Researcher (involved training)  October 2016 
4 Queries: 
- Fair processing statement  
- Role of funder  
- Agreement between the RCS and LSHTM 
October 2016 – May 2017 
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  Data sources 
The data set available to the study consisted of: 
 PROMs records for Hip and Knee replacement – 2009-2017 
 HES inpatient records for patients in PROMs survey – 2003-2017 
 ONS-HES linked mortality statistics 2009-2017 
PROMs 
This dataset included 791 474 number of PROMS procedures, of which:  
- 385 332 were hip replacements 
- 406 142 were knee replacements  
HES inpatient records 
This dataset included 6 104 484 HES episodes between 2003 and 2017 for the 791 474 
PROMs patients.  
Office for National Statistics mortality data 
This dataset included 45 854 registered number of deaths for this population for the 791 
474 PROMs patients. 
These data derived from death certification give the cause of death of an individual. The 
record is linked to the HES data set, enabling the individual’s previous medical history to be 
examined. 
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RCS secure server  
  Data linkage 
Below is a diagram of the data linkage processes that NHS Digital undertook and was 
subsequently undertaken to produce a dataset that was ready for analysis.  
 
 
 
 
  
NHS Digital 
                          
 
 
Linkage by encrypted HESID  
Secure Transfer 
HES episodes 
(2003 onwards) 
PROMs + linked 
corresponding 
HES episode 
ONS 
mortality 
PROMs linked to 
corresponding 
HES episode 
Use HES episodes to 
identify LTCs and 
patient outcomes 
ONS 
mortality  
HES LTCs 
and 
patients 
outcomes  
PROMs linked 
to 
corresponding 
HES episode 
ONS 
mortality 
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  Data cleaning  
The information which follows provides an account of full data cleaning conducted for the 
study, prior to data analysis. The project restricted the records to NHS hospital hip and 
knee replacement. Duplicate episodes of the index hip and knee replacement were 
removed. 
 
12.10.4.1 Duplicate records 
 
Duplicate PROMs Q1  
Some hip and knee replacement had several survey records associated with them that are 
not necessarily identical. Out of the many alternatives, one record has to be chosen to 
represent the hip or knee replacement.  
Duplicate records might have been created because a surgery was delayed and then 
reissued again at the operation. This may explain why a matched episode with a lower 
match rank has a complete record.  
 
 
 
 
 
 
 
Duplicate records were chosen using the following algorithm in order of priority:  
 
 
 
 
 
 
For the group of records that all relate to one hip or knee replacement, a single record was 
chosen using the above algorithm. Episode matches with a complete Q1 and Q2 were 
prioritised and chosen.  A match score was derived using the episode match rank (a rank 
Episode of care 
PROMs Q1 
PROMs Q1 
PROMs Q1 PROMs Q2 
Algorithm  
1. Had a complete Q2 
2. Highest match score  
3. Latest completed Q1 date 
4. Most recent scan date 
Figure 3- Selecting the one record to represent the hip or knee replacement  
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score which has been calculated by NHS Digital which evaluates the matching quality of a 
HES episode to a Q1 questionnaire). It uses a four-stage process that looks at a 
combination of patient identifiable fields, provider codes, operation codes and dates. 
As the match rank is a combination of three different scores the actual scores in each 
combination were calculated to derive an overall PROMS match score. This avoids the 
problem of some matches being ranked better matched in certain fields than others. A 
higher overall score signifies a higher quality match. The duplicate record with the 
highest matching scoring was chosen. For the remainder if match score and record 
completeness was identical the record with the latest completed Q1 date or most recent 
scan date were chosen. In the cases where there are duplicate records and all above fields 
are identical, a random number was generated to distinguish records and the lowest 
random number was chosen.   
 
Duplicate episodes of care  
After linkage with HES records a further 280 episodes of care were found to be duplicate 
records, but for the hospital treatment code. The majority of these duplicate records were 
recorded in both a private and an NHS trust hospital. The records were chosen in the 
following order of priority: PROMs Q2 completeness and then scan date. The duplicate 
record with a complete Q2 was chosen (n=115) and if both were complete or non-complete 
the duplicate with the latest scan date (n=25) was chosen. This is because the later scan 
date was closer in proximity to the admission date. As a result, 140 duplicate records were 
removed. 
 
12.10.4.2 Patients with multiple interventions 
There were some patients who had multiple hip and knee surgeries. As we are comparing 
the presence of comorbidities in PROMs and HES only the first surgery was included in the 
analysis to ensure there was only one record per patient.  
The further episodes while not included in the main analysis were analysed separately to 
test patient-reported coding consistency between the first and second intervention. This 
further validates the reliability of patient-reported comorbidity.  
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Table 4 – Number of surgeries per patient for both hip and knee replacement surgery.  
Number of surgeries Frequency Percent 
1 677 185 86.8 
2 97 386 12.5 
3 5 460 0.70 
4 508 0.07 
5 32 0.00 
6 4 0.00 
 
A number of patients had multiple surgeries including both primary and revision surgeries. 
Patients with hip replacement had up to five primary and revision surgeries whereas there 
were a maximum of six for knee replacement surgeries.  For the purposes of the analysis, 
only the first primary surgery was included. However, a further piece of analysis will be 
conducted to explore the consistency of coding across subsequent surgeries and whether 
there were any differences in recording of comorbidities between the first and second 
surgery. 
 
12.10.4.3 Investigating miscoding and response errors 
Previous research has identified a potential issue with the responses to the question in 
PROMS asking about comorbidities. There may be patients who misinterpreted the 
question about whether a doctor had ever told them whether they had any of the following 
comorbidities. Patients may have checked off the comorbidities, which were absent rather 
than present.  
This was investigated by comparing the number of patient-reported comorbidities against 
the number of HES reported comorbidities, mean reported quality of life and the number 
of discordant comorbidities.   
When looking at the number of reported PROMs comorbidities it was found that more 
patients reported having 10 rather than 9 comorbidities and more reported having 11 
comorbidities than 10. When looking at the HES recorded data in a similar way, the average 
number of HES comorbidities decreases rather than increases from greater than 6 PROMs 
reported comorbidities. 
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Table 5 – Agreement between PROMs and HES number of comorbidities in number of comorbidities reported in 
both HIP and knee replacement patients. 
PROMS # of  
comorbidities 
HES # of comorbidities Total 
0 1 2 3 4 5 6 7 8 
0 182566 57 815 16 216 3 854 679 93 13 0 0 261236 
1 47 505 139 645 46 416 9 611 1 446 151 11 3 0 244788 
2 10 511 35 077 52 379 15 896 2 930 351 32 2 2 117180 
3 2 246 6 562 15 187 11 602 3 054 448 54 3 0 39 156 
4 523 1 125 3 183 3 897 1 764 372 52 3 0 10 919 
5 121 206 563 886 639 207 25 1 0 2 648 
6 33 56 95 189 149 69 21 2 0 614 
7 10 16 29 32 16 21 2 0 0 126 
8 13 15 11 10 4 0 3 0 0 56 
9 18 24 6 4 2 0 0 0 0 54 
10 63 41 22 9 4 0 0 0 0 139 
11 137 68 38 18 8 0 0 0 0 269 
Total 243746 240 650 134145 46008 10695 1712 213 14 2 677185 
 
When also looking at mean quality of life scores (EQ-5D) patients with six or greater 
number of reported PROMs comorbidities had better reported quality of life compared to 
patients with only six comorbidities. The quality of life reported appeared to improve as 
patients had more comorbidities.  
Table 6 – The Q2 postoperative mean EQ-5D score and number of HES comorbidities by number of reported 
PROMS comorbidities for both hip and knee replacement surgery. 
PROMs 
# of comorbidities 
Mean number of  HES comorbidities Postoperative mean EQ-5D score 
0 0.40 0.79 
1 1.09 0.76 
2 1.72 0.70 
3 2.21 0.63 
4 2.60 0.57 
5 2.92 0.50 
6 3.09 0.48 
7 2.79 0.51 
8 1.80 0.53 
9 1.04 0.67 
10 0.92 0.78 
11 0.86 0.75 
 
Similarly, when looking at the level of agreement between PROMS reported comorbidities 
and HES recorded comorbidities patients reporting they had greater than 6 comorbidities 
had greater than 25% disagreement on at least three of the most common comorbidities.  
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As a result, patients reporting more than six comorbidities were removed as a substantial 
proportion of patients were incorrectly recording their comorbidities. 
Table 7- The percentage of patients undergoing hip and knee replacement surgery who had greater than 25% 
disagreement on at least three of the most common comorbidities (i.e. diabetes, heart disease, high BP, lung 
disease and arthritis) 
PROMs # of 
comorbidities 
Sum of agreement 
(HES and PROMs for diabetes, heart disease, high BP and lung 
disease and whether arthritis is present) 
% that 
have less 
than 3 in 
agreement 0 1 2 3 4 5 Total 
0 86 1 248 6 913 26 908 94 113 131 968 261 236 13.5 
1 13 309 3 504 25 231 91 460 124 271 244 788 11.9 
2 5 173 2 345 14 120 42 951 57 586 117 180 14.2 
3 7 112 1 014 4 913 14 144 18 966 39 156 15.4 
4 4 61 396 1 417 3 919 5 122 10 919 17.2 
5 2 24 128 353 944 1 197 2 648 19.2 
6 4 20 39 70 232 249 614 21.7 
7 2 4 11 22 41 46 126 31.0 
8 7 8 14 13 7 7 56 75.0 
9 7 22 14 6 4 1 54 90.7 
10 26 55 37 18 3 0 139 97.8 
11 17 135 68 34 13 2 269 94.4 
Total 180 2 171 14483 73 105 247 831 339 415 677 185  
 
12.10.4.4 Removal of revision surgeries   
PROMs field: Proc_revision_flag  
Revision surgeries were removed from the analysis cohort as patients undergoing revision 
surgery are likely to have more severe symptoms and are likely to constitute a different 
cohort of patients. As the interest of this study was patients accessing their primary 
surgery, operations tagged as a revision in PROMs were excluded from the analysis. 22 132 
hip operations and 13 464 knee operations were excluded.  
 
12.10.4.5 Removal of incomplete postoperative (Q2) questionnaires 
PROMs field: Q2_complete 
Q2 survey responses that were incomplete were removed.  68 478 hip operations and 72 
868 knee operations were removed. 
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12.10.4.6 Removal of second primary operations  
We investigated the number of second primary operations that occurred within the 
timeframe of index admission discharge and the Q2 questionnaire completion date. Second 
primary operations on a different joint or side might impact on the Q2 reports of severity of 
symptoms and quality of life so we wanted to remove any patients who had a second 
primary operation in this timeframe.  
Second primary on same joint and side were not removed as they were suspected to be 
miscoded primary surgeries that may be revision surgeries. Similarly, revisions were not 
removed as they are an outcome of interest.  
 
Table 8 – The number of second primary procedures before the Q2 questionnaire completion date for both hip 
and knee replacement surgery. 
Type  Number (%) 
Second Primary on same joint and side 1 246 (0.25) 
Second Primary on different joint or side 19 854 (3.97) 
Revision on the same joint and side 641 (0.13) 
Revisions on different joint or side 3 695 (0.74) 
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12.10.4.7 Flow chart of overall data cleaning 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
A total of PROMs episodes were 
included from 2009-2017 
N (791 364) 
Duplicate Q1 survey responses 
Duplicate Q1 responses: 21 454 
Pairs: 21 262 
Triple: 192 
Duplicates removed: 10 759 
 
 
 
 
Records after removal of duplicate Q1 
survey responses 
N (780 602) 
) 
Duplicate episodes: 280 
Duplicates removed: 140 
 
 
 
 
Records after removal of duplicate 
episodes 
N (780 462) 
) 
Further episodes removed due to 
coding errors:  
Number of patients who responded 
having greater than six 
comorbidities.  
PROMs episodes removed: 644 
 
 
Records after removing PROMs records 
that did not represent the first surgery 
N (677 067) 
) 
Some patients had multiple hip or 
knee replacements (or both) and as 
such only their first surgery was 
included: 
PROMs episodes removed: 103 395 
 
 
Records after PROMS records removed 
due to coding errors (RP3) 
N (676 428) 
) 
Revision surgeries: 22 132 hips,        
13 464 knees. 
 
 
Records after revisions removed  
(RP4 and RP5) 
 
N (640 832) 
) 
Records after Q2 incomplete removed 
(RP6) 
N (479 632) 
) 
Q2 survey responses incomplete: 
141 346 
Second primary operations on 
different side: 19 854 
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  Derivation of the comorbidity categories in HES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
ICD-10 codes drawn from the RCS 
Charlson, Quan Charlson and 
Elixhauser comorbidity indices  
N (309) 
 
‘Backward coding’ 
 conducted for each group of 
comorbidities and ICD-10 codes at the 
three-character category level which 
were common (>1%) when reported as 
being present in PROMs but missing in 
HES  
N (236) 
 
N(48  
 
N (780,602) 
) 
Codes identified: 52 
 Codes clinically irrelevant:  34 
 Not included because ratio of 
present in PROMs but not 
present in either PROMs or HES 
was less than two at the ICD-10 
four-character subcategory 
level: 2 
  
 
 
 
 
Total number of ICD-1  codes in final 
coding structure 
N (252) 
Clinically irrelevant:  55 
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  Derivation of Indicators 
 
12.10.6.1  PROMs 
 
Patient-reported comorbidities  
Patients are asked if they “Have you ever been told by a doctor that you have any of the 
following?” 
- Cancer in the last five years  
- Leg pain when walking due to poor circulation 
- Depression 
- Diabetes 
- Heart Disease (for example angina, heart attack or heart failure) 
- High Blood Pressure 
- Kidney Disease 
- Liver Disease  
- Lung Disease (for example asthma, chronic bronchitis or emphysema) 
- Diseases of the Nervous System (for example Parkinson’s disease or multiple 
sclerosis) 
- Problems caused by stroke 
 
Severity of joint problems 
PROMs fields: hr_q1/q2 and kr_q1/q2 
We used a previously validated approach by Neuburger et al.  to measure disease severity. 
We used the Oxford Hip Score (OHS) and the Oxford Knee Score (OKS) as our measures of 
severity of joint problems just before surgery. These are derived from patient responses to 
12 questions about pain and limits on physical functioning and everyday activities caused 
by the hip or the knee (Box 1 and 2). Responses to each question are measured on a five-
point scale, and values associated with each response are added up to produce an overall 
scale from 0 (worst) to 48 (best). Both instruments have been shown to be internally 
consistent, reliable and to correlate with surgeon assessed measures of symptoms. 
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OHS  
During the past 4 weeks… PROMs field  
1. How would you describe the pain you usually have from your 
hip? 
hr_q1_pain 
2. Have you had any trouble washing and drying yourself (all 
over) because of your hip?  
hr_q1_washing 
3. Have you had any trouble getting in or out of care or using 
public transport because of your hip? 
hr_q1_transport 
4. Have you been able to put on a pair of socks, stockings or 
tights? 
hr_q1_dressing 
5. Could you do the household shopping on our own? hr_q1_shopping 
6. For how long have you been able to walk before pain from 
your hip becomes severe? (with or without a stick) 
hr_q1_walking 
7. Have you been able to climb a flight of stairs? hr_q1_stairs 
8. After a meal how painful has it been for our to stand up from 
a chair because of your hip? 
hr_q1_standing 
9. Have you been limping when walking, because of your hip? hr_q1_limping 
10.  Have you had any sudden, severe pain –‘shooting, ‘stabbing’ 
or ‘spasms’ – from the affected hip? 
hr_q1_sudden_pain 
11. How much has pain from your hip interfered with your usual 
work (including housework)? 
hr_q1_work 
12. Have you been troubled by pain from your hip in bed at night? hr_q1_night_pain 
 
OKS  
During the past 4 weeks… PROMs field 
1. How would you describe the pain you usually have from your 
knee? 
kr_q1_pain 
2. Have you had any trouble washing and drying yourself (all 
over) because of your knee?  
kr_q1_washing 
3. Have you had any trouble getting in or out of care or using 
public transport because of your knee? 
kr_q1_transport 
4. For how long have you been able to walk before pain from 
your knee becomes severe? (with or without a stick) 
kr_q1_walking 
5. After a meal how painful has it been for our to stand up from 
a chair because of your knee? 
kr_q1_standing 
6. Have you been limping when walking, because of your hip? kr_q1_limping 
7. Could you kneel down and get up again afterwards? kr_q1_kneeling 
8. Have you been troubled by pain from your knee in bed at 
night? 
kr_q1_night_pain 
9. How much has pain from your knee interfered with your usual 
work (including housework)? 
kr_q1_work 
10.  Have you felt that your knee might suddenly ‘give way’ or let 
you down? 
kr_q1_confidence 
11. Could you do the household shopping on your own? kr_q1_shopping 
12. Could you walk down one flight of stairs?  kr_q1_stairs 
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 Duration of symptoms 
PROMs field: q1_symptom_period 
A categorical measure of symptom duration was derived from responses to a single 
question asking patients how long they had experienced problems with the hip or the knee 
on which they were about to have surgery. Four response categories included: ‘Less than 1 
year’; ‘1–5 years’; ‘6–10 years’ and ‘More than 10 years’. We defined longstanding 
problems as durations of symptoms of more than 5 years, but our results were robust to an 
alternative cut-off of 10 years 
 
 EQ-5D score 
PROMs field: q1/q2_eq5d_index 
The EQ-5D Index score derived from the EQ-5D profile. For every ‘2’ or ‘3’ present a 
fraction is deducted, the lower the score the worse the patient reported on the EQ-5D 
questions. The value is between -0.594 and 1 with 0 representing ‘death’.  
 
No overall improvement 
PROMs field: q2_success 
Patients are asked if overall, ‘how are your problems now, compared to before your 
operation?’. Five response categories included: ‘Much better’, ‘ A little better’, ‘About the 
same’, ‘A little worse’, ‘Much worse’. No improvement was defined as responses of ‘about 
the same’ or worse.  
 
Patient satisfaction 
PROMs field: q2_satisfaction  
Patients are asked ‘How would you describe the results of your operation?’. Five categories 
of responses for describing the results of the operation were ‘Excellent’, ‘Very Good’, 
‘Good’, ‘Fair’ and ‘Poor’. A binary variable was derived, giving a ‘1’ if patients described 
their results as only ‘Fair’ or ‘Poor’. 
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Patient-reported complications 
PROMs field: q2_wound, q2_bleeding 
Patients are asked: ‘Did you experience any of the following problems after your operation: 
Wound problems? Bleeding?’ A binary variable was derived whereby ‘1’ indicates a wound 
problem or bleeding after hip or knee replacement.  
 
Readmissions 
PROMs field: q2_readmitted 
Patients are asked: ‘Have you been readmitted to hospital since your operation?’ A binary 
variable was derived whereby ‘1’ indicate a readmission in six months after the hip or knee 
replacement.  
 
12.10.6.2 HES 
 
Ethnicity  
HES field: Ethnos 
Ethnicity was recoded into six groups 
- White/White British 
- Mixed background 
- Asian/British Asian 
- Black/Black British 
- Chinese and Other 
- Not stated or missing  
 
Sex  
HES field: sex/ PROMs field: Gender 
The HES field was more complete than the PROMs field and therefore the HES field was 
chosen as the primary variable. If a patient’s sex was recorded as either ‘Unknown’ or ‘Not 
stated’ in HES then their PROMs record was searched to see if a gender was reported.  
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IMD deprivation  
HES field: imd04_decile 
The HES field was recoded into five deprivation groups based on the IMD deciles.  
- IMD group 1 = Least deprived 10% + less deprived 10-20% 
- IMD group 2 = Least deprived 20-30% + less deprived 30-40% 
- IMD group 3 = Less deprived 40-50% + more deprived 10-20% 
- IMD group 4 = More deprived 20-30% + more deprived 30-40% 
- IMD group 5 = More deprived 40-50% + Most deprived 10% 
 
Emergency readmissions in 30 days 
HES field: admimeth 
All emergency readmissions in 30 days (readmissions after the index discharge date and 30 
days later) were identified. Emergency readmissions were then tagged if the admission 
method started with a “2” (any emergency admission).  
 
Critical Care  
HES field: tretspef 
The treatment speciality variable (available since 1989-90 onwards) identifies critical care 
or also known as Intensive Care Medicine as a treatment specialty. Any patients with a 
critical care episode in their index admission were tagged as having entered critical care.  
 
Length of stay 
HES field: disdate, disreadydate  
Length of stay was derived from originally calculating the time between the index 
operation date and the index discharge date or if available to the discharge ready date. A 
binary variable was derived for patients with a length of stay greater than the 50th 
percentile (>8 days) of patients who need further care.  
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Second episodes of care 
HES field: epiorder, tretspef 
Second episodes of care was derived from the whether a patient had a second episode of 
care in the index admission. Half the patients had a second episode of care in the same 
specialty and others transferred to other specialties.  
 
12.10.6.3 ONS 
 
30-day/90-day mortality  
ONS field:  date of death (dod)  
30-day and 90-day mortality was derived from the difference between the date of death 
and index procedure date. 12 death dates were a day before the index date but this may be 
due to recording error and were therefore included in the analysis. 90 dates of death were 
excluded as they were several years before the index procedure date.  
 
 
